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Abstract 
 
Depression is a National Health Priority in Australia and is one of the symptoms that 
menopausal women may experience.1 The number of menopausal women is increasing 
and the need to find effective and efficient management of depressive symptoms in this 
group is an emerging field of research. Physical symptoms such as low back pain, stiff 
and aching joints, and migraines or headaches are also symptoms menopausal women 
experience and the reason why they would consult an osteopath.  
 
The purpose of this thesis was to explore whether osteopathic manipulative treatment 
(OMT) has a role as an adjunct to standard care of depression in menopausal women. 
Two secondary aims were to investigate whether there are common osteopathic findings 
in menopausal women suffering depression and explore the acceptance of OMT in the 
management of depression in menopausal women. A mixed method, case study 
approach was used. Qualitative data was collected from during the intervention period, 
and at three and twelve months.  
 
The participants attended weekly cognitive behavioural therapy (CBT) consultations for 
eight weeks. During these eight weeks four osteopathic consultations were conducted. 
The participants psychological health (as measured by the Depression, Anxiety, and 
Stress Scale)2 and, menopausal symptoms (as measured by the Greene Climacteric 
Scale)3 were measured five times throughout the project . Data on the therapeutic alliance 
between participant and their osteopath and psychologist was also collected (as 
measured by the Working Alliance Inventory)4. Data relating to osteopathic examination 
findings was collected at each of the four OMT consultations for each of the participants.  
Data on the psychological health and menopausal symptoms was also collected at a CBT 
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consultation follow-up, three months after the last CBT consultation, and during an 
interview conducted twelve months after the beginning of the intervention period.  
 
Results of the quantitative data showed an improvement in depressive scores at the 
conclusion of the intervention period and the three and twelve month follow ups. The 
results of the quantitative data for the vasomotor symptoms associated with the 
menopausal transition showed an improvement during the first 20 weeks, however, these 
symptoms had returned to the same level of those at the beginning of the intervention 
period. The results of the quantitative data for the somatic symptoms associated with 
menopausal transition remained fairly constant over the data collection period. The data 
relating to the therapeutic alliance indicated that a greater bond was created between the 
participant and the osteopath when compared to the bond with the psychologist. The 
psychologists had higher scores in relation to the task and goal of the consultations. 
Osteopathic examination did indicate that there were common areas of dysfunction. 
Upper cervical, mid-thoracic, lower lumbar and sacral somatic dysfunctions were 
observed in all three participants.  Hypertonicity of the erector spinae muscles and 
uncompensated patterns of Zink were also noted. Right lower abdominal discomfort was 
also noted; two of the participants had symptoms associated with the digestive tract in this 
region.  
 
The interviews provided qualitative data, which was analysed using a thematic analysis 
approach. The themes that emerged from the qualitative data showed that there was a 
mix of curiosity and scepticism towards the role OMT may have in managing depression 
in menopausal women. The experience of attending both the OMT and CBT consultations 
was a positive one, however, the women experienced difficulty in articulating how OMT 
contributed to the positive changes they experienced. The women did not acknowledge 
psychological symptoms as part of the menopausal transition; the participants focused 
more on the physical symptoms.  
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The thesis concludes that there was preliminary evidence to recommend further research 
into the role of OMT role in the management of depression in menopausal women. The 
participants did accept OMT as part of the management strategy, however, education of 
relevant health care professionals and menopausal women would be beneficial for this 
intervention to be most effective. A clinical trial would be necessary to determine if 
common areas of dysfunction are present for depressed menopausal women and to 
formulate an OMT management strategy for this condition. Limitations of the study design 
are discussed. 
 
4 
 
Chapter 1  The Menopausal Transition and Depression  
Introduction  
The number of women going through the menopausal transition is increasing, both in 
Australia and globally. It is estimated that 19.5% of the Australian female population is 
within the menopausal phase of a female’s reproductive life.5    The menopausal transition 
is associated with distressing physical symptoms and can be associated with first onset of 
depressive symptoms. The burden of these conditions on the individual experiencing 
them, her family and friends and society as a whole can be significant.  
 
Osteopathy, as practiced in Australia may seem to be an unlikely source of management 
and support for menopausal women who are experiencing depression. However, the 
majority of patients that osteopaths treat are women.6  As the number of women within the 
menopausal age range increases, it is reasonable to expect that the number of 
menopausal women being treated by osteopaths will also increase; especially when some 
of the main symptoms reportedly experienced by menopausal women are associated with 
the musculoskeletal system.7  Osteopathy has a history of treating depressive symptoms, 
although there is very little current research to support the efficacy of osteopathic 
management for depressive symptoms.8,9,10 
 
This project aims to add to the current literature that investigates osteopathic manipulative 
treatment’s (OMT) role in providing adjunctive management of depression in menopausal 
women. It also explores whether there are consistent osteopathic findings that may 
provide the basis for osteopathic management of depression in menopausal women. It 
briefly explores whether there is a perceived awareness and acceptance of OMT as an 
adjunct to standard management of depression in menopausal women by the women who 
participated in the project. 
 
Within this chapter a brief look at the menopausal transition and depression will be 
presented highlighting the challenges these conditions have on individuals and the health 
care system and how they are managed.  
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Menopausal Transition 
i. Definition and Phases of the Menopausal Transition 
There are a number of terms used to refer to the final phase in a female’s reproductive life 
including peri-menopause, menopausal transition, and climacteric.11 Inconsistency in the 
use of the various terms used in the scientific literature can make it difficult to compare 
the material published in relation to the menopausal transition.  In order to bring a 
common usage of terms, the World Health Organization (WHO)12 defined the phases in 
their report published in 1996.  Figure 1 shows a pictorial representation of the phases 
defined as follows: 
 
 
Natural menopause: “the permanent cessation of menstruation resulting from the 
loss of ovarian follicular activity.”  It is recognised after twelve month time span of 
amenorrhoea “for which there is no other obvious pathological or physiological 
cause.”12, p 12-13  
 
 
Peri-menopause:  “should include the period immediately prior to the menopause 
(when the endocrinological, biological and clinical features of approaching 
menopause commence) and the first year after menopause.”  WHO recommended 
that the term ‘climacteric’ be replaced with the term peri-menopause.12, p 13 
  
 
Menopausal transition:  “reserved for that period of time before the FMP [final 
menstrual period] when variability in the menstrual cycle is usually  
increased.”12, p 13  (This term differs from peri-menopause as it does not include the 
first year after menopause.) 
 
Post menopause:  “dating from the FMP regardless of whether the menopause 
was induced or spontaneous.”12, p 13  
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Figure 1: Stages of the final phase of a woman’s reproductive cycle.  (FMP= final menstrual 
period) 
 
Despite clarity in these definitions, terms associated with menopause are still being used 
with some inconsistency. For example, the term ‘climacteric’ is still being used within the 
context of the menopausal transition. Grochans et al,13, p 125   define climacteric as the 
“transitional period, starting several years before and ending a few years after 
menopause”. Kirchengast14, p 147 uses the term “climacteric syndrome” to represent the 
symptoms that are associated with peri and post menopause (using WHO definitions as 
above). Hale11, p8   states that the term “menopausal transition” is now more commonly 
used, in a scientific context, than either “peri-menopause’ or ‘climacteric’ when referring to 
the menopausal phase. Therefore in this thesis the term “menopausal transition” will be 
used to cover the peri- and post-menopausal phases. 
 
The staging system is one method for determining the current phase of the menopausal 
transition a woman is experiencing. The value of the staging system can be associated 
with the ability to determine the probable cause of symptoms that are commonly 
associated with the menopausal transition. The Stages of Reproductive Aging Workshop 
(STRAW)15 proposed a classification system that looked at the various stages of a 
female’s reproductive life. The stage relevant to this project is the menopausal transition, 
which has two stages: -2 or early and -1 or late. Stage -2 is associated with a menstrual 
cycle that has a variable length. The variation is defined as seven days, or greater, 
difference from the normal length of the females normal cycle. Stage -1 is associated with 
two or more missed or skipped cycles and an interval of amenorrhea of 60 days or 
more.11, p 8  The STRAW staging system was used in the project as part of the Screening 
Interview to determine the menopausal status of each potential participant. 
 
12 months  
after FMP 
FMP 
Changes in menstrual 
cycle commence 
Menopausal transition 
Peri-menopause 
menopause 
Post menopause 
Climacteric 
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ii. Menopausal Epidemiology and Symptoms 
Menopausal transition symptoms can occur for a period of over six years. Peri-
menopause can last for up to ten years,16, p 54 with the average duration being three to four 
years. It is associated with changes in hormonal production levels and a decreased 
receptivity of the ovaries to hormonal stimulation.  Natural menopause occurs, for the 
majority of women, between the ages 48 - 52, with the average being 51.2.13, p125 Post-
menopause can be associated with continued fluctuation of circulating hormonal levels 
and similar symptoms to those which occur in the peri-menopausal phase for at least a 
further three years.13  
 
During the menopausal transition, up to 80% of women will experience one or more 
symptoms that are typically reported during this phase of a woman’s life.17,18,19,20   In 2011, 
approximately 2.1 million women in Australia were within the age range commonly 
associated with the menopausal transition (45-60 years) and it is projected from these 
figures that within ten years, this figure will increase to 2.4 million women.5  These figures 
suggest that over 1.5 million women in Australia are experiencing symptoms associated 
with the menopausal transition.  
 
In an American study 60% of women experiencing menopausal transition symptoms 
reported that they sought health care assistance for menopausal symptoms.21 In a study 
conducted by Gutherie et al,22  the rate and timing of women seeking medical 
consultations for menopausal transition symptoms was investigated. The study was 
conducted over a nine year period and was completed by 387 women. The study found 
that 86% of these women sought medical assistance. Annually, nearly one-third of the 
women sought medical assistance in response to menopausal transition symptoms. 
Women who experienced mood or vasomotor symptoms (hot flushes and night sweats) 
sought medical assistance more frequently.  
 
Symptoms and adverse health effects associated with peri-menopause include:  
 
a. vasomotor symptoms of hot flushes and night sweats associated with 
thermoregulatory disturbances. Hot flushes are experienced through the day and are 
associated with perspiration (that can often be severe), feeling of heat rising from the 
chest up into the neck and head, flushing and heart palpitations.12   Night sweats are hot 
flushes that occur at night and can lead to sleep disturbances.  
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b. urogenital atrophy and vaginal dryness. The changes within the vaginal mucosa 
associated with a decrease in estrogens can also lead to dyspareunia (painful 
intercourse). A decreased interest in sex may also occur.12,23   
 
c. increased risk of osteoporosis which is associated with an increased risk of bone 
fractures. Muscular aches and pains may also occur.  
 
d. mood swings, anxiety and depression. 
 
e. cognitive impairment, difficulty concentrating, tiredness, sleep disturbance. 
 
With the increased number of women likely to experience symptoms associated with 
menopausal transition, there is likely to be an increased demand on health services to 
assist in reducing the impact of these symptoms on women’s day-to-day life. Having an 
understanding of the frequency and severity of these symptoms may assist in determining 
how best to manage these symptoms.12 
 
Brown et al,16 in 2002, utilized data from the Australian Longitudinal Study on Women’s 
Health (ALSWH) to study symptoms experienced by peri-menopausal women.  Two 
surveys were conducted in 1996 and 1998 and 8,236 of the responses were used. The 
most frequently reported symptoms related to headaches/migraines (56%), severe 
tiredness (52%), stiff or painful joints (54%), back pain (55 %), hot flushes (44%) and 
night sweats (33%) (the vasomotor symptoms combined represent 77%). This study did 
not look at mood changes, irritability or reduced sex drive.  
 
Brown et al,16 indicated that pre-menopausal women also reported symptoms such as 
headaches, back pain, stiff joints, tiredness and difficulty sleeping. These symptoms were 
reported less frequently by pre-menopausal women than women who were classified as 
peri- or post-menopausal. Vasomotor symptoms were reported more frequently by peri- 
(73%) or post-(94%) menopausal women than premenstrual (28%) women. As the study 
was based on self-reported responses to a questionnaire, no data is available to 
determine the cause of the vasomotor symptoms experienced by the pre-menopausal 
women.  The classification of menopausal status of the women who participated in this 
study was based on self-reported menstrual bleeding.  This may lead to some women 
who are early peri-menopausal to incorrectly record their menopausal status. 
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Warren18 calls the non-vasomotor symptoms, such as mood changes, sleep disturbances 
and somatic complaints, “the ‘missed symptoms’ of menopause” because they had 
received less attention than the vasomotor symptoms. He notes that in three different 
studies, at least one of the non-vasomotor symptoms, or ‘missed symptoms’, was more 
prevalent than the vasomotor symptoms of hot flushes and night sweats. In Australia 
somatic symptoms were the most commonly reported menopausal symptom. The somatic 
symptoms (stiff or painful joints, back pain, and headaches/migraines) are the reason why 
peri-menopausal women may present to an osteopath for treatment in Australia. 
 
A recent study that may explain the presence of musculoskeletal symptoms demonstrated 
that there is a relationship between menopausal symptoms and muscle strength and 
quality. Lee and Lee24 measured the handgrip strength of 148 healthy, peri- and post-
menopausal women between the ages of 45 and 65. The Kupperman Index was used to 
measure the severity of the menopausal symptoms. The results showed that self-reported 
severe menopausal symptoms were significantly related to reduced muscle strength, 
even when adjusting for confounding factors (age, body mass index (BMI), smoking, 
alcohol, regular exercise, menopausal status, fasting insulin, total cholesterol, 
triglycerides and hs-CRP(a cardiac risk marker)). They presented the theory that declining 
sex hormones (estrogen, testosterone and DHEA-s) may have a significant role because 
sex hormones play a major role in the cause of sarcopenia (loss of muscle mass and 
function associated with aging). 
 
In 2003, Mishra and Lee,25  analysing data from the Australian Longitudinal Study on 
Women’s Health (ALSWH) confirmed these figures and noted that somatic symptoms 
such as low back pain and stiff or painful joints were more frequently reported (55% and 
54% respectively) than hot flushes (44%) and night sweats (33%). They also noted that 
women born in different countries experienced the menopausal transition differently. For 
example, women born in Asian countries had a shorter menopausal transition and this 
may account for Asian women reporting symptoms at a lower rate than women who were 
born in other countries. However, when comparing symptoms reported in regard to the 
stage of the menopausal transition, there was no significant difference in the prevalence 
of the symptoms reported between women born in different countries.   
 
The vasomotor and vaginal symptoms listed above have a direct link to the menopausal 
transition and changes in hormonal levels that occur during the menopausal transition. 
The other symptoms (anxiety, depression, sleep disturbances and muscular aches and 
pains) may be associated with factors other than the menopausal transition. These factors 
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may include the level of education, interpersonal stress, lifestyle behaviours, economic 
status and current health status.16,26  Duffy et al,23  for example noted that hot flushes 
were associated with low education, obesity, and low social support. In contrast, 
symptoms associated with vaginal dryness were associated with high education and high 
levels of social support.  
 
iii. Standard Management of Menopausal Transition Symptoms 
Hormonal replacement therapy (HRT) is considered the standard and most effective form 
of treatment for all of the symptoms of the menopausal transition.18  MacLennan et al.,27  
in a Cochrane Review of the effectiveness of HRT compared to a placebo, stated there 
was a significant reduction in the severity of symptoms experienced when using HRT 
compared with those placed on the  placebo. The women using the HRT reported a 
reduction in symptoms of 75% compared with a reduction of 57.7% in symptoms reported 
by the women using the placebo. Adverse events that led to a withdrawal from the trials 
included: breast tenderness, oedema, joint pain and psychological symptoms. Although a 
higher incidence of adverse reactions was reported by women using the HRT, the 
withdrawal rate of these women was not statistically different from the withdrawal rate of 
the women using the placebo. The review concluded that HRT was highly effective in 
alleviating hot flushes and night sweats. 
 
Before 2002 studies showed that HRT, taken long-term, reduced the risk of 
cardiovascular disease and fracture risk, however, increased the risk of breast cancer and 
thromboembolism. In 2002 the results of the Women’s Health Initiative (WHI), a long-
term, randomised controlled trial of HRT, confirmed there was a reduced risk of fracture 
however, they found there was no overall cardiovascular benefit and that an increased 
risk of breast cancer and thromboembolism existed.28 This led to a reduction of up to two-
thirds of the usage and prescription of HRT for menopausal symptoms.29 
 
MacLennan29 reviewed the literature again and published his results in 2007. The trials 
published after 2002 indicated that the side effects or risks associated with HRT could be 
decreased if HRT use was commenced during late peri-menopause, using lower HRT 
dosages with a non-oral application and reducing the progestogens. These studies 
indicated that with these changes the benefits outweighed the risks previously identified. 
This may see an increase in the use of HRT for menopausal symptoms. 
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With the decrease in usage of HRT since 2002 other forms of management were sought. 
The prescription of anti-depressants (selective serotonin reuptake inhibitors (SSRIs) and 
serotonin-noradenaline reuptake inhibitors (SNRIs)), has been identified as the second 
most successful management for relieving menopausal symptoms for women with 
contraindications to the use of HRT.18,30  Warren,18 in his literature review, stated that 
antidepressants have been found to significantly reduce the frequency and severity of hot 
flushes. A study by Barton et al,31 demonstrates that SNRIs improved hot flushes in 60% 
of women and other studies have shown similar results for SSRIs and SNRIs.27,32 Studies 
where antidepressants have been used to improve hot flushes, have also shown an 
improvement in mood and sleep disturbance. Few of the studies, however, showed a 
significant improvement when compared to the placebos used.   
 
Phytoestrogens and black cohosh, both derived from plants, have been trialled in the 
management of menopausal symptoms, however, at this stage there is little data to 
suggest either have a significant therapeutic effect.18  
 
Little literature is available on the osteopathic management of menopausal symptoms. 
Three studies have been located that suggest that OMT may have a role in the 
management of the symptoms, however, all recommend that further study is required. A 
more comprehensive presentation of these studies will be provided in the next 
chapter.33,34,35  
 
With the risks associated with HRT and no pharmaceutical management being totally 
effective in reducing the symptoms of the menopausal transition there is a place for the 
use of multi-discipline management of menopausal symptoms. The improvements in 
symptoms shown in the pilot osteopathic trials suggest that OMT may be a useful adjunct 
to the pharmaceutical management of menopausal symptoms.  
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Depression 
Depression is one of the symptoms that menopausal women may experience and may be 
somewhat overlooked due to the presence of hot flushes and night sweats.18   With the 
comorbidity of somatic symptoms (back pain, joint stiffness, etc), depression and 
menopausal symptoms, understanding the presentation of depression within this group of 
women is important for osteopaths to ensure that appropriate management strategies can 
be determined. The following summary of the literature provides an insight into the 
prevalence of depression, its effect on the individual and the community and current 
management strategies. 
 
Depression has become a national priority within the health care plan for Australia due to 
the impact that depression has on an individual and their family, and productivity at work.1 
Depression can be experienced for the first time during the menopausal transition and 
contributes to this burden.36  
 
i. Definition 
Depression is a complex condition that can last for short or prolonged periods of time. The 
International Classification of Diseases (ICD-10) outlines the criteria for depression.37  The 
ICD-10 categorises depressive episodes as severe, moderate or mild and are based on 
the number of symptoms a person experiences within a two week, or more, period of 
time. The symptoms associated with depression include: 
 
• Depressed mood; 
• Loss of interest in activities  
• Lack of energy or increased fatigue 
• Loss of confidence or self esteem 
• Feelings of self-reproach or excessive guilt 
• Thoughts of death or suicide, or suicide attempts 
• Diminished ability to concentrate, think or make decisions 
• Change in psychomotor activity; agitation or retardation 
• Sleep disturbance or 
• Change in appetite. 
 
Severe depressive episodes involve the first three symptoms and at least five other of the 
listed symptoms. A moderate depressive episode must have two of the first three 
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symptoms plus other symptoms so that a total of six or more symptoms are experienced. 
A mild depressive episode requires two of the first three symptoms be present and 
additional symptoms from the list so that a total of at least four are experienced.37  
 
The level of depression experienced by an individual can be measured reliably through 
self-reported scales. The Depression Anxiety and Stress Scale (DASS) is such a scale, 
and is used to determine the level of depression experienced over a period of time. The 
DASS has been widely used. For example, Hallam, Smith and Berk38  in a study of 106 
patients with unipolar or bipolar depression used the DASS as an instrument to measure 
the effectiveness of electroconvulsive therapy on depression.   Taylor, Lovibond, 
Nicholas, Cayley and Wilson,39  also utilized the DASS in their research investigating 
depression in chronic pain patients. Taylor et al, administered the DASS to 398  
individuals with chronic pain, 323 psychology clinic patients and 491 people from the 
general population. Crawford and Henry2  concluded that the DASS was a reliable and 
valid measure of depression, anxiety and stress. The reliability and validity of the DASS 
will be discussed in Chapter 4 of this thesis. 
 
ii. Epidemiology of depression 
Worldwide depression impacts on both the person experiencing depression and society 
as a whole. Ustan et al,40  state that in 2000, unipolar depressive disorders were the 
fourth leading cause of burden on health services of all diseases worldwide. This burden 
is “based on years of life lost from premature death and years of life lived in less than full 
health” and is the disability-adjusted life year (DALY).41, p2  This places depression in the 
same range as ischaemic heart disease and the combined impact of asthma and chronic 
obstructive pulmonary disease’s burden on the health services and societies of the 
world.42   People experiencing depression make up almost 12% of all total years lived with 
disability worldwide.  
 
In Australia today, depression represents the leading cause of non-fatal disability and it is 
estimated that depression will be the second leading cause of disability and death in 
Australia within 20 years.43,44 These figures are supported by Malhi et al,45  in their article 
discussing recommendations for the management of depression. Malhi states that 
depression is likely to be experienced by women 1.5 to 3 times more frequently than by 
men. These figures are supported by the figures collected by the Australian Bureau of 
Statistics where 7% of Australian women reported experiencing depression compared 
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with 5% of Australian men. Women in the menopausal age range, represent the fourth 
highest category of people reporting mental health disorders in Australia.46  
  
In 2008-2009, depression represented 34.3% of all mental-health related issues managed 
within the Australian health system. This accounts for 2.8% of all health related issues 
managed during 2008-2009.43  In 2009-10, 20% of hospitalisations for mental health 
issues were for people diagnosed with a depressive episode and mood disorders 
accounted for 17% of emergency care services associated with mental health.47  It is 
estimated that less than 50% of Australians experiencing depression are currently 
receiving medical care.44 These figures demonstrate how pervasive mental health issues 
are within Australia and why depression is a National Health Priority.48  
 
Depression, as previously stated, affects not only the person experiencing it, but also their 
spouse and family. Krantz and Moos49 studied the impact on the spouse and family of 
people suffering from depression. The study included 118 people who sought treatment 
for depression. Their findings were matched with a control group of people from similar 
locations and economic status who did not suffer from depression. The study showed that 
the spouses of the depressed patient reported more social and family problems over a 
period of twelve months than those in the control group. The divorce rate was higher in 
those persons whose depression did not change over the twelve month period than in the 
control group.  
 
Dudek et al,50 confirm the difficulties experienced by spouses of depressed patients. 
Spouses of depressed patients may be forced to take on more responsibilities, change 
occupations, seek additional sources of income and find they are making the decisions in 
major life events on their own. The stress this places on the spouse often leads to 
physical and psychological symptoms and then the spouse requires support and 
management of the health services. These studies provide an insight into the difficulties 
experienced by all people affected by depression and the increased level of demand on 
health and social services that is likely to occur.   
 
The impact on the health system and society is increased due to the occurrence of 
comorbidity (when more than one condition is present at the same time) for those 
experiencing depression. Between 33-66% of people with depression may also 
experience another form of mental illness such as anxiety, panic disorders and post-
traumatic stress disorder.51  The Australian Bureau of Statistics’ Year Book Australia, 
2012, showed that people suffering a mix of depression and anxiety accounted for 39% of 
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people with a mental health issue. Of the people suffering from a mood disorder, 64% 
also experienced a physical condition.52 Physical illnesses, especially those of a chronic 
nature or associated with pain, form the other comorbid conditions. Depression may occur 
after the physical condition has been present for a length of time or may contribute to the 
onset of a physical condition.51     Vyas et al,53  state it has been well documented that 
chronic conditions such as heart disease, hypertension, diabetes, chronic obstructive 
pulmonary disease, asthma and musculoskeletal diseases have a high prevalence of 
depression. Women within the menopausal transition are at a higher risk of experiencing 
heart disease, hypertension, and diabetes than premenopausal women.19  
 
Furthermore, depression is a risk factor in the development of osteoporosis. Eskandari et 
al,54  conducted a study between 2001 and 2003 of 89 premenopausal women with major 
depressive disorder (MDD) to determine if there was an increased prevalence toward low 
bone mineral density (BMD) compared to 44 healthy premenopausal women. One in five 
of the women with MDD had low BMD and that this deficit was of clinical significance; at 
least 2% less when compared to the control group. The differences observed were similar 
to those that occur with other risk factors associated with osteoporotic fractures, such as 
cigarette smoking, lack of exercise and absence of calcium supplement. This placed 
depressed women at an increased risk of osteoporotic fractures after menopause.  
 
A meta-analysis conducted by Yirmiya55  lends further support to the contention of the 
increased risk of osteoporosis in depressed persons. Yirmiyga’s study demonstrated that 
depressed individuals had lower bone mineral density than non-depressed individuals.55  
Cizza et al,56 attributed this to changes in the immune and endocrine systems that 
coincide with life style changes.  However, Kavuncu et al,57  in their study of 42 female 
patients with mild depression determined that a low BMD was not a prominent feature 
when compared to 42 healthy females. They did state that an increase in bone resorption 
was found in females with mild depression as compared to the control group. Women in 
the menopausal transition are more prone to suffer osteoporosis due to the reduction in 
estrogen.  
 
iii. Depression associated with the menopausal transition 
The menopausal transition occurs at stage in women’s lives that is often associated with 
changes within their family structure, social situation, work, economic status and health. 
These changes can be stressors that appear to increase mood disorders, such as 
depression. The physical symptoms associated with the menopausal transition, such as 
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hot flushes and night sweats, are directly related to the depressive symptoms; 
depression, in turn, may increase the occurrence and severity of the physical symptoms.58   
Grochans et al,13  state that approximately 90% of women suffer a wide range of mental 
health related symptoms during the menopausal transition. The symptoms can include 
sudden mood changes, difficulty dealing with day-to-day stressors, fatigue, nervousness, 
irritability, poor concentration, impairment of memory, and clinical depression. 
 
Cohen and colleagues found that peri-menopausal women with no prior history of 
depression have a significant risk of experiencing new onset depression or depressed 
mood.36  Cohen et al, used data collected from the Harvard Study of Moods and Cycles to 
study the onset of depressive symptoms in 460 women. The women were interviewed 
over a 36 month period, with interviews conducted every six months. Of these women 134 
remained premenopausal and 326 transitioned into a peri-menopausal status. Twice as 
many of the peri-menopausal women developed depression compared with those who 
remained premenopausal. Vasomotor symptoms appeared to increase the risk of 
depression occurring, as did the occurrence of major life events. This study compared the 
distribution of ages, education, parity and prior use of oral contraceptives between those 
women who transitioned to peri-menopause during the study and those who did not. 
Logistic regression models were used to control the differences in age between the two 
groups. 
 
Freeman et al, found a 2.5 times greater chance of women being diagnosed with a 
depressive disorder during the menopausal transition compared to premenopausal 
women.59  This study analysed the data obtained in the Penn Ovarian Aging Study 
(Pennsylvania, USA) of 231 women. The women included in the study had no history of 
being diagnosed with depression at the beginning of the study and were premenopausal. 
The study was conducted over an eight year period of time; data was collected at eight 
month intervals for the first six collections, and then at yearly intervals. Hot flushes, higher 
body mass index, smoking, PMS, employment and marital status were significant factors 
in the severity of the depression. Freeman et al state that the age of the participant was 
not a significant predictor for the onset of depression “in part because the cohort was 
balanced for age, observation time was constant, and the women were equally likely to 
have onset of depressed mood at any time.” 
 
In an Australian study of 500 women, it was demonstrated that peri-menopausal women 
showed a higher score relating to depression than women in the post-menopausal phase 
or those having had artificially induced menopause.60 These figures support the presence 
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of depression in peri-menopausal women and the need to ensure that depression is well 
managed within this group of women. 
 
Depression in peri-menopausal women is associated with impaired functioning in 
activities of daily living and their role in society. Bromberger and Lanzadi Scalea61 
reviewed 14 articles on the relationship between menopausal status and impaired 
functioning and found that eight of the reported studies showed depression was 
significantly linked with some level of impaired functioning. However, none of the studies 
measured the level of depression being experienced at follow-up. This makes it difficult to 
determine if the impaired functioning was due solely to depression or if other factors may 
have confounded the results. The impaired functioning was assessed as either activities 
of daily living and physical functioning or psychosocial and role functioning. One of the 
studies reviewed indicated that an improvement in functioning and physical health 
occurred with an improvement of depressive symptoms.  
 
Depression increases the risk of co-morbidities.36,55,56  Comorbidities, as previously stated 
can include: low back pain, joint stiffness, and cardiovascular disease. Another condition 
associated with peri-menopause include an increased risk of osteoporosis and 
osteoporotic fractures due to these women having several of the risk factors: age, female 
gender, and, estrogen deficiency.55  As previously stated, depression also increases the 
risk of osteoporosis.  These associated co-morbidities may well be the reason depressed 
peri-menopausal women present for OMT. Recognition that depression may be a 
component of the presenting symptoms by osteopathic practitioners is important in 
ensuring appropriate care can be provided. The standard management of depression will 
be discussed briefly. 
 
iv. Standard management of depression  
The most common management for depression in Australia today is the prescription of 
medications, followed by counselling.47  However, in recent years the percentage of 
referrals to psychologists by general practitioners, as part of their patient’s management 
plan, has shown an increasing trend, possibly due to the introduction of the Better Access 
to Mental Health Care Initiative.43   
 
Worsely et al,62  in their review article state selective serotonin reuptake inhibitor (SSRI) 
are the first choice of pharmacological management of depressive symptoms. Of those 
taking SSRIs, 50% only partially respond or fail to respond. There is also a high rate of 
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people discontinuing the SSRIs with 42.4% ceasing within the first month and a further 
30% within three months. There are also known adverse side effects from using SSRIs. 
These include decreased bone mineral density and sexual dysfunctions, both of which 
peri-menopausal women are at an increased risk of experiencing. Both of these 
conditions are associated with a lower quality of life, depressed mood and relationship 
difficulties. Worsely goes on to state that there is a need for adjunctive and alternative 
treatments for peri-menopausal women.62 
 
In a meta-analysis on the outcome of collaborative care for the management of 
depression in the USA it was found that collaborative care outcomes at six months, 
compared to standard care, showed an improvement. The outcomes were based on 
depression outcomes date and antidepressant medication compliance. Collaborative care 
compared to standard care had a positive effect on the standardised depression 
outcomes (standardized mean difference, 0.25; 95% confidence interval, 0.18-0.32). The 
collaborative care that was most common involved some form of case management that 
encouraged compliance in taking the medication supplied. A recommendation further 
research into collaborative care for the management of depression was made.63  
 
One counselling approach that is used to treat depression is cognitive behavioural 
therapy (CBT). CBT has been shown to be effective in the treatment of depression as well 
as depression associated with a con-current medical condition.64,65,66   Research on the 
efficacy of CBT for the management of menopausal symptoms, including both 
psychological and physical symptoms, is emerging. 67,68,69,70,71  The research looks at both 
group and individual CBT management for depressive symptoms in menopausal women.   
Kooshbooii69 studied 64 women who were randomly allocated to a group CBT program, 
individual CBT program or no CBT (control group). Their results showed a statistically 
significant improvement in depression in the two intervention groups compared to the 
control group. There was, however, no significant difference in the depression scores 
when comparing the group to the individual CBT program.  
 
Although current management of depression is better than no treatment at all, there are 
still people who remain unresponsive to treatment or who are unable to utilise current 
treatments available.   To support these people, other effect forms of management are 
required. The next chapter outlines what is known of OMT management of depression 
and peri-menopausal symptoms.  
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Chapter 2  Osteopathic Treatment of Menopausal Transition Symptoms and 
Depression 
This chapter provides an overview of osteopathy and reviews the literature that covers 
OMT management of menopausal symptoms and depression. The literature available is 
not extensive highlighting the potential for further research to determine the effectiveness 
of OMT in the treatment and role in managing depression in menopausal women. 
 
i. What is Osteopathy? 
Although osteopaths have been practicing in Australia for over one hundred years, 
osteopathy is still not as well known as similar professions such as physiotherapy and 
chiropractic. For those aware of osteopathy, depressive and menopausal symptoms may 
not be conditions perceived to fall within an osteopath’s scope of practice. An insight into 
the origin of osteopathy, the principles upon which it is based and techniques used within 
osteopathic consultations is deemed appropriate to set the scene for this project.  
 
In Australia osteopathy is a form of manual therapy largely focused on restoring normal 
function to the body via the musculoskeletal system. It is based on osteopathic philosophy 
which the Glossary of Osteopathic Terminology states as follows: 
 
“a concept of health care supported by expanding scientific knowledge that 
embraces the concept of the unity of the living organism’s structure (anatomy) and 
function (physiology). Osteopathic philosophy emphasizes the following principles: 
1. The human being is a dynamic unit of function. 2. The body possess self-
regulatory mechanisms that are self-healing in nature. 3. Structure and function 
are interrelated at all levels. 4. Rational treatment is based on these principles.”72, p 
1242  
 
These four fundamental principles are a synthesis of the founder of osteopathy, Dr 
Andrew Taylor Still’s philosophy of osteopathy. Dr Still developed the practice of 
osteopathy in the 1860’s as an alternative to the medical practices of that time. His 
experience of the medical practices used in the 1800’s highlighted the deficiencies in the 
medical system, as death was a common outcome. He believed there had to be a better 
way to assist people in restoring health so he undertook the study of the human body and 
physiology and found that working via the musculoskeletal system to create changes in 
the patient’s body led to an improvement in the outcome of medical conditions 
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experienced by his patient’s. An example of the success of his new system of health care 
can be seen in the management of the 1918 flu pandemic. During this pandemic, 650,000 
people within America died and worldwide this figure was as large as 40 million.  This was 
an era before antibiotics were available and many people died of complications such as 
pneumonia. Osteopathic management for these patients included: manipulative 
treatment, isolation, hygiene and fluid intake. Medical treatment was largely dependent on 
calomel (containing mercury) and strychnine. Of those receiving medical care 25-60% of 
patients who developed pneumonia died and of those patients with pure influenza 5-15% 
died. Patients receiving care from osteopaths had a death rate of 10.1% and 0.2% 
respectively.73   
 
Although there is a current debate as to whether these principles are still relevant in 
current clinical practice,74,75,76  the principles support an osteopath in managing conditions 
that go beyond those perceived to be related to the musculoskeletal system, as they form 
a part of their clinical reasoning. It is interesting to note that these principles share 
similarities to those of the biopsychosocial model developed by Engel in 1977.77 
Williams78 discusses the psychological benefits from receiving OMT. He notes that the 
thorough physical examination and length of consultation allowed for a good rapport to 
develop between the osteopath and the patient and this was associated with a positive 
approach, removal of fear and improved understanding.  
 
The first osteopaths to practice in Australia, at the beginning of the 1900s, completed their 
training in America where they had equivalent practicing rights as medical practitioners. 
However, their scope of practice was limited in Australia as the Australian Medical 
Association and regulatory bodies at that time did not acknowledge their qualifications as 
being equivalent to Australian medical practitioners. This led osteopaths to limit their 
practice to osteopathic manipulative treatment (OMT), a ‘therapeutic application of 
manually guided forces….to improve physiologic function and/or support homeostasis that 
has been altered by somatic dysfunction’.72, p 1240  OMT is the form of osteopathy still 
practiced in Australia today and osteopaths are largely perceived to mainly treat muscular 
or joint problems. This perception is supported by a study undertaken by Burke6  who 
found that the majority of patients consulting osteopaths present with acute or sub-acute 
musculoskeletal problems. 
 
In Australia, osteopaths are university trained primary practitioners. National registration 
with the Osteopathy Board of Australia is required to practice osteopathy in all states of 
Australia. An osteopaths’ training allows them to recognise conditions that may be treated 
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osteopathically and those that require referral to a medical practitioner or other health 
discipline. They utilise a wide range of techniques that range from the obvious direct 
techniques to very subtle indirect techniques. A definition and description of these 
techniques is available in the Appendix 1. 
 
This broad range of techniques, coupled with the osteopathic principles, enables the 
osteopath to treat a variety of conditions and people all ages. Some of the conditions that 
research has shown osteopathy may have a role in assisting, outside the musculoskeletal 
conditions, include: psychological conditions, immune system disturbances,  pneumonia,  
dysmenorrhea,  constipation, otitis media, vertigo, chronic obstructive pulmonary  
disease, irritable bowel disease, depression, fever, chronic prostatitis, cough,  
tinnitus, asthma, kidney mobility changes, hypertension, chronic fatigue  and 
childbirth.79,80,81,82,83,84,85,86,87,88         
 
Osteopathy in America has had a long history of research and the early results of this 
research were largely published in osteopathic publications. This meant that most of this 
research was not viewed by non-osteopathic practitioners and was not widely 
acknowledged. Current research demonstrating the efficacy of OMT in assisting in the 
management of conditions outside of the musculoskeletal system is growing, with 
contributions from osteopaths in many countries around the world. 79,80,81,82,83,84,85,86,87,88,89 
 
OMT has been shown to have a positive impact on the quality of life of patients who 
consult osteopaths. A study conducted in Central and Southern Italy demonstrated that 
OMT had significantly improved quality of life after one month of treatment.89  The study, 
involving 988 osteopathic patients, utilized the SF-36v2 Health Survey, which identifies 
both physical and mental aspects associated with quality of life. The SF-36 was 
completed pre and post the four osteopathic consultations. The mean SF-36 score after 
the four OMT consultations was 11.6 points higher (95%Cl  9.7-13.4) than the score prior 
to commencement of treatment. The effect sizes for the mental and physical components 
of the SF-36 were similar (standardized effect size 0.77, 0.67-0.87). The authors state 
that confounders were controlled for during this time, although they do not specify how 
this was done. The study was not blinded and the authors acknowledged that there was 
the potential for spontaneous improvement or other factors not recorded. 
 
A study researching the efficacy of OMT and chronic low back pain, also measured the 
influence of OMT on quality of life on these patients. The study measured changes in 
quality of life using the SF-36 Health Survey. The study showed a significant improvement 
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in mental health within the intervention group compared to those in the no-intervention 
control group at 1 month (p = 0.4).90            
 
The ability of OMT to improve quality of life for other conditions, such as constipation and 
primary dysmenorrhoea, has also been researched.83,86 In both of these studies, the 
quality of life was significantly improved. Brugman et al’s83 study of the effect of 
osteopathic treatment on chronic constipation also measured the effect on quality of life 
using the patient assessment of constipation quality of life (PAC-QOL) and found a 
statistically significant improvement (-0.93, d = 2.95, p<0.001). Schwerla et al’s86 study on 
the effects of osteopathic treatment on primary dysmenorrhoea measured the effect on 
quality of life via the Short-form 36 Health Status Questionnaire (SF-36). A change in the 
mean physical component score of the SF-36 showed a positive impact for the 
intervention group with a meand difference of changes 6.2, 95%Cl 1.2 to 11.1, p = .015. 
The ability of OMT to improve the quality of life in patients lends support for the potential 
that OMT may be suitable in assisting depression in menopausal women. The limited 
number of research performed in this area provides room for further research to be 
conducted on the ability of OMT to positively  influence quality of life. 
 
ii. Osteopathic Treatment of Menopausal Transition Symptoms 
There is little literature published on the efficacy of OMT for menopausal symptoms, 
beyond two unpublished dissertations. Only one published study discusses osteopathic 
treatment of menopausal symptoms. Cleary and Fox,91  published the findings of their 
1991-2 study of 30 women between the ages of 50 and 60 who experienced menopausal 
symptoms. Half of the participants received osteopathic treatment while the control group 
received a placebo or sham treatment. The sham treatment varied from the intervention 
by applying the force to a joint adjacent to the joint diagnosed to be restricted, instead of 
the restricted joint. Participants filled out a questionnaire on their symptoms prior to 
commencing the trial, at each OMT consultation and at the follow-up; a total of twelve 
questionnaires were completed. Blood levels of 11 hormones were measured prior to 
commencing the trial and at weeks 5 and 15 of the trial. (Hormones measured included: 
oestradiol, follicle stimulating hormone, luteinizing hormone, thyroxine, testosterone, sex 
hormone binding globulin, prolactin, cortisol, IGF/1, thyroid stimulating hormone, and 
growth hormone.) Each participant attend an OMT consultation weekly for ten weeks and 
then a follow-up five weeks later.   
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Results showed that the intervention group had a much greater reduction in menopausal 
symptoms for hot flushes (p = 0.016), night sweats (p = 0.021), urinary frequency (p = 
0.021), and depression (p = 0.042) than the control group between weeks one and ten of 
the trial. When comparing symptoms reported, by the two groups, between weeks one 
and fifteen, urinary frequency (p = 0.168) and depression (p = 0.290) showed no 
significant difference. All other measures recorded between week 1 and 15 showed 
similar reductions in menopausal symptoms to those recorded between weeks one and 
ten. Of the blood hormonal levels, only testosterone showed a significant difference (p = 
0.028) with the intervention groups testosterone levels dropping. Measures for changes in 
neck and back pain took an average of five weeks to show a reduction in the intervention 
group. The reduction of back pain and neck pain was greater in the intervention group (p 
= 0.04 and p=0.06 respectively).     
 
Although this study showed an improvement in the intervention group there are limitations 
in relation to the study. One is the lack of identification of the questionnaires used for 
menopausal symptoms and neck and back pain. No reliability or validation of the 
questionnaires is possible. The other major limitation is the technique used for the 
intervention group. The authors named the technique as Fox’s technique and stated it 
was developed by Fox. Although a description was given, it is not a technique that is 
commonly known or utilised within the osteopathic profession, nor could it readily be 
reproduced from the information provided. 
 
An unpublished dissertation, by Mueckler,92 describes a study she conducted of 13 peri-
menopausal women, aged between 44 and 53. The study’s goal was to determine if OMT 
has a beneficial effect on symptoms experienced by peri-menopausal women. The 
women were monitored for six weeks without OMT and this acted as the control. At the 
end of the six week period the women attended their first of two osteopathic consultations 
and treatment. A second OMT consultation occurred three weeks later, with a final 
collection of data occurring after a further three weeks. The study used the SF-36 to 
monitor changes in quality of life and the menopause rating scale (MRS II) self-evaluation 
instrument to monitor changes in menopausal complaints. 
 
Mueckler stated that the women’s health perception improved, however the areas of 
improvement were different for each individual woman. Overall, the MRS II scores 
indicated that during the control period psychological complaints increased a small 
amount (+2.4 points) and during the treatment period they decreased significantly (-12 
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points). The genital and somato-autonomic troubles declined during the control period and 
either slightly decreased or remained the same during the treatment period. 
 
The SF-36 scores showed an improvement during the control and treatment periods for 
all measures except the mental health and social competence scores. These decreased  
(-2.8 and  -7.7 respectively) during the control period and increased during the treatment 
period (+8.9 and +5.7 respectively). Physicial pain showed almost no change (-0.3) during 
the control period and health state showed no change at all. Physical pain improved by 
+4.9 points during the treatment period and health state improved +7.7 points during the 
treatment period. 
 
Mueckler noted that the sample size was too small to determine whether OMT had 
significantly improved the quality of life and menopausal symptoms of the participants. 
However, she concluded that there was a trend that indicated improvement occurred and 
that further studies were indicated. 
 
A second dissertation by Bone93  describes a study whose aim was to determine if OMT 
was an effective form of management for peri-menopausal symptoms. Six women 
between the ages 45-55 years with peri-menopausal symptoms participated in the study. 
Each participant completed a self-administered Menopause Quality of Life Questionnaire 
(MENoQL), the Greene Climacteric Scale (GCS) and completed a hot flush frequency and 
intensity journal. The MENoQL was completed in weeks 3, 5, 7 and 9 of the trial. The 
GCS was completed weekly for 8 weeks and the journal was completed daily for 8 weeks. 
OMT consultations occurred between weeks 3 and 6 of the trial, amounting to four OMT 
in total. Each participant was interviewed after the completion of the trial and data from 
this added a qualitative aspect to the study. 
 
Results from the study calculated  the largest effect sizes for change using the formula: 
 
Post-Intervention Score  –  Pre-Intervention Score 
Pre-Intervention Standard Deviation 
 
The largest changes were noted for the psychological, sexual and vasomotor domains in 
the MENoQL  as well as the vasomotor domain in the Greene Climacteric Scale (range = 
3.5 – 5.7). The musculoskeletal domains in both outcome measures showed intermediate 
effects (range = 2.5 – 3.0) and smaller effects were noted on the Greene Climacteric 
Scale anxiety and depression domains (range = 0.3 – 1.0).”p 62   
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Scores for the physical (p < 0.0005) and psychological domains (p = 0.007) in the 
MENoQL scores between the three stages of the study indicated a difference had been 
achieved. However, no difference was noted for the vasomotor or sexual domains (data 
not shown).  The Greene Climacteric Scale scores for the somatic (p < 0.006), vasomotor 
(p = 0.013) and anxiety (p = 0.005) domains all showed a statistical significance between 
the three stages of the study. 
 
Bone commented that the study showed that the perceived intensity of peri-menopausal 
symptoms could be improved over a four-week period of OMT. 
 
The results of all three studies indicated a positive trend in the improvement of the self-
reported menopausal symptoms of the participants during the intervention phases. These 
studies do, however, have limitations. Although all three studies show an improvement in 
symptoms, the number of participants was small in all studies and this limits the 
conclusions that can be drawn as to the significance of the results. Inconsistencies 
between the methodology of the studies makes comparison of results difficult.  Treatment 
phases varied from two consultations over a three week period to ten consultations over a 
ten week period. The type of control varied between studies, as did the type of 
intervention used. The instruments used to measure the changes were also different for 
each study. 
 
These three studies suggest that OMT may be a viable management option for the 
management of menopausal symptoms. They provide a platform for further studies to be 
developed. 
iii. Osteopathic Treatment of Depression 
Osteopathy has had a long history of involvement of treating mental health issues. In 
1915 in the USA an osteopathic psychiatric hospital was built to cater for those suffering 
from mental health issues. This hospital was unique in its approach: all patients received 
three osteopathic treatments per week and were encouraged at other times to do 
activities both inside and outside the hospital. It was so effective that a train station was 
built at the edge of its grounds in order to meet the demand of travellers who sought the 
services of this hospital.8  Since this time, only a few published studies have examined the 
efficacy of OMT in the management of depression.  
 
A year long trial, in 1961, of psychiatric patients, with a variety of diagnoses one of which 
included depression, with the technique known as cranial technique or ‘osteopathy in the 
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cranial field’ is presented in Magoun’s book “Osteopathy in the Cranial Field”.9  The study 
conducted at the Still-Hildreth Osteopathic Hospital compared the cranial rhythmic 
impulses of 102 psychiatric patients to those of 62 subjects without a psychiatric illness. 
Of the 102 patients, 33 were diagnosed with depression. The study demonstrated that 
there was ‘considerably less freedom of sutural motion, especially in the cranial base and 
around the temporal bone, as well as less vault resiliency’.9, p 314  It was noted that the 
benefits that could be assigned to the cranial technique application was difficult due to 
other management approaches being used at the same time. However, they noted that 
there were ‘sufficient cases’ who demonstrated an improvement in their psychiatric 
symptoms when other management approaches had ‘been disappointing’. They noted 
that the cranial rhythm increased toward a normal level during times of improvement and 
slowed during periods of regression in their symptoms.     
 
In 2001, Plotkin et al,10 published an article on the results of their pilot study that assessed 
the impact of OMT as an adjunct to standard psychiatric management of depression in 
premenopausal women. Seventeen women with newly diagnosed depression were 
randomly assigned to either a control group (osteopathic structural examination only) and 
intervention group (OMT). The OMT consisted of a wide variety of techniques, depending 
on the nature of the dysfunction and were at utilised at the practitioner’s discretion. All 
participants were prescribed paroxetine (an anti-depressant) and a weekly psychotherapy 
consultation for eight weeks. The practitioners administering the medication and 
psychotherapy were blinded as to which group the participants were allocated to. There 
were no significant differences between the two groups in relation to age or severity of 
depression. Each participant had three consultations with the osteopath during the eight 
week period. At the end of the study, all participants in the intervention group had reduced 
their depression scores to the normal range, while one third of the control group tested 
normal. Plotkin’s findings indicate that OMT may be a useful adjunctive treatment for 
reducing depression in premenopausal women and that further research is warranted. 
 
In a research project completed in 2001, Wharton94  studied the impact on depression 
levels using osteopathic visceral manipulation techniques. Eleven women, with 
depressive symptoms as measured by the Beck’s Depression Index (BDI) participated in 
the project. They attended four osteopathic consultations over a two week period. The 
treatment consisted of superficial and deep abdominal palpation, mobilisation of the small 
and large intestine, iliocaecal valve, sigmoid colon, diaphragmatic inhibition, liver 
palpation and pump and brining the patient’s knees to their chest and holding for 30 
seconds.  The BDI was completed at time of admittance to the project, pre-treatment and 
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post-treatment. There was a significant difference in the BDI scores (p = 0.0121) The 
study demonstrated that there was an improvement on the levels of depression 
experienced by all the women who participated.     
 
The history of osteopathic intervention in mental health conditions and two pilot studies 
support that likelihood that OMT may be suitable as an adjunct to current management 
strategies for depression. However, like the studies for OMT management of menopausal 
symptoms, insufficient evidence is available and more studies are required.  
 
Research Aims 
The literature review in chapter one provides an insight into the growing number of 
women within the menopausal age range, the extent to which menopausal symptoms 
impact on the daily lives of these women and the need for further research into effective 
management of menopausal symptoms. The literature review also provided a basic 
overview of depression and the current management strategies. The research indicates 
that there is a need for further research into effective management of depression. The 
literature does indicate that collaborative management of depression has a better 
outcome than standard care alone and recommends that further studies into collaborative 
care of depression is warranted.63 OMT, although not a forum for encouraging compliance 
with medication, may be an additional form of collaborative care due to its ability to 
manage physical symptoms.    
 
In chapter two the literature review indicated that there is little osteopathic research 
conducted in OMT for depression or menopausal symptoms. The research has consisted 
of small projects with small sample sizes. These projects do suggest that there is a role 
for OMT in the management of depression and menopausal symptoms. This project 
aimed to add to this data by firstly investigating the effects of OMT and standard care 
(CBT) on the depression levels in depressed menopausal women. Australian menopausal 
women most frequently reported symptoms associated with the musculoskeletal system 
(stiff and aching joints, back pain and headaches/migraines).7 It is, therefore, reasonable 
to expect that osteopaths in Australia would be treating menopausal women for these 
musculoskeletal symptoms and that some of these women will also be experiencing 
depression.7  
 
Secondly, the project sought to provide insight into whether there are common 
osteopathic examination findings that could be used to facilitate a management strategy 
28 
 
for osteopaths treating depressed menopausal women. Having a treatment protocol 
would assist osteopaths in focusing their management of these women to provide the 
most favourable outcome.  
 
Finally, the thesis was designed to explore acceptance of OMT as an adjunctive 
management to standard care of depression in menopausal women.  As OMT, in 
Australia, is largely seen as addressing musculoskeletal problems,6 the question of 
whether menopausal women would accept OMT as part of their management strategy for 
depression is important if OMT is to have such a role.  
 
Possible mechanisms of how  OMT may influence depressive symptoms in menopausal 
women have yet to be determined. The research to date has been directed at determining 
whether a positive effect has been observed or not.91,92,93  Meukler,92 does attempt to 
provide theories as to how the form of OMT she utilizes in her study may influence 
depressive symptoms, however, there is no evidence to support these theories at this 
stage. In Chapter 5 a discussion on the correlation between osteopathic examination 
findings and relevant research related to the effects of OMT is included to provide insight  
as to how OMT may influence depression in menopausal women. 
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Chapter 3  Methods 
Introduction 
This chapter describes the participants, instruments used and procedure.  
Participants 
i. Inclusion Criteria 
To be eligible to participate in the project participants were required to be females 
between the age of 45 to 60. The Greene Climacteric Scale (GCS)3 was used as an initial 
screen and participants were required to have a minimum total score of 22. The minimum 
score was determined by adding the mean scores for the GCS subscales of the clinical 
sample provided in Greene’s Guide to the Greene Climacteric Scale.95   A base line score 
of 10 in the depression subscale of the GCS was required to meet the inclusion criteria of 
depression. A score of 20 or less on the depression scale of the DASS was also required. 
Details of these two instruments are provided further in this chapter. 
 
Initially, the inclusion criteria were limited to those women who were peri-menopausal.  
However, this excluded the majority of the women who inquired about the project. In an 
attempt to increase the number of participants, an amendment was made to include any 
woman experiencing menopausal symptoms that were not medically induced.  
 
ii. Exclusion Criteria 
Participants were screened for significant health concerns and excluded if they were had 
no signs or symptoms associated with the menopausal transition or depressed mood. 
Other exclusion criteria included: 
• Coexisting infectious disease, medical or surgical conditions 
• Suspected or known malignancy 
• History of migraine 
• History of headaches occurring on a regular basis (eg weekly) 
• History of non-evaluated trauma 
• History of drug abuse (Other medications must be evaluated for impact on the 
study.) 
• Signs of genitourinary or gastrointestinal disease 
• History of recurrent unresolved back pain 
• All symptoms and signs of a herniated nucleus pulposus 
• Specific dermatomal patterns of paresthesia (sensory loss) 
• Straight-leg-raising test having at least one of the following: 
o 50% of normal 
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o Cross-over pain 
o Positive bowstring sign 
o Two of the following neurologic signs: 
o Deep tendon reflex alteration 
o Muscle wasting 
o Weakness 
o Sensory loss 
• Use of muscle relaxants or pain medication 8 hours before examination 
• History of lumbosacral surgery, fractures, or recent (48 h) spinal manipulation 
• Greater than 30% of ideal weight 
• History of work-related injury or accidental injury with unresolved legal action 
• Pregnant or suspected pregnancy 
• Uncooperative subject 
• History of seizure disorder 
• Service in the Middle East during the Gulf War 
• History of mental illness prior to menopausal symptoms occurring 
 
The exclusion criteria cover a broad scope of potential health factors that may confound 
the data collected and/or place a participant at risk. They were also chosen as they are 
consistent with exclusion criteria published in other studies.10  An army barracks is  
located within 5 km of the University Teaching Clinics. Because there was a potential that 
a member of the Armed Forces may have inquired about the project, and it is possible 
that  this person, or persons, may have participated in armed combat and suffered from 
mental health issues as a result.96 There were no exclusion criteria based on ethnicity, 
economic status or educational background.  
 
iii. Description of the Participants 
Of the 40 enquiries about the project, thirteen women attended a screening interview. 
Eight of these women met the criteria to participate in the project. Of these eight, only 
three completed all components of the project and the data collected from these three 
women form the basis of the results and discussion.  Table 1 provides a breakdown of the 
demographic information about the three participants who completed the project. 
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Table 1: Demographic details of the three participants 
Demographic 
variables 
 Participants  
Patricia* Dianne* Sarah* 
Age 48 48 48 
Place of birth Australia Australia Australia 
Marital Status Married Married Married 
Number of Children Two One None 
Education Degree Degree Masters 
* Pseudonyms have been used to maintain anonymity of participants 
 
Measures 
i. The Greene Climacteric Scale (GCS) 
The Greene Climacteric Scale (GCS)3  is a commonly used self-report questionnaire that 
measures symptoms associated with the menopausal transition. The GCS consists of 21 
items divided into three sub-sets, one of which can be further divided.  Psychological 
symptoms are assessed in items 1 – 11 and this sub-set can be divided into anxiety 
(items 1 -6) and depression (items 7 – 11). Somatic symptoms are assessed in items 12-
18 and vasomotor symptoms are assessed in items 19 – 20.  Item 21 that can highlight 
the need for further investigation into sexual dysfunction. 
 
Participants’ experience of menopausal symptoms at the time of completing the GCS are 
given on a four point Likert scale ranging from “Not at all” (0) to “Extremely” (3).  A sample 
item from this scale is “Heart beating quickly or strongly”. Total scores range from 0 – 63. 
Scores for the psychological scale range from 0 – 33; depression and anxiety subscale 
scores range from 0 – 15 and 0 – 18, respectively. Depression and anxiety scores of 10 
or more indicate severe levels of these symptoms 
 
Test-retest reliability coefficients reported were: psychological scale 0.87 (mean = 19.62, 
SD = 9.69), somatic scale 0.84 (mean = 7.18, SD = 4.57) and vasomotor scale 0.83 
(mean = 6.46, SD = 2.79).97,98   Travers et al,99 undertook a normative study of the GCS in 
Australia.  Five hundred women were recruited from 1598 women participating in the 
Longitudinal Assessment of Ageing in Women (LAW) study. They were aged between 40-
80 years, and were divided into four age groups (40-49, 50-59, 60-69 and 70-79). All 
participants completed the Greene Climacteric Scale (GCS) and the Kruskal-Wallis test (a 
non-parametric analytic technique) was used to compare the scores by age group, 
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menopausal status and by the use of estrogen and progestagen (HT) or estrogen therapy 
(ET). The results determined that it was sensitive to distinguish between the various 
symptoms associated with the menopausal transition and therefore was a useful tool to 
measure the menopausal symptoms within the Australian population. However, the 
authors noted that as all participants were from a specific geographical region, there was 
an under-representation of some groups within the wider Australian population.  A copy of 
the GCS is available in Appendix 2. 
 
ii. The Depression Anxiety Stress Scale (DASS) 
The DASS was used to measure the mental health status of the participants.100 The 
DASS is a 42-item self-report inventory that assesses depression, anxiety and stress. 
This instrument has the ability to determine levels of anxiety and stress which can be 
closely associated with changes in affect. The reliability and internal consistency of this 
scale has been assessed using Cronbach’s alpha with scores of .91, .84 and .90 for 
depression, anxiety and stress, respectively.2,101 The DASS’s depression scale had a 
cross correlation of r = 0.74 with the Beck Depression Index (BDI).101 
 
The DASS consists of three self-reported scales, each containing fourteen questions that 
are divided into subscales of 2-5 questions with similar content. The participant’s 
experience of symptoms over the past week are given on a four-point Likert scale ranging 
from “Did not apply to me at all” (0) to “Applied to me very much, or most of the time” (3). 
A sample item from this scale was “I found myself getting upset by quite trivial things”. 
Total scores range from 0 – 126, with high scores indicating high levels of depression, 
anxiety and stress. The DASS severity ratings102 are shown in Table 2. 
 
A copy of the DASS is available in Appendix 2. 
 
Table 2: DASS Severity Ratings 
 Depression Anxiety Stress 
Normal 0-9 0-7 0-14 
Mild 10-13 8-9 15-18 
Moderate 14-20 10-14 19-25 
Severe 21-27 15-19 26-33 
Extremely Severe 28+ 20+ 34 
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iii. The Working Alliance Inventory (WAI) 
The Working Alliance Inventory (WAI) is a self-report, 36 item instrument that measures 
the working alliance between practitioner and patient.4  It is composed of three subscales, 
Bond, Task, and Goal, each consisting of 12, non-overlapping items.  Each item was 
scored on a seven-point Likert-type scale ranging from “Never” (1) to “Always” (7). A 
sample item from this scale was   “[Patient’s name] and I agree about the steps to be 
taken to improve his/her situation.”  
 
The WAI scoring has a positive and negative polarity. If there is a negative polarity for the 
question, then you use the opposite value in your scoring, e.g. if a 2 is circled, when 
scoring it is given a weighting of 6. If there is a positive polarity for the question, then the 
number circled is the score that is given, e.g. if a 6 is circled when scoring it is give a 
weighting of 6. Scores range from 7 – 252, with high scores indicating a higher level of 
agreement with the bond, task or goal that occurred within the consultation. 
 
Internal consistency of the subscale scores, based on samples of 29 and 25 actual clients 
and their therapist range from .85 to .92 for the client version and .68 to .87 for the 
therapist version. The total score internal consistency was .93 for the client version and 
.87 for the therapist version.103  Construct validity of the WAI subscales is supported by 
correlation values of r = 0.47-0.93, P<0.001.104 A copy of the WAI is available in Appendix 
2. 
 
The subscales measure the level of agreement between the practitioner and patient on 
bond, tasks and goals that occur within the consultations.  The Client and Therapist 
versions were used. The consultations for both CBT and OMT were undertaken by 
different practitioners. Two osteopaths provided the OMT and three provisional 
psychologists provided the CBT. The WAI was used to determine if results may have 
been skewed by differences in rapport between the practitioner and participant.  
 
iv. The STRAW Criteria 
The STRAW Criteria was developed at the Stages of Reproductive Aging Workshop 
(STRAW) in 2001 to indicate the stage of menopausal transition and post-menopause 
that a woman is experiencing based on changes to their menstrual cycle.105 It was used in 
the current study as a measure of the menopausal status. 
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v. Osteopathic Examination Notes 
The osteopathic examination included an evaluation of the standing posture, fascial 
tension, asymmetries in bony landmarks, an examination for somatic dysfunctions of the 
spine and other joints of the body, examination of the soft tissues of the body (muscles, 
tendons, and ligaments) and the cranial mechanism (where indicated). All findings were 
recorded on the initial and subsequent consultation forms.  A copy of the OMT initial and 
subsequent consultation forms are available in the Appendix 3. 
 
The consultation forms also included recorded information on the techniques used to 
address any dysfunctions found during the examination, as well as management advice 
given. Management advice included: exercises, diet, stress management or other 
activities that would aide in the recovery of the patient’s presenting symptoms. 
 
This information was analysed to determine if there may be trends in specific areas of 
dysfunction found in the depressed menopausal women. 
 
Implementation 
i. Non-treatment Waiting Period 
A non-treatment waiting period of four weeks was implemented. The waiting period 
commenced from the time the participant agreed to join the project and signed the 
General Informed Consent Form. The non-treatment waiting period was designed to  
provide the time to instruct the practitioners conducting the interventions on the project 
protocol. Once the practitioners were briefed they were then required to contact 
participant to arrange the initial consultation.  It was decided that a common starting time 
of four weeks after the participant joined the project was appropriate to ensure a 
consistent starting time for both the osteopathic and counselling to occur for all 
participants. 
 
ii. Timing of Data Collection 
Data was collected at the Screening Interview, at three points within the eight week 
treatment period, and at three month and twelve month follow-up. The project protocol 
was to collect the data in weeks -4, 1 (being the first week of treatment), 5, 8 and 20. Data 
collected in week one for the DASS and GCS was collected immediately prior to the 
35 
 
counselling consultation. In two of the case studies, the consultation schedule and data 
collection varied slightly due to the practitioner’s or participant’s schedule preventing 
consultations occurring as per the study design. The variation was one week difference in 
most cases.  Table 3 shows when each piece of data was collected according to the 
project protocol. A more comprehensive table of the sequence of events, when 
consultations occurred and when data were collected is available in Appendix 4. 
 
iii. Follow-up 
The first follow-up was scheduled to occur three months (week 20) after the conclusion of 
the eight week treatment period. The follow-up took the form of a final CBT consultation in 
order to monitor the mental health and well-being of the participant. The DASS and GCS 
instruments were completed by each participant during this consultation. 
 
The second follow-up occurred approximately twelve months after commencing 
participation in the project. This follow-up consisted of an interview of the participants that 
was up to 60 minutes in duration. The DASS and GCS were completed at this interview 
by the participant. 
 
 
Procedure 
i. Recruitment 
Participants were predominantly sourced from the northern suburbs of Melbourne, 
however, any woman willing to travel to the University Clinics, where all treatment took 
place, was considered for participation in the project. Recruitment strategies included: 
sending a letter of introduction and flyers and posters to: 
 
• all medical clinics within Bundoora and surrounding suburbs who were willing to 
display the flier and poster;  
• gyms, that had only female members. located in the surrounding suburbs; 
• osteopathic, naturopathic and psychology clinics in the surrounding suburbs 
• placing posters around the RMIT University Bundoora West Campus 
• advertisement in the local Leader newspaper 
• Beyond blue and Depressionet websites 
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• web page on RMIT University’s website 
• advertisement in the RMIT internal newsletter for staff 
 
The response rate and number of participants recruited from each strategy are detailed in 
the Appendix 5.  
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Table 3: Timeline of when data was collected 
 Screening 
Interview* 
Week 1 Week 2 Week 3 Week 4 Week 5 Week 6 Week 7 Week 8  Week 
20 
 Twelve 
Months 
CBT              
Instruments PLS 
SIC 
Screening 
Form 
GCS/DASS  
TIC 
STRAW 
PIC 
DASS 
GCS 
WAI 
   DASS 
GCS 
WAI 
  DASS 
GCS 
WAI 
 DASS 
GCS 
 
  
Interview 
DASS 
GCS 
OMT              
Instruments  OIC 
OCF 
WAI 
OCF** OCF** OCF** OCF  
WAI 
  OCF  
WAI 
    
 
 
KEY: 
PLS  =   Plain Language Statement   PIC = Psychology Informed Consent Form   
SIC   =  Screening Interview Consent Form  DASS = Depression Anxiety Stress Scale 
GCS =  Greene Climacteric Scale   WAI = Working Alliance Inventory (Client and Therapist Versions) 
TIC   =  Trial Informed Consent Form  OIC = Osteopathic Informed Consent Form 
OCF – Osteopathic Consultation/Hx Form (**  = only completed in one of these weeks) 
 
*A four weeks non-treatement period occurred between the Screening Interview and Week 1.  
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ii. screening 
a. initial screening 
The initial screening process took place via telephone and email. All persons inquiring 
were provided with a basic description of the purpose of the project and a brief description 
of the criteria for participating.  
 
Those who met the criteria were given a brief description of what participation in the 
project would entail and asked if they had any further questions, if they were interested in 
having more detailed information sent to them, and if they would be interested in 
attending a screening interview. Women requesting more information were sent the Plain 
Language Statement (PLS). Interested women received the PLS, the Screening Interview 
Consent Form and a time was arranged for the Screening Interview.   
 
All Screening Interviews were held at RMIT University, Bundoora. Copies of the Plain 
Language Statement, Screening Interview Consent Form and Initial Enquiry Form  can be 
found in Appendices 6 and 7. 
 
b. Screening Interview 
The goal of the screening interview was to gather more detailed information regarding the 
person’s symptoms and their ability to meet the inclusion criteria. This interview was 
conducted by the author, a registered osteopath, who had the required knowledge to 
determine whether there were significant health concerns that would place the potential 
participant within the exclusion category. 
 
During the interview general demographic information was collected (date of birth, marital 
status, number and age of children, place of birth, ethnic or cultural background, highest 
level of education completed, occupation, and postcode). Menopausal status was 
determined via the STRAW Criteria and Greene Climacteric Scale (GCS).  
 
If the interviewee did not score 22, or over, in total for the GCS, or 10 or above in the 
depression subscale, then they were informed that they were not eligible to participate 
and no further information was gathered from the interviewee. They were advised as to 
why they had failed to meet the criteria and asked if they had any questions. If they were 
seeking support for their current symptoms referrals to appropriate support groups or 
health professionals was supplied.  
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Those women who met the GCS study criteria were then asked a series of questions to 
determine if they had any health complaints that would exclude them from the trial. The 
process was also designed to detect any significant health issues that would place them 
at potential risk of harm, either physically or psychologically, if they were to participate in 
the trial. 
 
Any person not meeting the criteria was advised why they were excluded and during this 
discussion relevant referrals given to support them manage the symptoms they were 
experiencing. Those meeting the criteria were given more detailed information as to what 
would be required of them if they participated in the trial.  Those who agreed to participate 
in the study were asked to sign a General Informed Consent Form and advised that they 
would be contacted to organise a date and time for their first appointments. 
 
All the women admitted to the project were advised that they could withdraw from the 
project at any time without any ongoing bias or prejudice. All treatment was provided free 
of charge. 
 
Copies of the Screening Interview Form and General Informed Consent Form are located 
in Appendices 6 and 7. 
 
iii. Study Interventions 
a. Cognitive Behavioural Therapy 
Cognitive behavioural therapy (CBT) was chosen as the style of counselling provided to 
the participants as it is a widely used style of counselling in Australia.106  It is a well 
evaluated form of treatment for depression.101  CBT is an approach based on problem 
solving and changing negative thought processes and habits that limit and control a 
person’s behaviour.107,108    
 
Three provisional psychologists provided the one-on-one CBT consultations.  To provide 
a consistent approach to the CBT sessions for each participant, eight modules of the 
‘Back from the Bluez’ treatment manual were used.109 The treatment manual provided a 
consistent framework for each of the provisional psychologists to structure the CBT 
consultations. The modules provided participants the opportunity to work through topics 
relevant to developing better management skills of their depressive symptoms. During 
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each CBT consultation the participant was provided with one of the modules to take home 
and work through. Questions or insights gained from working through the module could 
then be used as the focus for the next CBT consultation. Written permission to use the 
modules in this project was obtained. An example of one of the modules is found in 
Appendix 8. 
 
Participants attended a one hour CBT consultation on a weekly basis for eight weeks, and 
a one hour follow-up consultation three months later. Each participant consulted the same 
provisional psychologist for the duration of the intervention. During the three month period 
when no CBT consultations were scheduled, participants were able to attend CBT 
consultations if this was felt to be necessary by either the participant or the provisional 
psychologist. This was to ensure that there was no risk to the participant’s mental and 
emotional health during the three month interval. Participants were advised that any 
consultations attended during this period would be at their own expense. Participants 
were also able to continue with CBT consultations after the three month follow-up 
consultation if this was felt to be necessary by both the participant and the provisional 
psychologist. These consultations would also be at the participants own expense. 
 
b. Osteopathic Manipulative Treatment (OMT) 
Osteopathic manipulative treatment (OMT) is based on the principles developed by Dr A. 
T. Still in the 1800s.8 OMT performed in this project was consistent with examination, 
treatment and management commonly used by osteopaths within the Australian 
osteopathic profession.6  OMT covers a wide variety of techniques ranging from very 
subtle to the very obvious techniques. The osteopathic practitioners were free to choose 
the most suitable techniques for the individual participant as determined from the 
examination and medical history. This was aimed to mirror normal OMT practice. A 
summary of techniques and explanations is available in Appendix 1. The osteopaths were 
instructed to treat the participant as they would treat patient’s in their own clinical practice. 
A document outlining the study protocol was provided to each osteopath; a copy of this 
protocol is available in Appendix 9.   
 
OMT consultations followed a format that reflects general osteopathic practice: case 
history taking, examination, informed consent to management plan of diagnosis, 
treatment, and other management advice.8   Examinations, as previously stated, may 
include any neurological, orthopaedic, physical examination and osteopathic examination 
as indicated by the symptom presentation and medical history of the patient. If the history 
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or examination indicated, referral for other examinations such as x-rays, would be 
undertaken. These additional examinations would indicate that the participant did not 
meet the inclusion criteria and the participant would be excluded from the project. They 
would be given advice on the best management plan for the suspected health problem 
and time to ask questions regarding this management to ensure that best practice and 
care of the participant occurred. No participant required such referrals. 
 
Four OMT consultations were included in the treatment period during the first eight weeks 
of the intervention period. The project protocol determined that three of the consultations 
were scheduled for weeks 1, 5 and 8 to coincide with the data collected in the CBT.  As 
previously noted, there was some variation in this due to either the practitioner’s or 
participant’s availability.   The fourth consultation was scheduled between weeks 1 and 5, 
as deemed appropriate by the osteopath. The initial consultation was scheduled to take 
45 – 60 minutes. The subsequent consultations were 30 – 45 minutes in duration. Each 
participant saw the same osteopath for all four treatments. This was designed to mimic 
general osteopathic practice as much as possible. 
 
c. Protocol for Study Interventions 
To facilitate the process and timeline of the project, each of the provisional psychologists 
and osteopaths were provided with a document outlining the protocol for their specific 
discipline. This protocol outlined: 
 
The procedure to follow during the project for each participant 
• Type of assessments required 
• When to schedule consultations, and the duration of each consultation 
• When to administer the instruments 
• What constituted an adverse event and the procedure to follow should such an 
event occur 
• Where to keep the files to keep them secure 
• What information was to be recorded during the OMT examination and treatment   
• A session outline for CBT 
• Contact details of the researcher, senior supervisor, Head of School (Health 
Sciences) and Ethics Committee. 
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They were also provided with a copy of the Drop Out Form and the Adverse Event Form. 
Copies of the CBT and OMT protocols, drop out forms and adverse event forms are 
available in Appendices 9 and 10.   
 
To assist the practitioners follow the project protocol patient files were provided prior to 
the first consultation. The file contained all the documents the practitioners required for 
each consultation; including informed consent forms, a check list, patient record form, 
GCS, DASS, WAIs, and workbook as appropriate. A checklist was provided for each 
session. A copy of the check lists is available in Appendix 9.  
 
d.  Interview 
Participants were invited to attend an interview approximately twelve months after they 
were admitted to the trial. The interview was unstructured. Five broad topics were used to 
guide the discussion during the interview. These included: 
 
a. the participant’s experience of the menopausal symptoms and how they 
impacted on their day-to-day life 
b. what they had hoped to gain by participating in the clinical trial 
c. whether the osteopathic manipulative treatment was a factor that 
influenced their decision and why  
d. what their expectations were of the counselling and osteopathic 
manipulative treatment 
e. what their experience of participating in the trial was and whether they 
noticed any changes to their menopausal symptoms 
 
Prior to the commencement of the interview, the participants signed an informed consent 
form; a copy is available in Appendix 7. The interview took no longer than 60 minutes and 
was recorded. The recording was transcribed by an independent transcription company. 
Participants were sent a copy of the transcription so that they could add or modify 
comments prior to analysis. 
 
Participants who attended the interview were offered a $30 gift voucher. 
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Statistical Measures 
i. Clinical Significance and Reliable Change 
The results of the DASS and GCS for each participant were evaluated using Clintools 
Software for Windows (Reliable & Clinical Change Generator, V3.5). The Clintools 
program has been designed to calculate whether the results demonstrated a clinically 
significant and reliable change.110  A clinically significant change occurs “when the client 
moves from the dysfunctional to the functional range during the course of therapy”.111, p 50  
The reliable change figures account for measurement errors in the clinical significant 
calculations and provides the ability to determine if there has been a recovery, 
improvement, unchanged or deterioration of the patient’s condition as a result of the 
treatment they received.112 In this project the confidence interval of 95% was used to 
determine if the results represented a clinically significant change.   
 
The statistics used to calculate the clinical and reliable change for the DASS scores were 
sourced from Brown et al’s study into the psychometric properties of the DASS and the 
Manual for the Depressin Anxiety Stress Scales for the clinical and normal samples 
respectively.113,114  The statistics used to calculate the clinical and reliable change for the 
GCS scores were sourced from Greene’s Guide to the Greene Climacteric Scale95  and 
factor analysis.97  Table 3 provides these figures. 
 
Table 4:  Test-retest, clinical and normal sample means and standard deviations for 
the DASS and GCS 
 DASS GCS 
 Depression Anxiety  Stress Psychological Somatic Vasomotor 
Test-retest reliability 
 
r = .713 r = .785 r = .813 r = .87 r = .84 r = .83 
Standard deviation used to 
measure reliability 
 
9.25 9.06 12.45 9.69 4.57 2.79 
Clinical sample mean 
 
10.65 10.90 21.1 19.62 7.18 6.46 
Clinical sample standard 
deviation 
 
9.3 8.12 11.5 9.69 4.57 2.79 
Normal sample mean 
 
6.34 4.7 10.11 7.42 3.25 1.79 
Normal sample standard 
deviation 
6.97 4.91 7.91 6.41 3.64 1.12 
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ii. Thematic Analysis 
The transcripts of the twelve month follow-up interviews were analysed using a thematic 
analysis protocol. Thematic analysis is a widely used qualitative analytic method.112   It 
provides a method to identify themes within qualitative data and analyse these themes. 
The process recommended by Braun and Clarke112  was used in this project as it provided 
clear guidance in the steps to take to identify and analyse the themes contained within the 
interview material.  
 
The process for analysing the transcripts included the following three steps: 
a. The transcripts of the individual interviews were read several times and 
notes made. These notes consisted of statements that stood out from the 
others because they summarized an idea the participant was talking about 
or were stressed by the participant and were relevant to the research topic. 
b. From these statements codes were created. The codes were single words 
or short phrases that expressed the idea or sentiment of the statements. 
Statements or ideas that had similar aspects were given the same code. 
c. The codes were then collated into themes using a mind map (a diagram 
used to organise information). Three broad themes emerged from all three 
participants. 
 
Study Design 
A mixed method, case study design has been utilized. Collection of data at scheduled 
times enabled any changes in depression and menopausal symptoms during and after 
the intervention to be observed. The qualitative data provided insight into the acceptance 
of OMT as an adjunctive therapy and participants’ experience of the combined 
intervention. The case study approach provided a framework for the data collected to be 
analysed within each case study and between the case studies.  
 
Ethics  
Ethics approval was granted by the RMIT University Human Research Ethics Committee 
to undertake this project (HREC project number 61/10). Two amendments were applied 
for and approved: the first amendment allowed the inclusion criteria to be modified to 
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include menopausal women of any phase; the second amendment included the approval 
to conduct the interviews at the twelve month follow-up.  
 
All of the women who attended the Screening Interview gave written informed consent for 
the data to be collected and those women who were eligible to participate in the project 
gave written informed consent prior to their participation in the project and before 
commencing the cognitive behavioural therapy and osteopathic manipulative treatment. 
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Chapter 4  Results 
Introduction 
Of the 40 women who enquired about this project, eleven attended the screening 
interview. Eight of these women met the criteria to participate in the project and three 
completed the CBT and OMT consultations and follow-up interview. A breakdown of these 
figures is available in Appendix 5.    
 
Results of the three participants are presented in this chapter. The results will be 
presented individually for each participant in the following format: 
 
i. Description of the participant 
ii. The Screening Interview 
iii. Osteopathic Consultation Results 
a. osteopathic consultations – presenting symptoms and examination results 
b. osteopathic treatment 
iv. DASS and GCS Scores 
v. Reliable and Clinical Change Results (DASS and GCS) 
vi. WAI Scores 
vii. Adverse Events 
 
Following the presentation of the quantitative data for each participant, the thematic 
analysis of the data collected in the interviews will be presented. A summary of analysis 
for each participant will be followed by the major themes that were observed collectively. 
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Case Study 1 
The participant in case study 1 will be known as ‘Patricia’. 
 
i. Description of Patricia 
Patricia was a 48 year old, married woman. She was born in Australia, had completed a 
degree level qualification and was a mother of two teenage boys. She had responded to 
an advertisement placed in the local newspaper inviting participants for this research 
project. 
 
ii. Screening Interview  
The Screening Interview data confirmed that Patricia was in the late peri-menopausal 
stage having experienced an interval of more than 60 days between menstruations. This 
was backed up by a diary she had maintained for the previous two to three years. Patricia 
stated she had been experiencing depression and anxiety symptoms since the onset of 
the peri-menopausal symptoms, however, had no other major physical injuries or 
impairments.  She had consulted her general practitioner, within the last six months, 
regarding the depression and anxiety symptoms she had been experiencing and had 
been taking the prescribed medication, aurorix (moclobemide), to assist in the 
management of these symptoms. Patricia stated she consulted a manual therapist on a 
regular basis for general maintenance and agreed to put these consultations on hold 
during her participation of the first nine weeks of the research project. 
 
The Depression, Anxiety and Stress Scale (DASS) administered at the time of the 
Screening Interview (week -4) showed relatively low scores for depression and anxiety, 6 
and 5 respectively. However the stress score was higher at 26. Patricia met the criteria to 
be included into the project as she did not exceed the maximum of score of 20. It is 
probable that the medication that Patricia was taking is a reason the depression and 
anxiety scores were in the mild to moderate score range.  
 
The Greene Climacteric Scale (GCS) score overall was 30 which was above the mean 
score of the menopause clinic sample of 22.9,95 and indicated that Patricia was 
experiencing menopausal symptoms. The psychological score was 17 and again was 
greater than the mean score of the menopause clinic sample of 12.33. In the subset of the 
48 
 
psychological scale for depression and anxiety Patricia scored 12 and 5 respectively. 
She, therefore, met the criteria for inclusion to the project in regards to the GCS.   
 
iii. Osteopathic Consultation Outcome 
Patricia attended four OMT consultations in total; they occurred in weeks one, three, five 
and nine from the beginning of the treatment phase of the study. Over the four 
consultations the main symptoms Patricia presented with included: anxiety, tingling over 
the cheek (this was not disclosed during the Screening Interview), constipation and 
bloating, and hip stiffness.  The most consistent examination finding over the nine weeks 
was a dysfunction at the occipitoatlantal (OA) joint, however the severity of this 
dysfunction decreased by the fourth consultation. The other consistent finding was an 
uncompensated pattern of Zink, which was found in three of the four consultations. Other 
examination findings that were noted in two of the four consultations included 
hypertonicity of the erector spinae muscles (levels varied), somatic dysfunction at T4, L1, 
left sacroiliac joint, left cranial suture restrictions associated with the temporal bone, and 
descending colon irritation. Table 4 shows examination findings for all four consultations.  
 
iv. Osteopathic Treatment 
A variety of osteopathic techniques were utilized throughout the four consultations and 
included:  articulation, myofascial release, HVLA, inhibition, MET, visceral manipulation, 
and soft tissue technique. The application varied within each treatment depending on the 
examination findings. This is consistent within general osteopathic management 
throughout Australia.6 Summaries of treatment can be found in Table 5  below.  A key to 
the abbreviations is available in Appendix 1. 
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Table 5: Osteopathic presenting symptoms and examination findings for Patricia for each osteopathic consultation 
Examination Consultation 1 Consultation 2 Consultation 3 Consultation 4 
Presenting Symptoms Tension in Tx – L>R 
 
Anxiety 
 
Occasional HA (dull, but 
sometimes didn’t realise), 
tingling in face cheeks 
bilaterally L>R 
 
 
2 days after ttt a lot of tingling 
in L side of face for about a 
week. Worse than it has been 
for a long time. 
 
Coccyx – feels like no padding 
– no falls 
 
Bowel – constipation. Usually 
regular. 
Feels bloated 
Mild stiffness in hips 
 
Feels run down, cold sore 
 
No Cx or should pain 
Menstrual cycle – 21-60 days. 
Generally regular. 2-3 days 
duration. No issues. Last cycle 
2 days bleeding, 2 days none, 
then started again 2 days later. 
OK. Significantly less tingling 
on L side of face. 
Starts 4 days after ttt. Less 
frequent, less intensity. 
 
L buttock – tender to touch; 
notices when in bed 
 
No illnesses. 
 
No tension in neck/shoulders 
. 
Bowels started to move – 
metamusil. 
 
42 day menstrual cycle – light. 
No issues. 
 
Bowels NAD 
 
Cx NAD 
 
Last 2-3 days feels like 
stretched lower back. Hasn’t 
walked for 2 weeks. 
 
Pt lost 5-6 kgs – puts it down 
to anxiety & not eating. 
 
Pt looks healthy & well. 
 
Menstrual cycle – currently at 
day 32 with no menses. 
Zink Fascial Patterns OA – left 
CT – left 
TL – right 
LS - right 
OA – right 
CT – left 
TL – right 
LS - right 
OA – right 
CT – left 
TL – right 
LS - left 
OA – left 
CT – left 
TL – right 
LS - right 
Fascial 
tensions/restrictions 
From right shoulder to 
xiphisternum 
Weight bearing on right 
 
 Fascial tension over lower 
thoracic and rib region 
Muscles Hypertonic:Thoracolumbar 
erector spinae – bilateral 
Generalised muscle tension 
Hypertonic: masseter, 
suprahyoid, CES, anterior 
neck muscles 
Hypertonic: 
Pterygoids R>L, neck muscles 
on the L between OA and C3 
 
Somatic dysfunctions 
of the vertebral 
OA – decreased anterior glide 
– right* 
C3 – ERS left 
T3 -  FRS left 
OA – decreased anterior glide 
L and R. L OA painful 
T2 – FRS-L 
SIJ – left restricted 
OA – decreased motion on the 
L 
C2 – FRS R 
T4 - FRS L 
OA – slight decrease motion 
on L 
T6-10 – sidebent L 
L innominate – slight posterior 
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column or joints T4 -  FRS left* 
T12 – Extended bilaterally* 
L1 – FRS right* 
Right anterior rib cage 
TMJ deviated to R L1 – ERS R 
L shoulder poor quality motion 
in abduction 
rotation 
Ribs 6 – 10 – decrease 
inspiration 
Cranial  Restriction of suture between 
frontal and temporal bone and 
temporal and occipital bone on 
L 
Restrictions were reduced 
compared to previous 
consultation 
 
Standing Flexion Test Slight positive right   Slight positive left 
Visceral  Descending colon Descending colon rigid  
Other Cx prepositioning – NAD 
(Verbal informed consent 
gained) 
Cx prepositioning – NAD Lipoma noted over R SIJ  
* noted as significant findings by clinician 
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Table 6: OMT performed and advice given to Patricia for each consultation 
Technique Treatment 1 Treatment 2 Treatment 3 Treatment 4 
Soft tissue TES, CES, LES CES, antr R cervicals, 
suprahyoid mm, masseter 
Antr cervicals TES 
Articulation Thoracic spine, right anterior 
rib cage 
  Tx 
Myofascial Release T4, breathing, right anterior 
cervicals using breathing and 
arm MET 
Temporalis and over cranial 
sutures around temporal bone, 
sacral float 
Antr pelvis bilat, 
Left lower ribs, L innominate Left psoas 
HVLA OA, T12/L1, T4 OA OA   
Inhibition Left diaphragm  Descending colon, pterygoids L diaphragm 
MET  SIJ L innominate, L4/5, pelvic rot OA, rib cage 
Visceral  L Large intestine L Large intestine  
Response to 
treatment 
‘great response as no pulling 
was noticed post treatment’ 
   
Advice Continue with walking May experience post ttt HA d/t 
increased blood flow and sore 
throat d/t loosening of neck soft 
tissues and lymph nodes 
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v. Scores for Greene Climacteric Scale (GCS) and Depression Anxiety Stress Scale 
(DASS) During Treatment Period. 
Patricia attended eight counselling sessions in nine weeks, with a follow-up at 22 weeks 
following the first consultation. The DASS and GCS were collected in weeks 1, 5, 9 and 22 
from the initial consultation, and at a twelve month follow-up interview.  
 
Figure 2 shows the scores for the different scales at each collection point for the DASS. 
Total DASS scores dropped by the end of the eight counselling consultations, and again at 
the follow-up three months later. A slight increase occurred at the twelve month follow-up. 
This slight increase at the twelve month follow-up is due to the slight increase between week 
20 and the twelve month follow-up scores for the anxiety subscale (score of 1 and 4 
respectively). The depression subscale scores showed a consistent decline from week 1 to 
the twelve month follow-up; the only increase occurred in week 6.  
 
 
 
Figure 2: DASS scores for Patricia at each collection point 
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The total GCS scores at the week 20 and twelve month collection period were lower than 
those collected at the first consultation (week 1). The score at week nine collection point was 
higher than at week one due to an increase in the psychological scale score. The peak in the 
scores for the psychological scale at week 9 was higher than the score collected at week 1. 
This was an anomaly as the general trend was in a decline in scores. Figure 3 provides a 
breakdown of the scores for each subscale of the GCS.   
 
 
Figure 3: GCS Scores for Patricia at each collection point 
 
 
 
The depression subscale scores showed a decrease at the week twenty-two collection point 
and twelve month follow-up.  The downward trend was disturbed at week 9 with an increase 
in score of 8. The anxiety subscale scores showed a decrease at the week twenty-two and a 
rise at the twelve month follow-up. An increase occurred in week 9 which mirrors the 
increase of score shown in the depression subscale score at this collection time.  Figure 4 
displays the scores for the subscales of the depression scale of the GCS. 
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Figure 4: GCS subscale scores for depression and anxiety for Patricia 
 
vi. Reliable and Clinical Change Results for DASS and GCS 
Patricia’s scores for the DASS’s  anxiety and stress subscales met all the criteria to indicate 
that a reliable change had occurred at week 22. A reliable change was not recorded at any 
other time for the DASS. 
 
A clinically significant change in Patricia’s depression and anxiety subscale scores occurred 
in data collected at the twelve month follow-up. A clinically significant change in Patricia’s 
stress subscale scores occurred at the week 22 and twelve month follow-up. No clinically 
significantly change occurred during the treatment period for any of the scales. 
 
Patricia’s GCS scores for the psychological subscale did not demonstrate a reliable change 
or clinically significant change in any of the data collected. Appendix 11 contains tables with 
a breakdown of scores for all reliable and clinical change calculations. 
 
vii. WAI scores  
WAI scores were collected at weeks 1, 5 and 9 of the consultation period for both the 
osteopath and Patricia, and the psychologist and Patricia.  The scores for Bond, Task, Goal 
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and Total Score are summarised in Table 6. Patricia’s scores were consistently higher than 
those of the osteopath across all three domains. The differences between Patricia’s and the 
Osteopath’s scores decreased over time.  
 
The scores associated with the psychologist and Patricia showed some variability. Patricia’s 
scores in week one were lower in each category than the psychologist. In week five and nine 
Patricia’s scores were all higher than the psychologist’s. Patricia’s Task and Goal scores 
were higher for the CBT than the OMT, however, the Bond scores were generally higher for 
the OMT than the CBT. 
 
viii. Adverse Events 
No adverse events were recorded in either the osteopathic or counselling sessions. 
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Table 7: WAI scores recorded by the osteopath, psychologist and Patricia, during the intervention period 
 Bond Task Goal Total Score 
Week OMT P CBT P OMT P CBT P OMT P CBT P OMT P CBT P 
1 61 84 73 69 56 77 79 76 58 81 80 74 175 242 232 219 
5 66 76 77 84 57 72 70 84 61 73 73 84 184 221 220 252 
8 70 81 74 78 64 71 74 84 59 73 73 84 193 225 221 246 
 
Key:   CBT = psychologist, OMT = Osteopath, P = Patricia 
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Case Study 2 
The participant in case study 2 will be known as Dianne. 
 
i. Description of Dianne 
Dianne was a 48 year old, married woman. She was born in Australia, had completed a 
degree level qualification and was a mother of one 23 year old son. She had responded to 
an advertisement placed in the local newspaper inviting participants for this research project. 
 
ii. Screening Interview 
The Screening Interview data collected indicated that Dianne was in the early peri-
menopausal stage having not experienced an interval between menstruations of more than 
60 days. Dianne had no significant medical conditions or history of psychological health 
problems. She took supplements (glucosamine, multivitamin, spirilina, fish oil, flaxseed oil 
and iron), however, was on no other medications. 
 
The Depression, Anxiety and Stress Scale (DASS) administered at the time of the Screening 
Interview showed relatively low scores for depression and anxiety, 9 and 10 respectively. 
However the stress score was higher at 34. Dianne met the criteria to be included into the 
project as she did not exceed the maximum of score of 20 in the depression subscale.  
 
The Greene Climacteric Scale (GCS) score was 29, and above the mean score of the 
menopause clinic sample of 22.9,95  indicating that Dianne was experiencing menopausal 
symptoms. The psychological score was 18 and again higher than the mean score of the 
menopause clinic sample of 12.33. In the subset of the psychological scales for depression 
and anxiety Dianne scored 8 and 10 respectively. She, therefore, met the criteria for 
inclusion to the project in regards to the GCS.   
 
iii. Osteopathic Consultation Outcome 
Dianne attended four OMT consultations at weeks one, three, six and nine from the 
beginning of the consultations. The most consistent findings for Dianne were somatic 
dysfunctions of T6, L4 and the sacrum which were observed in all four treatments. A somatic 
dysfunction of C2 was noted in the first three consultations only. Hypertonicity of the psoas 
muscle was present in three of the four treatments, with the left psoas being more notably  
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Table 8: Osteopathic presenting symptoms and examination findings for Dianne for each osteopathic consultation 
Examination Consultation 1 Consultation 2 Consultation 3 Consultation 4 
Presenting Symptoms  Neck pain – nil 
LB pain – nil 
L knee – ‘dodgy’ – clicks, 
grinding 
 
L hip discomfort – occasionally 
can’t put weight on – present 
for many years. 
 
Reactive airways – smoke or 
other pollutants – wheeze and 
cough. SOB. For last 2 years 
 
Concerned about weight. 
 
Increased anxiety. 
 
Periods – irregular. Heavier; 
increased clots. Shorter bleed 
time. Breast tenderness; 
abdominal bloating; feels 
angry/irritable pre menstrually 
 
Frontal HA and behind eyes. 7-
8/10. Can feel nauseous, 
dazzles in eye – relates to 
anxiety – not present on 
waking 
Fatigue still problem. 
 
No HA 
 
Period. L sided LB pain – 
severe (usually has continual 
LBP). Difficult to get pain relief. 
Pain ceased 2 days after start 
of period. Shorter bleed time; 
lighter; no clots. 
Another period – short bleed 
time. R sided low abdominal 
quadrant pain. Less intense 
than previous period. Took 2 
analgesic. 
 
High anxiety – lots of job 
interviews. 
 
 
Post R hip pain 
Post ttt – achey. Eased after 5 
days. 
 
Period – central LBP L>R, no 
abdominal pain, clots with this 
period. 
Slight improvement with yoga. 
 
Difficulty lifting L leg. Different 
from R pain. Not altered by 
exercise. 
Zink Fascial Patterns OA – left 
CT – right 
TL – right 
OA – left 
CT – right 
TL – left 
OA – left 
CT – right 
TL – right (slight) 
OA – right 
CT – left 
TL – right 
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LS - left LS - right LS – right (slight) LS - left 
Fascial 
tensions/restrictions 
Tension noted over posterior 
neck and L buttock 
Reduced thoracic kyphosis. 
Tension noted at L upper 
trapezius, TL, L lateral lower 
back region, R buttock 
 
Right inguinal area Occipital tightness 
Muscles Hypertonic: 
left psoas 
left LES 
L gluteals 
Hypertonic: left psoas 
left LES 
R piriformis 
CES 
Hypertonic: 
LES – L>R 
CES 
Hypertonic: 
Right psoas 
 
Somatic dysfunctions 
of the vertebral 
column or joints 
C2 – FRS right 
T6 -  FR left 
L4 -  ERS left  
Sacrum – rot L 
 
L hip - NAD  
C2 – FRS right 
T6 -  FR left 
L4 -  ERS left  
Sacrum – rot L 
R innominate – anterior 
L hip - posterior 
C2 – FRS right 
T6 -  FR left 
L4 -  ERS left  
Sacrum – rot L 
R innominate – posterior 
 
T6 -  FR left 
L4 -  ERS left  
Sacrum – rot L 
 
Cranial     
Standing Flexion Test Negative + right + right negative 
Seated flexion test Negative + right negative + left 
Visceral    Ovary palpation – very  
tender, R & L 
Other     
Orthopaedic screen Cx ROM – decreased 
sidebending left 
Lx ROM – NAD 
Squish – NAD 
Lx ROM - NAD 
Squish – NAD 
Lx ROM - NAD 
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Fabere, Thomas’, Squish, 
Moderate Craigs – NAD 
Neurological screen  Cranial nerve screen – NAD 
Scapulohumeral –ve right and 
left 
Reflexes: 
C5 - +2 R & L 
C6 - +2 R & L 
C7 - +2 R, +1 L 
L4 - +2 R & L 
S1 - +2 R & L 
Scapulohumeral –ve right and 
left 
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Table 9: OMT performed and advice given to Dianne for each consultation 
Technique Treatment 1 Treatment 2 Treatment 3 Treatment 4 
Soft tissue CES CES, LES LES, CES LES 
Articulation Thoracic region Thoracics Lx and Cx 
Myofascial Release Right inguinal area 
HVLA T6 Right innominate T6 
Inhibition Right piriformis Suboccipital region 
MET Sacrum (with respiration) and 
L4 
Sacrum (with respiration), 
L4 
C2, L4, sacrum sacrum 
Counterstrain Left psoas, suboccipital 
inhibition 
L gluteals and L psoas Right and left psoas 
Response to treatment Ovaries – decreased 
tenderness  
Decreased left low back 
pain 
Advice Continue exercise as can do 
within restrictions of shift work. 
Take flaxseed oil again (for 
GLA). (Reacts to EPO – 
evening primrose oil). 
Feels anxious at the 
moment as waiting for the 
results of a job interview. 
Continue to exercise and 
take flaxseed oil 
Continue with exercise 
(finds this helps with 
tension) and flaxseed oil 
Continue exercises 
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hypertonic than the right in two of these consultations. Table 7 shows examination findings 
for all four consultations. A key to the abbreviations is available in Appendix 1. 
 
iv. Osteopathic Treatment 
A variety of osteopathic techniques were used throughout the four consultations, including:  
articulation, myofascial release, HVLA, inhibition, MET, visceral manipulation, and soft tissue 
technique. The applications varied within each treatment depending on the examination 
findings. This is consistent with general osteopathic management throughout Australia.6  
Summaries of treatment can be found in Table 8 below.  A key to the abbreviations is 
located in Appendix 1. 
 
v. Scores for Greene Climacteric Scale (GCS) and Depression Anxiety Stress Scale 
(DASS) During Treatment Period. 
Dianne attended nine counselling sessions in nine weeks, with a follow-up at 20 weeks 
following the first consultation. The DASS and GCS were collected in weeks 1, 6, 9 and 20 
from the initial consultation (week 1).  
 
The DASS depression subscale scores dropped to zero by the end of the intervention period 
at week 9. This score increased slightly at the week 20 and twelve month follow-ups. The 
DASS anxiety subscale scores dropped to zero by the end of the intervention period at week 
9. The score increased slightly at the week 20 follow-up, with a slightly higher score at the 
twelve month follow-up. Although there was an increase at the twelve month follow-up it did 
not return to the original score recorded at week 1. For both the depression and anxiety 
subscales there was an increase in the scores at week 6 that exceeded the week 1 scores. 
The DASS stress subscale score had a similar pattern of change, however, the score at the 
twelve months showed a greater increase than that of the depression and anxiety subscales. 
This increase was responsible for the magnitude of the total score at the twelve month 
follow-up. Figure 5 shows the scores for the different scales at the collection points.  
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Figure 5: DASS scores for Dianne at each collection point 
 
 
 
The total score of the GCS peaked at the week six collection date and rose again at the 
twelve months follow-up. These peaks were primarily influenced by a rise in the scores for 
the psychological scale that occurred at week six and the twelve month follow-up. This is 
consistent with the DASS scores recorded at week 6. The scores for the somatic scale of the 
GCS showed a peak at week six and then plateaued. The scores for the vasomotor scale of 
the GCS oscillated between a score of zero and two from the first week of consultations to 
the follow-up at twelve months. Figure 6 shows the scores for the different scales at the 
collection points. The subscale scores for depression and anxiety followed a similar trend to 
those of the psychological scale of the GCS and DASS (Figure 7). 
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Figure 6: GCS scores for Dianne at each collection point 
 
 
Figure 7: GCS subscale scores for depression and anxiety for Dianne 
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vi. Reliable and Clinical Change Results for DASS and GCS 
Dianne’s scores the DASS’s stress subscale met all the criteria to indicate that a reliable 
change had occurred at weeks 9 and 20. A reliable change was not recorded at any other 
time for the DASS. A clinically significant change in Dianne’s stress subscale occurred at 
week 9 and 20. The depression, anxiety subscales did not show a clinically significant 
change at any stage. Detailed results are available in Appendix 11. 
 
Dianne’s GCS scores for the psychological scale did not did not demonstrate a reliable 
change or clinically significant change in any of the data collected. Appendix 11 contains 
tables with a breakdown of scores for all reliable and clinical change calculations. 
 
vii. WAI scores  
WAI scores were collected at weeks 1, 6 and 9 of the consultation period for both the 
osteopath and Dianne, and the psychologist and Dianne. The scores for Bond, Task, Goal 
and Total Score are located in Table 9.  Dianne rated the osteopath more positively than the 
provisional psychologist on each dimension at every time period. The scores for the Task 
subset demonstrated the closest correlation between the Dianne and osteopath throughout 
the data collection period. The osteopath’s scores for the Bond subset remained consistent 
throughout the treatment phase, however Dianne’s scores decreased over this period. In 
relation to the scores for the Goal subset, the osteopath’s scores increased slightly while 
Dianne’s decreased.  
 
The scores associated with the psychologist and Dianne, showed that Dianne had higher 
scores for Task and Bond than the psychologist’s. There was a greater difference between 
these scores than those observed between the osteopath’s and Dianne’s. The greatest 
similarity between Dianne’s scores and the psychologist’s scores were in relation to the 
Bond. Dianne’s scores for the Bond increased between weeks one and nine in relation to the 
psychologist, where they decreased between Dianne and the osteopath.  
 
viii. Adverse Events 
No adverse events were recorded in either the osteopathic or counselling sessions. 
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Table 10:  WAI scores recorded by both the osteopath, psychologist and Dianne during the intervention period 
 Bond Task Goal Total Score 
Week OMT D CBT D OMT D CBT D OMT D CBT D OMT D CBT D 
1 72 77 76 62 79 78 58 61 65 78 58 68 216 233 192 191 
5 70 65 70 57 71 71 59 74 71 80 57 75 212 216 186 206 
8 73 68 74 72 80 78 53 74 70 74 49 71 223 220 176 217 
 
Key:   CBT = psychologist, OMT = Osteopath, D = Dianne 
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Case Study 3 
The participant in case study 3 will be known as ‘Sarah’. 
 
i. Description of Sarah    
Sarah was a 48 year old, married woman. She was born in Australia, has completed a 
master degree level qualification and has had no children. She responded to an 
advertisement placed in the local newspaper inviting participants for this study. 
 
ii. Screening Interview 
The Screening Interview data indicated that Sarah was in the early peri-menopausal stage 
as she had not experienced an interval between menstruations of more than 60 days. Sarah 
had consulted her general practitioner within a six month period of the interview due to lack 
of energy and for a general check-up. She stated that she had been diagnosed with anxiety, 
which manifested with chest pains of a benign nature. Sarah indicated that she was taking 
iron, vitamin B12 and vitamin D supplements and using a prescribed cream for basal 
carcinoma that Dianne indicated was being well managed.  
 
The Depression, Anxiety and Stress Scale (DASS) administered at the time of the Screening 
Interview showed scores for depression and anxiety of 19 and 9 respectively. However the 
stress score was higher at 29. Sarah met the criteria to be included into the project as no 
lower limit for the depression score was designated and she did not exceed the maximum of 
score of 20.  
 
The Greene Climacteric Scale (GCS) score overall was 23 which was above the mean score 
of the menopause clinic sample of 22.9,95  and indicated that Sarah was experiencing 
menopausal symptoms. The psychological score was 12 and was just less than the mean 
score of the menopause clinic sample of 12.33. In the subset of the psychological scale for 
depression and anxiety Sarah scored 7 and 5 respectively. Sarah, therefore, met the criteria 
for inclusion to the project in regards to the GCS.   
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iii. Osteopathic Consultation Outcome 
Sarah attended four OMT consultations; in weeks one, four, five and eight of the treatment 
phase of the study. The most consistent findings over the eight week period were somatic 
dysfunctions at C2, L3 and the sacrum. Hypertonic lumbar and cervical erector spinae and 
psoas muscles were another consistent finding. During the consultations at week 4 and 5, 
Zink fascial patterns were noted to be uncompensated.   Table 10 shows examination 
findings for all four consultations. A key to the abbreviations is available in Appendix 1. 
 
iv. Osteopathic Treatment 
A variety of osteopathic techniques were utilized throughout the four consultations and 
included:  articulation, myofascial release, HVLA, inhibition, MET, functional, counterstrain, 
and soft tissue technique. The application varied within each treatment depending on the 
examination findings. This is consistent within general osteopathic management throughout 
Australia2. Summaries of treatment can be found in Table 11   below.  A key to the 
abbreviations is available in Appendix 1. 
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Table 11: Osteopathic presenting symptoms and examination findings for Sarah for each osteopathic consultation 
Examination Consultation 1 Consultation 2 Consultation 3 Consultation 4 
Presenting symptoms R thigh pain with going up 
stairs – for last three 
months 
 
LBP – central, intermittent 
 
Occasional neck stiffness 
 
HA – for last 2 days – NAR 
 
R rotator cuff tear – 1 year 
ago – osteo ttt 
Med elbow discomfort 
 
R knee pain 
Always feeling tired. 
 
Period – regular (28 days). 
Has pre period. Short bleed 
time 1-3 days. Hot 
flushes/sweats in the past. 
Slight LBP with period. Mild 
dysmenorrhoea (onset last 
3 years). 
 
L temp – feels warmer, dry 
mouth (mod-severe). 
Had period as usual. No HAs 
premenstruation. More LBP 
post period and some 
digestive discomfort. 
 
Minimal post ttt soreness. 
 
R thigh pain improved but 
returned. 
HA for  2 days (4 days post ttt) 
– felt dehydrated. 
 
R thigh pain – nil 
 
Some R SIJ discomfort 
Increased stress – busy time 
of year 
 
Some anxiety. More tension. 
Some shoulder tension  
HAs – nil 
 
Period – nil Has. Nil or minimal 
dysmenorrhea – very slight 
‘dragging’ down sensation. 
 
R thigh pain – quite good until 
helping mother who was unwell. 
Stressed & uncomfortable 
sleeping. 
 
Work – good, not too stressful.  
Zink Fascial Patterns OA – left 
CT – right 
TL – left 
LS - right 
OA – left 
CT – left 
TL – right 
LS - left 
OA – left 
CT – left 
TL – right 
LS - left 
OA – left 
CT – right 
TL – left 
LS - right 
Fascial Tension in cervical fascia,   Occipital tightness 
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tensions/restrictions and slightly reduced spinal 
curves 
Muscles Hypertonic: 
R psoas 
 
Hypertonic: left psoas 
left LES 
CES   
Hypertonic: 
LES  
CES – R > L 
Upper traps 
Hypertonic: 
Right psoas 
LES 
R CES 
Gluteals 
 
Somatic dysfunctions 
of the vertebral 
column or joints 
OA R posterior 
C1 L rot 
C2 FRS R 
T5 ER R 
L3 ERS L 
Rib 1 – L superior 
Sacrum – L on L 
R hip - compressed  
OA – NAD 
C1 – L rot 
C2 – FRS R 
T5 – ER R 
L3 – ERS L 
Sacrum – L on L 
RAI GH jt 
C2 – FRS right 
L3 -  ERS right  
Sacrum – L on L 
R innominate – posterior 
 
C2 – FRS R  
L3 – ERS R 
R innominate – posterior 
Sacrum L on L 
 
Cranial     
Standing Flexion Test Negative negative negative positive R 
Seated flexion test Negative negative negative negative 
Visceral  Pt commented that there was 
some digestive discomfort 
  
Other     
Orthopaedic screen Lx active ROM – NAD. S/B 
“feels” tight 
Hip – decreased internal rot. 
Lx active ROM – decreased 
sidebendig R 
FABERE – L positive 
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Short R leg 
ELY’s test – NAD 
FABERE – R decreased 
ROM 
Modified Craig’s – sh R leg 
R groin pain 
Neurological screen  Psoas – R  strong L weak  
Rectus fem – R and  L 
strong 
Quads – R and  L strong 
 
Psoas – R and L strong   
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Table 12: OMT performed and advice given to Sarah for each consultation 
Technique Treatment 1 Treatment 2 Treatment 3 Treatment 4 
Soft tissue LES CES, LES LES, CES, upper traps R gluteals, CES and LES 
Articulation Thoracic springing   Thoracic 
Myofascial 
Release 
    
Functional C2    
HVLA L3 L3, T6 Right SIJ (prone), L3 R innominate (prone), L3 
Inhibition Suboccipital suboccipitals Suboccipital inhibition Suboccipital region 
MET Sacrum and C1 Sacrum, C2 Sacrum, C2 Sacrum, C2 
Counterstrain  L gluteals and L psoas   
Response to 
treatment 
    
Advice Continue supplement and 
exercise regime. 
Consider stress management 
Continue supplements and exercise Continue to exercise as 
possible due to busy time of 
year 
Continue exercises 
Stress management 
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v. Scores for Greene Climacteric Scale (GCS) and Depression Anxiety Stress Scale 
(DASS) During Treatment Period. 
Sarah attended six counselling sessions in eight weeks, with a follow-up at 20 weeks 
following the first consultation. She also attended three counselling sessions in between 
week eight and the follow-up at 20 weeks. The DASS and GCS were collected in weeks 1, 6, 
8 and 20 from the initial consultation and at a twelve month follow-up.  
 
The scores of the DASS dropped overall at the end of the eight week treatment period, and 
continued this trend at the 20 week follow-up period, with a slight increase at the twelve 
month follow-up.  At the twelve month follow-up there was a slight increase in the depression 
score and anxiety scores. However, the stress scale score increased and this pushed the 
total score higher at the twelve month follow-up. All subscale scores were lower at the twelve 
month follow-up than those collected in week 1 of the intervention period. Figure 8 shows the 
scores for the different scales of the DASS at each collection point.  
 
 
Figure 8: DASS scores for Sarah at each collection point 
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The total score of the GCS decreased steadily up to the 20 week follow-up collection period 
and then increased at the twelve months follow-up. This increase was primarily influenced by 
a rise in the scores for the psychological and vasomotor scale. The score at the twelve 
month follow-up for the psychological subscale did not rise to that of the score collected in 
week 1 of the intervention. The scores for the somatic and vasomotor subscales were the 
same at week 1 and 12 month follow-up collection points. Figure 9 shows the scores for the 
different scales of the GCS at each collection point.  
 
 
Figure 9: GCS scores for Sarah at each collection point 
 
The depression subscale scores of the psychological scale showed a marginal increase 
between the week 20 and twelve month collection periods; both were lower than that 
recorded in week 1 of the intervention. The anxiety subscale scores of the psychological 
scale also showed a marginal increase between week 20 and twelve month collection 
periods; both of were lower than that recorded in week 1 of the intervention.  Figure 10 
shows the scores for the psychological subscales of the GCS at each collection point. 
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Figure 10: GCS subscale scores for depression and anxiety for Sarah 
 
vi. Reliable and Clinical Change Results for DASS and GCS 
Sarah’s scores for the DASS’s stress subscale met all the criteria to indicate that a reliable 
change had occurred at week 9 and 20. A reliable change was not recorded at any other 
time for the DASS. 
 
A clinically significant change in Sarah’s depression subscale score occurred in the data 
collected at week 9 and the stress subscale scores at weeks 9 and 20. No other clinically 
significant change was recorded.  
 
Sarah’s GCS scores for the psychological scale did not demonstrate a reliable change or 
clinically significant change in any of the data collected. Appendix 11 contains tables with a 
breakdown of scores for all reliable and clinical change calculations. 
 
vii. WAI scores  
WAI scores were collected at weeks 1, 5 and 8 of the consultation period; they were 
completed by both the osteopath and Sarah, and the psychologist and Sarah. The scores 
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reported by Sarah were generally slightly higher than those recorded for the osteopath.  The 
scores for the Goal showed the biggest discrepancy between the osteopath and Sarah.  The 
scores for Bond and Task showed variations over the collection period with no particular 
pattern being observed.  
 
The scores for the counselling sessions showed a trend where Sarah’s scores for each 
category decreased over the eight weeks while the scores for the psychologist increased. 
The scores for the Task and Goal showed greater similarities for weeks one and five, 
however, differed in week eight, where the psychologist’s rose and Dianne’s fell. The scores 
for Bond, Task, Goal and Total Score are located in Table 12.   
 
viii. Adverse Events 
No adverse events were recorded in either the osteopathic or counselling sessions. 
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Table 13: WAI scores recorded by both the osteopath, psychologist and Sarah during the intervention period 
 Bond Task Goal Total Score 
Week OMT S CBT S OMT S CBT S OMT S CBT S OMT S CBT S 
1 76 80 69 71 76 83 72 69 72 82 70 73 224 245 211 213 
5 74 83 79 69 79 80 75 76 70 84 75 73 223 247 229 218 
8 75 77 81 61 81 84 80 68 71 91 80 69 227 252 241 198 
 
Key:   CBT = psychologist, OMT = Osteopath, S = Sarah
78 
 
Mean Values of the DASS and GCS scores of the Combined Case Studies 
This section provides tables of the mean values for the combined case studies for the DASS, 
depression, anxiety and stress scales, and the GCS, psychological scale. A reliable change 
or clinically significant change was not demonstrated for any of the mean values, except for 
the DASS Stress scale at week 20.  Appendix 11 contains tables with a breakdown of scores 
for the reliable and clinical change calculations.  Figure 11 shows the mean scores for the 
DASS Depression Scale for the three participants. The mean depression scores after week 
five collection point show a steady decrease that was maintained between week twenty and 
the twelve month follow-up.  
 
 
Figure 11. DASS Depression scores showing the mean score of the three participants 
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The mean scores of the DASS Anxiety Scale are shown in Figure 12. A decrease in scores 
continues up to the week twenty collection point, however there is a slight increase in the 
mean anxiety score at the twelve month follow-up. 
 
 
 
Figure 12. DASS Anxiety scores showing the mean score of the three participants 
 
 
 
The mean scores of the DASS Stress Scale are shown in Figure 13 and shows a similar 
pattern to that of the Anxiety Scale. The increase at the twelve month follow-up is slightly 
greater than that shown in the Anxiety Scale. The Stress Scale was the only scale that 
showed a reliable, clinical change of 95% confidence at week 20. This change did not meet 
the criteria to be a reliable change and no other clinical or reliable change occurred at any of 
the other data collection points. 
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Figure 13. DASS Stress scores showing the mean score of the three participants 
 
 
 
The mean scores of the GCS Psychological Scale are shown in Figure 14. There is a 
minimal increase in mean score at the week five collection period and then a decrease that 
continues to the week twenty collection period. There is an increase in mean scores at the 
twelve month follow-up point. The mean score for the GCS Psychological Scale is consistent 
with the trends shown for the DASS. A positive trend in the improvement of the self-reported 
depression experienced by the participants in this project is apparent. 
 
 
81 
 
 
Figure 14.  GCS Psychological scores showing the mean score of the three participants
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Thematic Analysis of Interviews 
The following is a summary of the interviews for all three participants, with relevant quotes. 
During the initial analysis, three broad themes emerged consistent with the structure of the 
interviews. These broad themes included: motivation for participating; experience of 
menopausal symptoms; and experience of OMT and counselling. The broad themes were 
then further analysed to arrive at overall themes. Each individual participant’s summary will 
be provided under the three broad themes before the final emerging themes will be 
presented.  
 
i. Case Study 1 – Patricia 
a. Motivation for Participating. 
Patricia’s motivation for inquiring and participating in the project was triggered by a need to 
understand what was happening to her and a desire to gain more knowledge about the 
menopausal transition. Patricia stated “…I didn’t know where it [peri-menopause] was going 
to head. I didn’t know if it was going to get worse, become more frequent, I didn’t know much 
about it.” This lack of knowledge proved to be the catalyst to find answers. Patricia had 
spoken with her GP about the symptoms she had been experiencing, however, was still left 
with unanswered questions. She was surprised to be experiencing menopausal symptoms 
and stated “I’m not 50.” Patricia had believed that menopausal transition symptoms would 
not occur until midway through her 50s and had little idea that symptoms could start in her 
40s. 
 
Prior to participating in the project Patricia had no expectation her depressive or menopausal 
transition symptoms would change. “I wasn’t thinking about how much I wanted to get out of 
the project; I thought if I learnt something, that would be great.”  The thought that she might 
learn something had an altruistic component. She expressed a desire to support the 
increasing awareness of the effect of the menopausal transition and the need to find better 
ways to manage menopausal symptoms. She stated that “… the other 50% is, “Finally 
someone is looking at this.” …someone was looking at women and menopause and what’s 
going on in their life at this age, and thinking about, “How can we help women?”  So that … 
played a big part in me participating.” 
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b. Experience of the Menopausal Transition Symptoms 
Patricia described hot flushes and changes associated with peri-menopause that she was 
experiencing as “…making me very anxious and that bothered me.” The unexpected onset 
of symptoms created a sense of being overwhelmed, confused and uncertain, and these 
symptoms were dominating her life. She had also noticed a deterioration in cognitive 
functioning, stating “I’ve only noticed it in the last two years, that the brain is just not there at 
some point in the cycle. Yeah, it’s just not there, not working.”  As stated previously these 
contributed to her need to find answers so that she could feel more in control of what was 
happening to her. 
 
c. Experience of the OMT and Counselling 
Patricia’s overall experience of the OMT and counselling was very positive. Although Patricia 
had experienced osteopathy prior to her participation, which had been favourable, she 
wasn’t sure how OMT assisted her and was unable to describe any specific outcomes from 
this part of the intervention. However, she stated that her experience of OMT was “excellent, 
excellent”.  She was unable to say if she felt that OMT had helped her menopausal transition 
symptoms but summed up her experience by stating “I know I felt better, but I couldn’t say if 
it then crossed over [to feeling psychologically better].  I just felt better, just physically; it was 
really good.” 
 
In contrast Patricia was able to articulate what she gained from the counselling. She noted 
how she was able to apply the CBT approach had continued doing so during the time 
between the end of the project and the interview. Patricia started questioning the relationship 
between her physical symptoms and psychological symptoms; did one type of symptom 
aggravate the other.  She stated “I’ve spent some time wondering about the relationship 
between what’s going on in my body and what’s going on in my head.  So sometimes I think 
about when there’s a lot going on in my head, does that make my [physical] symptoms 
worse?  Or when my [physical] symptoms are worse, does that make what’s going on in my 
head worse?” By learning to observe the relationship between her physical and 
psychological symptoms, Patricia had a greater ability to control what was happening to her. 
Patricia was empowered to separate her thoughts from what she was feeling. 
 
Patricia achieved what she was looking for from the project; an understanding of what was 
happening to her and her body and ways of managing them. Her experience of the 
osteopathic practitioner was that they were thorough and knowledgeable and the 
“practitioner…educated me about my body and what it was doing”. She learned to 
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differentiate what she was feeling and what she was thinking from the psychologist. Her 
participation allowed further knowledge to be gained about the menopausal transition and 
ways to manage it.  
ii. Case Study 2 - Dianne 
a. Motivation for Participating 
Dianne stated her motivation to participate was due to an awareness of how difficult it can be 
to recruit participants in research projects. When she read the advertisement in her local 
newspaper she identified with being menopausal and felt that this would be a way of offering 
something to her community.  She stated “I was aware of how difficult it was to get 
participants to actually participate and fulfill all of the requirements [of the study]  … I like to 
involve myself in community things, I like to give back.  So if I could give back a little bit, that 
was what my goal was.” 
 
Dianne had no previous experience with osteopathy and knew little about it. She was curious 
and somewhat sceptical about osteopathy’s role in helping her with her menopausal 
symptoms.  This was highlighted in her comment “I remember thinking, ‘How can that 
conceivably help me with menopause?’  And I remember speaking to other people, and they 
even said to me, “So what is that going to do?” [laughs] And I’m like, “I have no idea, but I’m 
going to give it a go.”   This is somewhat surprising as Dianne was scared of the thought of 
having manipulation performed on her and yet her need to contribute to her community and 
knowledge gained from research enabled her to overcome these fears. She recalled an 
incident where she discussed the project with work colleagues who visited either an 
osteopath or chiropractor on a regular basis. She recalled thinking “So I’m the only one 
sitting around this whole table that was scared stiff.”     
 
Despite her fear and not expecting any significant personal gain, Dianne did state she felt 
she had benefited from participating in the project. She stated that “as the study moved 
forward I started to realise I got more out of it than what I was giving”. 
 
b.  Experience of the Menopausal Symptoms 
Dianne’s menopausal symptoms did not include the common vasomotor symptoms of hot 
flushes and night sweats. She experienced headaches and migraines, severe back pain that 
could leave her unable to walk or sit, extremes in her emotions that ranged from “really low 
to really severe”, changes to her menstrual cycle which became irregular, severe 
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dysmenorrhea and heavy bleeding and clotting. Dianne’s attention was drawn mainly to her 
physical symptoms and she played down her changes “emotions”. She did state that her 
symptoms “deplete me of energy and I’ve got no patience for anything”.  
 
The changes to her menstrual cycle had an impact on her daily life in a number of ways. She 
stated that for the first 24 hours of her menstruation she would often be unable to leave the 
house or get out of bed. One of the ways that Dianne noticed how the menopausal transition 
impacted on her daily life was when she was on holiday. “So we’re in South Australia and I’m 
at the hotel and I get a headache, and anyway, I didn’t even put two and two together, got 
the period.  We could not drive back from Adelaide to Melbourne because I couldn’t sit in the 
car for those eight hours.  We had to delay to the next day.  Once I’ve got through that first 
24 hours with that pain, then I seem to, it seems to subside and come good.”   
 
Dianne did state that when she was very busy at work her periods could commence without 
her being aware of them. She would not get the debilitating pain. She had some insight into 
how being busy reduced the symptoms by stating “Interestingly enough though, if I am at 
work and I’m so busy doing emergencies and things, I can get home and have got my period 
and not even known. It’s when I’m on my days off it’s more pronounced.  And whether it’s 
because I’m so relaxed at home and I’m not really doing anything, and then I’m at work and 
I’m so, I’m concentrating so much on four patients, I don’t have time to be thinking, you 
know, “What’s wrong with me?”  
 
Dianne had not associated her symptoms to her menopausal status until she participated in 
the project. “I certainly didn’t connect the headache to the period, and I certainly didn’t 
connect the back pain to the period, and I certainly didn’t connect the fact I could hardly 
move, like I’d be thinking, “What have I done to my back?  This is really bad.  I can’t sit, like 
there’s no position I can get in.”  I didn’t connect that to the period either.  As the 
menopause, as my symptoms or my peri-menopause is moving towards menopause and my 
periods are becoming further and further apart it’s become, its worse”. The increasing 
intensity of Dianne’s symptoms and impact on her life may have also been a factor in her 
ability to overcome her fear of OMT. The fear of her physical symptoms getting worse 
overshadowed her fear of physical treatment necessary to manage them.   
 
c. Experience of the OMT and Counselling 
The statements Dianne made about her experience of OMT were contradictory. She focused 
on what had not changed in some statements and then in other statements acknowledged 
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the improvements she had noted. Dianne stated that “the manipulative therapy didn’t really 
help me with the headaches.” This statement was followed with “But from a physical point of 
view her therapy helped.” Dianne stated she had noted some significant differences in her 
symptoms and posture which she attributed to the OMT. This ambivalence can be linked to 
her fear of having manual treatment.  
 
During her OMT Dianne had been advised of the way her posture was contributing to her 
physical symptoms. She had not been aware of this and had not thought that she needed to 
change the way she held her body.  It was not until she was doing an exercise class that 
Dianne was aware of the significant change that had occurred in her posture. “I always 
angled myself on an angle, and I thought I was angling myself on the angle to look at the 
instructor.  After [the osteopath] fixed me the first time all of a sudden I could stand straight 
and my feet were straight on, and for the moment I was like this glimmer of, “Oh my God.  
I’ve been crooked all these years.” Dianne was able to notice this change after her first OMT 
consultation.  
 
On the day of her last OMT consultation Dianne nearly cancelled as her period had started 
and she was experiencing significant pain. She noted that the osteopath did not want to let 
her leave the treatment room until she was feeling more comfortable. Dianne was surprised 
that the OMT was able to assist in reducing her pain levels. She stated “…it hurt.  So she 
was very mindful of that.  The interesting thing was that it did subside, as in whatever it is 
that she did, it did help the acuity of my pain that I had.”  
 
One of the outcomes of participating in the project noted by Dianne was a change in the way 
she communicated with her patients at work. She appeared to become more open, less 
defensive and more empathic in her manner with her patients. She stated “So that was 
another thing I suppose I gained from having those sessions is when I went back to work I 
gave a lot more whereas before I wouldn’t even tell them my name.” The CBT consultations 
provided Dianne with greater insight into the value of counselling sessions and more 
empathy when she referred her own patients for counselling. 
 
Dianne had some positive outcomes from participating in the project and noted that “it did 
significantly help”. However, even though nothing adverse happened in the OMT 
consultations she appeared unable to overcome her fear of manual therapy. She 
commented that her menstrual related symptoms  “…was much, much better.  Now that it’s 
been a couple of months since I’ve had any, and I haven’t had any therapy at all, it’s 
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returned to exactly what it was previously.  So I’m very tempted to go back [laughs] and have 
some more therapy.” Dianne wasn’t sure if she would have regular manipulation and asked 
herself whether she should have more osteopathic consultations given they had improved 
her symptoms.  She finished the interview by saying “so I will eventually, one day [laughs]”. 
 
iii. Case 3 - Sarah 
a. Motivation for Participating 
Sarah’s motivation for inquiring and participating in the project was triggered by the impact of 
the menopausal symptoms she was experiencing. She was experiencing a number of 
physical and emotional symptoms, of which a noticeable change in mood was one. Sarah 
stated “I just didn’t feel right is probably a good way to put it.” She spoke about getting to the 
point of thinking “I need some help”.  
 
The prospect of having osteopathic treatment was a motivating factor due to her expressed 
dislike of using medication. Sarah had previously had osteopathic treatment and had a 
positive experience of it. Although she was not certain how osteopathy would help with her 
mood, she believed it would be beneficial for the physical symptoms she was experienced. 
Participating in the project also meant that both the physical and emotional symptoms could 
be addressed and finances did not need to be considered.  Her comment that she “didn’t 
know a lot about it [osteopathy] but it appealed to me more than some of the other options” 
supports her desire to find a drug free way of managing her symptoms.  
 
Sarah also appeared to want a form of nurturing that was not as readily available from her 
usual sources at the time of the project. She states that she “felt withdrawn from friendships” 
and that she sought activities such as eating to meet her need to feel better. This is 
highlighted in her statement that she would “…eat six blocks of chocolate…to try and sort of, 
I don’t know feel better or something”. Sarah felt out of control and she wanted help in 
changing this. 
 
The final motivating factor for Sarah inquiring and joining the project was that the 
interventions were convenient to get to.  “Also I was attracted by the location – being at 
RMIT Bundoora was easy for me to get to because of where I live – if it had of been in city, 
more difficult to get to, possibly wouldn’t have applied.”   
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b. Experience of the menopausal symptoms 
Sarah  had experienced a number of menopausal symptoms prior to entering the project:  a 
reduction in sex drive, sweating and night sweats, memory problems associated with finding 
the right words, shorter attention span, forgetfulness, poor concentration, irritability, 
frustration, depression, physical discomfort, confusion, feeling in conflict with herself and out 
of control.  
 
Sarah struggled to admit that one of the symptoms she was feeling was  depression and had 
told the psychologist that she “felt like a fake” attending the counselling sessions, “because 
you know, I mean I’m not clinically depressed but I just don’t feel right”. In the interview 
Sarah struggled to acknowledge that she was depressed and stated “I don’t know if I was … 
depressed but I was feeling very down, very much withdrawn and unhappy and looking for 
something I guess.” Feeling down, withdrawn and unhappy are indicators of being 
depressed, and yet Sarah didn’t want to label them as such. Sarah did eventually 
acknowledged her depression by stating “I just felt yeah, withdrawn from friendships and 
yeah, I guess … I thought I was depressed.”  
 
Sarah commented that her memory was noticeably different. She noted that there were 
times when she was unable to find words or lost track of the conversation and that this 
reminded her of her 80 year old mother. Peri-menopause was also having an adverse 
impact on her concentration and ability to focus. She stated “I find my attention is a bit 
shorter I think than it used to be….I sort of wander off a bit in my mind.” Sarah stated she 
was frustrated by these changes.  
 
The physical symptoms Sarah was experiencing were also bothering her. Beside the 
vasomotor symptoms, Sarah noted feeling  “physically more bloated, physically more 
uncomfortable … a lot more lethargic and heavy.”  The combination of physical, mental and 
emotional symptoms were described by Sarah as “being in conflict with yourself” and she 
experienced a loss of control. 
 
c.  Experience of the OMT and Counselling 
 
“I found it really useful, well I thought both the person I had for the osteopathy and the 
counselling were excellent, you know I felt very comfortable with them.  I thought they were 
very professional, I felt very cared for by them which … I guess I wasn’t expecting.” This 
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comment by Sarah highlights the positive experience she had in participating in the project 
and how the combination of OMT and counselling filled the need for nurturing or comfort that 
she was seeking. She stated that she no longer needed to “eat six blocks of chocolate” 
because the OMT and CBT had helped her develop new strategies of looking after her self.  
 
Sarah found OMT beneficial for her physical symptoms and also commented that it helped 
her mood. She stated “I guess in terms of my mood it was helpful because again, someone 
was caring for me. And doing yeah, doing the manipulation and helping me to understand 
my body a bit more as well…” The physical support of the OMT was well complemented by 
the counselling which provided Sarah with a means to find “other approaches to situations”.  
It helped her identify when she was over doing exercises and other work and this had 
reduced her feeling of being worn out all the time. 
 
Sarah was very clear that the combination of OMT and counselling worked well. She 
summed this up by saying “I certainly would recommend doing that sort of conjunction, the 
two things together.  Although she had not considered combined therapy before, she noted 
how effective the mind/body synergy created by the OMT and CBT was. “I do really think … 
how you feel affects your body and vice versa, yeah.” 
 
iv. Thematic Analysis of the Combined Case Studies    
A thematic analysis of the combined case studies was undertaken. From this analysis global 
themes emerged that provided insight into the perception of the role of OMT in the 
management of depressive and menopausal symptoms.  
 
The osteopathic management of menopausal and depressive symptoms elicited scepticism 
or curiosity, “I remember thinking, “How can that conceivably help me with menopause?”[D]. 
Scepticism also appeared to be the response of the friends of one of the participants. “So 
what is that going to do?” was the response of the people this participant had received when 
telling them of her participation in the project. The scepticism was expressed mainly by the 
two participants who had little or no knowledge of osteopathy. The one participant who had 
received OMT was not sure how it could influence her mood changes and physical 
symptoms, however, “…it [osteopathy] appealed to me more than some of the other 
options”[S] and she was curious enough about the potential benefits to enquire and 
participate in the project. 
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The other motivational factor appeared to be altruistic in nature. Two of the participants 
stated that one of the motivating factors was a desire to add to the knowledge on 
menopausal symptoms and how the symptoms could be treated. Giving back to the 
community through participating was another aspect of this altruistic motivational force. This 
desire to add to the knowledge had another aspect to it; the participants wanted to 
understand what they were experiencing as all three implied that they were unprepared for 
the extant and variety of symptoms they experienced. One even felt she was too young at 48 
to be experiencing peri-menopausal symptoms. 
 
The overall theme in regard to OMT as an adjunct to CBT was a positive one. All three 
women commented on feeling physically better because of the OMT component of the trial, 
and could see the benefits of the CBT on their mood and handling of day-to-day matters. 
Despite these positive changes, the women did not find it easy to articulate how OMT had 
helped them. Only one participant stated that she could see the how the combination of 
OMT and CBT was beneficial for both her physical and psychological symptoms. She stated 
“I certainly would recommend doing that sort of conjunction, the two things together.”[S]  
 
In regard to menopausal symptoms, the main focus of the women appeared to be on the 
physical symptoms associated with the menopausal transition. Although the participants 
were aware that the project was looking at the depressive symptoms associated with the 
menopausal transition, this was not given the same weighting. The participants were 
generally comfortable speaking about their physical symptoms, but needed to be prompted 
to acknowledge their mood changes. One participant highlighted this when she told the 
psychologist she ‘felt like a fake’. She went on to say “…because you know, I mean I’m not 
clinically depressed but I just don’t feel right.” This would suggest that there is still some 
reluctance in women to acknowledge mental health changes during this phase of their life. 
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Chapter 5  Discussion    
Background 
Life expectancy is increasing and this has led to the number of women within the 
menopausal age range to increase. The number of menopausal women in Australia is 
anticipated to increase to 20% of the female population within the next ten years.5 
Symptoms associated with the menopausal transition go beyond the commonly discussed 
hot flushes and night sweats to include somatic and psychological symptoms. Peri-
menopausal women with no history of major depression are twice as likely to develop 
depressive symptoms for the first time.36 Although drugs are available to treat menopausal 
and depressive symptoms, they are not 100% successful and side effects can be serious.27, 
28,62 
 
More women than men consult osteopaths in Australia.6  As somatic symptoms are 
frequently reported by Australian menopausal women, it is reasonable to assume that 
osteopaths treat menopausal women.16   A few small studies demonstrating OMT has a 
positive effect on depression and menopausal symptoms have been reported.9,10,91,92,93,94 
 
Aims and Objectives 
The primary focus of this project was to investigate the effects of OMT and standard care 
(CBT) on depression levels in depressed menopausal women. The project had two 
secondary foci:  to provide insight into whether there are common osteopathic examination 
findings that could be used to facilitate a management strategy for osteopaths treating 
depressed menopausal women; and explore the participants’ acceptance of OMT as an 
adjunctive management to standard care of depression in menopausal women.  
 
Principal Findings 
A mixed method, case study design was used to answer the research questions. Depressive 
symptoms were scored lower at the end of the project, however, a reliable change was not 
demonstrated for depression during the project, and a clinically significant change was only 
observed at two of the fifteen data collections. Common osteopathic examination findings 
were observed and are listed below.  A positive response to the OMT as an adjunct to CBT 
was reported by all three participants.  
 
92 
 
DASS and GCS Data 
The data collected on the levels of depression assessed via the DASS and GCS showed 
that all three participants had a reduction in their self-reported level of depression from the 
first recorded score to the final recorded score. Two of the participants achieved a clinically 
significant change in the DASS depression scores at the twelve month follow-up, and one 
participant also achieved a clinically significant change at the three month follow-up. Not all 
criteria were met to determine that there was a reliable change. Although it is not possible to 
determine whether this was due to the CBT alone, CBT and OMT, or other reasons, it 
suggests that further studies are indicated in this area of research. A study with a larger 
sample size that randomised the allocation of participants into three groups that included: 
CBT only, OMT only, and CBT and OMT, would provide greater opportunity to compare 
clinical outcomes.  
 
Stress scores showed the reliable change and clinically significant changes for all three 
participants at the three month follow-up. Reliable and clinically significant changes occurred 
at the end of the intervention period for two participants and at the twelve month follow-up for 
one participant. Again it is not possible to determine which intervention contributed to these 
changes, however, these results do support including management of stress and anxiety 
through CBT and OMT, in future research into the role of OMT in the management of 
depressive symptoms. 
 
Vasomotor scores from the GCS for two of the participants reduced by the end of the 
intervention period and at the three month follow-up. However, the scores increased at the 
twelve month follow-up, returning to the same level recorded in week one of the intervention. 
Reliable change and clinically significant changes were recorded for the vasomotor scale of 
the GCS for two of the participants (one at week 20 and the second at the twelve month 
follow-up).  The decrease in vasomotor symptoms over the first five months may suggest 
that the interventions did assist in this decrease. However, as vasomotor symptoms vary 
over time, it is not possible to conclude that either the OMT or CBT did have any influence 
on the vasomotor symptoms. Thus, designing a study that monitors changes to vasomotor 
symptoms at more frequent intervals and with a larger sample size, may assist in 
determining whether these changes are attributable to OMT and/or CBT. 
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Common Osteopathic Examination Findings 
Over the four OMT consultations the most common examination findings for all three women 
were: 
• Upper cervical somatic dysfunction 
• T4-6 somatic dysfunction 
• L3-4 somatic dysfunction 
• Hypertonicity of the erector spinae muscles, particularly in the lumbar and cervical 
region 
• Uncompensated patterns of Zink 
• Sacral somatic dysfunction 
 
The most consistent examination findings related to somatic dysfunctions of the upper 
cervical region and the pelvic region. Associated muscle and fascial restrictions in this area 
were also observed. Within osteopathic philosophy a somatic dysfunction may lead to 
altered blood flow over time due to changes in nerve supply to the blood vessels and/or 
stretching or constriction of blood vessels due to abnormal tension in fascial or muscle tissue 
surrounding the blood vessel.8   
 
Menopausal women have been shown to have reduced cerebral blood flow (CBF). As 
estrogen has been shown to enhance CBF, lower CBF is noted with the onset of peri-
menopause and hypoestrogenic states.115,1116,117,118,119  If the reduced CBF is compromised 
further by a cervical somatic dysfunction, this may further aggravate symptoms menopausal 
women experience.  
 
Studies have been conducted on the effect of placing the cervical spine in the neutral and 
non-neutral positions on blood flow because of the instances of serious adverse 
neurovascular events that have been associated with treating the cervical spine. Thomas et 
al120  undertook a study of the effect of positioning the cervical spine in positions associated 
with manual therapies.  Their study concluded that in asymptomatic participants, blood flow 
to the brain was not compromised due to the positions they placed the cervical spine in. 
They did note that although the mean values showed no significant difference, certain 
individuals had marked changes in blood flow in certain positions. This suggests that factors, 
known or unknown, may make some individuals more susceptible to changes in blood flow 
to the brain than others. The influence of lowered estrogen on blood flow may be one of 
those factors in menopausal women.  
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Thomas’s study findings are in contrast with a study conducted by Mitchell.121  Mitchell 
placed 120 healthy people in maximal cervical rotation and assessed the impact on vertebral 
artery (VA) blood flow. The study showed that a significant decrease occurred in the VA on 
the contralateral side to the rotation introduced. No significant difference was observed in the 
ipsilateral side. Conversely, one study of cervical spinal manipulation showed that 
hypoperfusion in the anterior lobe of the left cerebellum occurred. This study did not state 
whether there were areas of the brain where perfusion remained the same or increased.122  
 
All three studies conducted their research on healthy, asymptomatic participants and the 
studies cannot predict the outcome if the interventions were applied to symptomatic 
participants. As these studies placed the cervical spine in a pre-manipulation position, it is 
difficult to determine whether the position of a cervical vertebra with a somatic dysfunction 
would have a similar effect. 
 
The effect of cervical manipulation on CBF has limited research to date. Jensen123 studied 
the effect of spinal manipulation on two patients diagnosed with vertebrobasilar ischemia 
that demonstrated an improved vertebral arterial flow after spinal manipulation.  The 
physiological mechanism for these changes is yet to be determined, however, Jensen 
suggested that it may be associated with changes to the autonomic nervous system. 
Quesnele et al124  studied the effect of cervical spine position and cervical spine 
manipulation on the vertebral arteries in 10 healthy subjects. There results indicated that no 
significant changes in blood flow were observed. From the current research it is not possible 
to determine that treatment of the cervical region in menopausal women with depression 
would assist in increasing CBF. 
 
McPartland et al125  studied the effect of OMT on endogenous cannabinoids and mood. The 
study demonstrated that OMT increase two endocannabinoids (anandamide and 
oleylethanolamide) levels. The study used the Drug Reaction Scale (DRS) to measure the 
cannabimimetic effects. The study showed an significant increase in scores for descriptors 
“good, high, hungry, light-headed and stoned”  and a significant decrease in scores for 
descriptors “inhibited, sober, and uncomfortable”. The authors suggest that the reason that a 
patient’s mood may improve after OMT is due to the increase in endocannabinois. 
McPartland also states that anandamide causes release of nitric oxide which has been 
hypothesised to cause vasodilation.  Treatment of the cervical region in depressed 
menopausal women may improve mood via the release of the endocannabinoids. 
 
 
95 
 
 
All three women demonstrated an uncompensated Zink fascial pattern in at least two of the 
OMT consultations.  JG Zink, DO,126  found that patients with an uncompensated pattern 
were more likely to have poorer health and to take longer to return to good health. Two of 
the three participants were observed to have a compensated fascial pattern during their last 
osteopathic consultation. This coincided with fewer examination findings. Uncompensated 
Zink fascial patterns for two of the participants corresponded with their stating that their 
anxiety and stress levels were high. In a larger study, the correlation between self-reported 
anxiety stress levels and Zink’s fascial patterns could provide the basis for developing an 
objective monitoring tool for stress levels in menopausal women.  
 
 
All three participants were found to have discomfort in the right lower abdominal area. Two 
of the participants stated they were having symptoms associated with digestion (either 
discomfort or constipation). In particular, Patricia’s increase in depressive symptoms was 
preceded by constipation for a period of at least three weeks prior to the noted increase. 
Dysfunction associated with the digestive tract is worthy of noting as there is evidence to 
suggest that dysfunction in this system may be associated with central nervous system 
(CNS) dysfunction and depression.83,127,128,129,130 There is growing evidence to suggest that 
the type and number of microbioata present within the digestive tract has the ability to 
influence brain chemistry and therefore behaviour and mood. This influence is known as the 
brain-gut axis. The brain-gut axis is regulated via neural, hormonal and immunological 
systems. Studies have demonstrated that the brain-gut axis is not only associated with gut 
inflammation, chronic abdominal pain syndromes and eating disorders, but with a person’s 
stress response and overall behaviour.127 The potential connection with disturbance of the 
gut and depression is currently hypothesised to be associated with alterations in the 
hypothalamic-pituitary-adrenal (HPA) system.127   
 
Although largely anecdotal, OMT may have a role to play in the improved function of the 
digestive tract. A small pilot study examining the influence of OMT on six people with chronic 
constipation, reported an improvement in the overall severity of the constipation and quality 
of life.83  Wharton’s94 study, previously mentioned, suggested that visceral techniques had a 
positive effect on the depressive symptoms experienced by 11 women. Within this study 
mobility dysfunctions of the small and large intestine were assessed for and treated. Though 
more rigorous research is required to demonstrate a causal link between OMT and an 
improvement in depressive symptoms, the findings in Wharton’s study suggests that OMT, 
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using visceral techniques to the digestive tract, may be beneficial to menopausal women 
experiencing depression.    
 
At the final consultation, all three women had a reduction in the number of examination 
findings. Although this only correlated with decreased scores for depression in the DASS 
and GCS in two of the three women, it may be indicative that fewer dysfunctions within the 
body and improvements in the overall degree of dysfunction may be associated with 
improved mood levels. Further research is required to determine if a correlation between the 
number and severity of the dysfunctions and mood levels exists.   
 
The data relating to the therapeutic alliance indicated that a greater bond was created 
between the participant and the osteopath when compared to the bond with the 
psychologist. This is an unexpected finding as the participants had twice as many 
consultations with the psychologists than they did with the osteopaths. It is beyond the scope 
of this thesis to determine why the bond was stronger between the participant and the 
osteopath. The hands-on aspect, or therapeutic touch, that occurs within an osteopathic 
consultation may be a significant factor in creating the bond.131 The increased bond, if due to 
the OMT, may impact on the use of hands-on sham treatments in OMT research. Therefore, 
further research investigating the therapeutic alliance and its influence on the outcome of 
OMT consultations is also indicated. 
 
Compared with the osteopaths, the psychologists had higher scores in relation to the task 
and goal of the consultations.  The findings of this research project suggest that educating 
osteopathic practitioners in regard to the potential role of OMT in managing depression in 
menopausal women is warranted in future studies.  
 
Perceived role of OMT in Managing Depression in Menopausal Women 
The analysis of the data gained from the interviews suggests that the role of OMT in 
managing depression in menopausal women may be met with widespread scepticism and 
curiosity. However, the curiosity of the role OMT was also one of the motivating factors for 
the women who participated, as well as the women who inquired about the project. None of 
the participants had any clear idea as to how OMT may be useful in the management of 
depression or other menopausal symptoms. Despite this lack of understanding the women 
were not deterred from participating in the project. The willingness of the women to  
complete the project suggests that there is an acceptance for OMT management of 
depressive symptoms in menopausal women. 
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The participants’ experience of both CBT and OMT were positive, however, there was 
difficulty articulating the specific improvements in physical wellbeing achieved via the OMT 
and whether OMT had a positive impact on their psychological symptoms, as noted by the 
participants and the improvement in the DASS and GCS scores. During the interviews 
physical symptoms were noted by the participants as adversely impacting on their mental 
health. When the physical symptoms improved the connection with improved mood 
appeared to be overlooked. The somatic scores of the GCS did not vary considerably 
throughout the project. This is at odds with the statements made by the participants that they 
felt physically better and may reflect the lack of conscious connection between the 
participants’ improved physical state and mental state. A larger study may provide evidence 
that there is a correlation between improvement of physical symptoms and improvement 
mental health and support the role of OMT in the management of depression in menopausal 
women.  
 
Although the principles of osteopathy and the few small studies undertaken suggest that it is 
possible to influence both the physical and psychological symptoms of the menopausal 
transition, it is probable that in Australia this is not recognised because of a public perception 
that osteopathy is primarily sought to alleviate painful musculoskeletal conditions.6  
Menopausal women are, therefore, likely to consult an osteopath to seek a resolution of the 
somatic symptoms associated with the menopausal transition as their primary complaint and 
not the psychological or vasomotor symptoms. The participants in this study indicated that 
they would not have thought of seeking OMT for their vasomotor or depressive symptoms.  
Due to the focus on the musculoskeletal system by osteopaths in Australia, it is also 
reasonable to conclude that the majority of osteopaths practicing in Australia are not 
consciously aware of the impact OMT may have on the mental health issues their patients 
are experiencing, particularly menopausal women. Future studies would provide an 
evidence-based platform for education of the osteopathic profession, as well as other health 
professionals and the community, in this area.  
 
Limitations 
The major limitation of this project is the small number of case studies. Although providing 
some detailed understandings of the experiences of three women, the small numbers limit 
the ability to draw conclusions. The research does, however, allow for future research 
questions to be considered and explored through larger studies. 
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The three women, although meeting the criteria for inclusion, did not have particularly high 
depression scores. This may have impacted on the ability to determine whether the clinical 
change observed in two of the participants was limited by the difficulty in measuring changes 
to these already ‘moderate’ levels of depression. In future studies the determination of the 
level of depression for inclusion into the study may need to be reviewed. However, 
consideration of the potential risks of adverse events occurring with women who have higher 
scores for depression would need to be undertaken to ensure that protocols were in place to 
protect the mental and physical wellbeing of the participants.   
 
Although a schedule for consultations and data collection was created, there was variation in 
when the DASS, GCS and WAI data was collected and intervals between both osteopathic 
and counselling consultations in each of the three case studies. This occurred due to the 
commitments that both participant and practitioner had outside of the trial. This does, 
however, reflect what occurs in the consultative process in the community. How to account 
for discrepancy in the timing of data collection in a clinical trial would have to be considered. 
Given the demands on participants and practitioners time, this is likely to be an ongoing 
issue. 
 
Due to intra-practitioner and inter-practitioner reliability being reported to be poor,132, 133,134 
caution needs to be taken when interpreting the osteopathic examination findings. Intra- and 
inter-practitioner reliability relates to agreement of palpatory examination findings by a single 
examiner on repeated assessments, and agreement between different examiners on their 
examination findings of the same patient, respectively. Although the current research 
indicates that inter-practitioner reliability is poor, in practice osteopaths are required by law to 
note down their examination findings and treatment of such findings.135 Osteopaths treat the 
dysfunction they find. The protocol for this project aimed to mimic osteopathic practice in the 
community as closely as possible. Future clinical trials that researched the osteopathic 
management of depression in menopausal women would need to consist of a larger number 
of osteopaths in order to represent osteopathic practice in the community. With sufficient 
clinical records showing a trend in regions of the body that were assessed to be 
dysfunctional, it would be reasonable to conclude that there is a correlation between the 
recorded findings and symptoms as this is what osteopaths actually treat.  
Addressing how osteopaths are educated in the examination of patients is beyond the scope 
of this study. It may be addressed in future research based on the most effective way to 
improve inter-practitioner reliability. 
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Utilising the University Psychology Clinic limited the ability to add further participants to the 
project as the waiting time for an appointment increased to a minimum of three months. This 
impacted on the projects protocol and the willingness of potential participants to join the 
project as they did not wish to wait that long. This aspect was observed for those women 
enquiring in late November and December. Ideally, as part of any future research design, 
consideration should be given to addressing lengthy waiting times that my deter participants 
and limit the recruitment of an adequate sample size from which to draw conclusions. 
 
Funding of the project was also limited and this impacted on the study design and precluded 
a clinical trial. Ensuring that adequate funds were available would be an essential factor for 
any further investigation so that adequate resources for both recruitment and the 
consultations could be ensured. This would also enable registered psychologists to be 
engaged to undertake the CBT and allow greater ease in scheduling appointments for both 
the participant and the psychologist.  
 
Participants participated in both CBT and OMT during the intervention period. It is therefore 
hard to determine which treatment caused the improvements.  This project was not designed 
to evaluate the efficacy of OMT and CBT combined, compared to OMT or CBT interventions 
individually. Future research on the efficacy of OMT for treating depression in menopausal 
women is required to answer this question. 
 
Recommendations for Future Research 
As the participants in this study had anxiety and stress levels similar or higher than those for 
depression it is recommended that any future study include all three conditions.136,137,138 It is 
often difficult to separate these three psychological conditions and limiting a study to just one 
prevents a total psychological wellbeing from being fully addressed.  
 
It is also recommended that the inclusion criteria include women experiencing menopausal 
symptoms independent of their menopausal status, as the symptoms experienced are the 
same, even if the prevalence may differ. It is also likely that the ability to recruit sufficient 
participants would be greater, as one of the main reasons for the low participant numbers in 
this study was due to the original inclusion criteria being limited to peri-menopausal women.  
 
This project also highlights the potential for future research that involves: 
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• Assessing the influence of OMT on existing osteopathic patients who are undergoing 
CBT for mood disorders 
• Influence of OMT on mood disorders at all stages of life  
• The relationship between Zink fascial patterns and mood disorders 
• The incidence of existing osteopathic patients with mood disorders. 
• Training and educational requirements required to better prepare both osteopaths 
and psychologists working collaboratively in the management of depressive 
symptoms 
Summary 
Although no significant conclusions can be made, the outcomes of this study do suggest that 
there is preliminary evidence that OMT as an adjunct to standard care for menopausal 
women experiencing depression, has a positive impact. All women had lowered depression 
scores at the end of the three month and twelve month follow-up. All women experienced a 
positive outcome from the OMT from a physical point of view. One of the women 
acknowledged that the combination, although seemingly unlikely, had an impact on the 
changes she observed.  
 
There were common osteopathic findings, both from the musculoskeletal system as well as 
the visceral systems that suggest that there may be common dysfunctions in menopausal 
women experiencing depression. A clinical trial is needed to confirm that common 
osteopathic findings are present and would provide the basis for a management protocol to 
be developed. 
 
With the increasing number of menopausal women within Australia, and the 
recommendation that a multi-disciplinary approach may provide a better success rate in 
alleviating depression in menopausal women, OMT may be a positive addition to standard 
care of menopausal women experiencing depression and further research is warranted.    
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Appendix 1a:  Osteopathic Techniques  
Articulation or articulatory technique.  Where the practitioner passively moves a patient’s 
joint through its range of motion in a repetitive, rhythmic fashion. The aim is to improve range 
of motion in all planes.   
Counterstrain (CS).   Is a system of diagnosis and treatment based on the finding of tender 
points within the musculoskeletal system.  Once the tender point is found the patient’s body 
is positioned in such a way that the patient reports they are no longer aware of the tender 
point when it is palpated, and the practitioner feels a relaxation of the tissues. This is known 
as the position of maximal comfort and is held for approximately 90 seconds. The patient is 
slowly returned to a neutral position. The technique is used to treat somatic dysfunctions and 
soft tissue hypertonicity.     
Cranial technique.   A technique originally developed for manipulating the bones of the 
skull. Gentle hands on techniques are applied to manipulate the bones of the cranium and a 
similar approach can be applied to all regions of the body.  The technique application 
encourages fine or small changes to the body and in particular the primary respiratory 
mechanism  (PRM)  The PRM is considered to be the breathing of all the tissues and all 
cells of the body. Influencing the PRM is considered to assist the homeostatic mechanisms 
of the body restore health to the body.  Also known as cranial osteopathy or osteopathy in 
the cranial field.    
Functional technique.    The practitioner moves the area being treated to a point of balance 
and applies a force to encourage a spontaneous change in the tissues. The technique is 
initiated by moving the tissues in a direction of ease with minimal force. Further motion in 
different planes are performed until a sense of balanced tension in all directions is found. 
The final motion introduced is either inhalation or exhalation. This balance in tension is held 
until a release of the surrounding tissues is felt.     
HVLA – high velocity, low amplitude thrust.  This technique is a form of direct technique 
application. The joint is positioned into the position of restricted motion and a quick, 
moderate amount of force is applied by the practitioner to move the joint past the restriction 
so that full range of motion is restored.  
Inhibition technique.  The practitioner applies pressure to the tissue being treated, with 
either finger pads, palm of hand, or elbow, and holds the pressure until the tissues are felt to 
relax and a reduction in tension is achieved.  
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Muscle energy technique (MET).     The practitioner places the dysfunctional joint or tissue 
so that the barrier is engaged. The patient is then directed to initiate movement in a precise 
direction while the practitioner prevents movement from occurring by applying a resisting 
force equal to that produced by the patient.   The muscles of the patient are actively used in 
order to create a change within the joint range of motion and tissue tension.    
Myofascial release technique.   There are various was of applying this technique. In 
general the myofascial tissues are engaged and moved either into a resistance of movement 
or toward an ease of motion. Various planes of motion may be engaged and different forces 
applied (compression, traction, torsion). The release can occur by continually flowing the 
ease; holding the tissues at a point of balanced tension and then moving to the next point of 
balanced tension until a release is felt; or holding the tissues at a point of balance until a 
release is felt.   Functional technique is considered by some osteopaths to be a form of 
myofascial release.  
Sacral float technique.   Pressure is applied to the sacrum in order to reduce the tension of 
the soft tissue structures surrounding it. As the tension reduces the sacrum can appear to 
float between the two innominates and movement can be felt that is associated with 
respiration. The procedure stops when the sacral motion is felt to be smooth and even 
and/or the reduction in tension in the surrounding soft tissues is maintained without pressure 
being applied.  
Soft tissue technique (STT).  Application of a force to the either the superficial or deep 
connective soft tissues of the body in a rhythmic fashion, and may fall under the term 
‘massage’.  The initial forces applied gentle and designed to stretch the tissues laterally or in 
a linear direction. Pressure may vary from superficial to deep, and traction or compression 
forces may also be included. The technique is complete when an improvement in tissue 
tension and motion is palpated. A lubricant to prevent discomfort due to skin resistance may 
be used, but is not always necessary. 
Visceral technique.   A set of techniques where gentle force is applied to an organ to 
enhance the organ’s mobility in relation to it’s surrounding structures. The  technique may 
also be applied to improve the motility of an organ, which is described as the inherent motion 
of the organ which is independent of motion introduced by an external force.  
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Appendix 1b:  Orthopaedic Tests  
Cervical prepositioning.   This test assesses whether a technique has an adverse impact 
on the blood flow through the vertebral artery. The cervical spine is placed in the position the 
technique is to be applied and held for 10 – 30 seconds. The spine is then returned to 
neutral position for a further 10-30 seconds. The test is positive if signs of vertebral basilar 
insufficiency (VBI) are observed. Signs of VBI may include: diplopia, dysphagia, dysarthria, 
dizziness, perioral and/or fascial parasthesias, drop attacks, nystagmus.     
Craig’s Test.  This test assesses for anteversion or retroversion of the neck of the femur. 
With the patient prone, the practitioner flexes the patient’s knee to 90o and palpates the 
greater trochanter of the femur. The hip is then rotated internally and externally until the 
point is found where the greater trochanter is parallel with the table. The angle of the hip is 
then measured, either by a goniometer or using the angle of the leg in relation to the vertical. 
An increase in angle suggests femoral acetabular impingement and potential damage to the 
labrum of the acetabulum.  Normal hip anteversion is 8-15o.    
Ely’s Test.  This test assesses for contracture or spasticity of the rectus femoris muscle. 
With the patient in the prone position, the knee is flexed passively by the practitioner. The 
test is positive if the patient’s hip flexes. Other indicators of a positive test are inability of the 
patient’s heel to touch their buttock, or if pain or tingling sensation occurs in the back of the 
patient’s leg.  
FABER test.    With the patient supine, the practitioner places the patient’s hip being 
examined into flexion, abduction, and external rotation. This may be achieved by placing the 
ankle on the side being examined on the knee of the other leg and slowly lowering the knee 
on the side being assessed. The test is positive occurs if pain is felt during the test. The test 
indicates that the hip or sacroiliac joint dysfunction.   Also known as Patrick’s test. The test 
may also be known as FABERE in which case extension of the hip is also introduced.  
Scapulohumeral reflex (Shimizu).  This test assess for dysfunction of the upper motor 
neurons cranial to C3 vertebral level. The spine of the scapula and acromion are tapped in a 
caudad direction. A positive result is indicated by elevation of the scapula or abduction of the 
humerus.     
Squish test.   This test assesses dysfunction of the sacroiliac joint. The patient lies in the 
supine position. The practitioner applies pressure on the ASISs inwards at an angle of 45o 
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and in a posterior direction.  The test is positive if pain is felt when the pressure is applied, or 
reduced motion is noted.  
 
Seated flexion test. This test assesses the motion of the sacrum in relation to the ilium. The 
patient is seated with the feet resting on the floor. The practitioner places their thumbs on the 
PSISs and monitors the movement of the PSISs as the patient forward bends. A positive test 
occurs if one PSIS moves further anteriorly and superiorly than the other. 
 
Standing flexion test. This test assesses the motion of the ilium in relation to the sacrum. 
The patient stands with feet at hip distance apart. The practitioner places their thumbs on the 
PSISs and monitors the movement of the PSISs as the patient forward bends. A positive test 
occurs if one PSIS moves further anteriorly and superiorly than the other. 
 
Thomas test. This test assesses for contracture of the hip flexors.  The patient lies supine 
and brings one knee to their chest, while the other leg remains straight. The test is positive if 
the practitioner observes the straight leg lifting off the table when the knee on the other side 
is brought toward the patient’s chest. Observation of excessive lumbar lordosis prior to the 
patient bring knee to the chest is also indicative of contracted hip flexors.  
 
References 
 
Magee DJ.  Orthopedic Physical Assessment. 4th Ed. Missouri:Saunders Elsevier. 2006 
 
Shimizu T, Shimada H, and Shirakura K. Scapulohumeral reflex (Shimizu). Its clinical 
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Appendix 1c:  Osteopathic Terminology 
Bind.   The point where resistance to motion of a tissue or joint that can be palpated. 
 
Barrier.   The point where motion stops. This may be due to normal physiology of the 
tissues ability to move or may be due to dysfunction or pathological change to the tissues. 
 
Direct technique.    A technique that takes the tissues up to barrier. It may involve the 
tissues being directed through the barrier to create a change and improve movement of the 
tissue or joint. 
 
Ease. Direction of motion of a tissue or joint where no significant resistance is palpated. 
 
Indirect techniquie.   A technique that takes the tissues away from the barrier. 
 
Somatic dysfunction.   “Impaired or altered function of related components of the somatic 
(Body ramework) system; skeletal, arthorodial and myofascial structures, and their related 
vascular, lymphatic, and neural elements. Somatic dysfunction is treatable using osteopathic 
manipulative treatment.” 1, p 1106 
 
References. 
 
1.  Educational Council on Osteopathic Principles (ECOP) of the American Association 
of Colleges of Osteopathic Medicine (AACOM). Glossary of Osteopathic Terminology. 2011.   
In:   Chila AG. Ed. Foundations of Osteopathic Medicine. 3rd Ed. Philadelphia:Wolters 
Kluwer. 2011. 
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Appendix 1d:  Key to Abbreviations 
Appendix Table 1: Key to abbreviations 
Abbreviation  
Antr anterior 
Bilat bilateral 
C1, C2, C3, C4, C5, 
C6, C7 
Cervical vertebra 1, 2, 3, 4 , 5, 6, 7 
CES Cervical erector spinae muscles 
CT Cervicothoracic joint or junction 
Cx Cervical vertebra 
d/t Due to 
ERS left or ERS - L Vertebrae is positioned in an extended, rotated and sidebent left 
position 
ERS right or ERS - R Vertebrae is positioned in an extended, rotated and sidebent right 
position 
FRS left or FRS - L Vertebrae is positioned in a flexed, rotated and sidebent left position 
FRS right or FRS - R Vertebrae is positioned in a flexed, rotated and sidebent right 
position 
HA headache 
HVLA High velocity low amplitude thrust 
Kgs kilograms 
L1, L2, L3, L4, L5 Lumbar vertebra 1, 2, 3, 4, 5 
L Left 
lat lateral 
LB Low back 
LBP Low back pain 
LES Lumbar erector spinae muscles 
L on L Left on left 
LS Lumbosacral joint or junction 
Lx Lumbar vertebra 
Med medial 
MET Muscle Energy technique 
Mm muscles 
NAD Nothing abnormal detected 
NAR No apparent reason 
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OA Occipitoatlantal joint  
Pt Patient 
Quads Quadriceps muscles 
R right 
RAI gh jt Right anterior inferior glenohumeral joint 
Rectus fem Rectus femoris muscle 
R>L, L>R Right side greater than left side; Left side greater than right side 
Rot rotation 
SIJ Sacroiliac joint 
SOB Short of breath 
T1, T2, T3, T4 – T12 Thoracic vertebra 1, 2, 3, etc to 12 
Temp Temporal region 
TES Thoracic erector spinae muscles 
TL Thoracolumbar joint or junction 
TMJ Temporomandibular joint 
Traps trapezius 
ttt treatment 
Tx Thoracic vertebra 
+ positive 
-ve negative 
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Appendix 2 Instruments 
 
 
Appendix 2a: The Greene Climacteric Scale 
Appendix 2b: The Depression, Anxiety and Stress Scale  
Appendix 2c: The Working Alliance Inventory 
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Appendix 2a: The Greene Climacteric Scale (GCS) 
The Greene Climacteric Scale 
Please indicate the extent to which you are bothered at the moment by any of these 
symptoms by placing a tick in the appropriate box. 
Symptoms Not at 
all 
A little Quite a 
bit 
Extremely Score 
0 - 3 
1. Heart beating quickly or strongly
2. Feeling tense or nervous
3. Difficulty in sleeping
4. Excitable
5. Attacks of panic
6. Difficulty in concentrating
7. Feeling tired or lacking in energy
8. Loss of interest in most things
9. Feeling unhappy or depressed
10. Crying spells
11. Irritability
12. Feeling dizzy or faint
13. Pressure or tightness in head or body
14. Parts of body feel numb or tingling
15. Headaches
16. Muscle and joint pains
17. Loss of feeling in hands or feet
18. Breathing difficulties
19. Hot flushes
20. Sweating at night
21. Loss of interest in sex
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Appendix 2b:  Depression, Anxiety and Stress Scale (DASS) 
DASS        ID No:                                          Date: 
Please read each statement and circle a number 0, 1, 2 or 3 which indicates how much the 
statement applied to you over the past week.  There are no right or wrong answers. Do not 
spend too much time on any statement. 
 
The rating scale is as follows: 
 
0 Did not apply to me at all 
1 Applied to me to some degree, or some of the time 
2 Applied to me to a considerable degree, or a good part of time 
3 Applied to me very much, or most of the time 
1 I found myself getting upset by quite trivial things      0       1       2        3 
2 I was aware of dryness of my mouth    0       1       2        3 
3 I couldn’t seem to experience any positive feeling at all    0       1       2        3 
4 I experienced breathing difficulty (eg, excessively rapid 
breathing, breathlessness in the absence of physical exertion) 
   0       1       2        3 
5 I just couldn’t seem to get going    0       1       2        3 
6  I tended to over-react to situations    0       1       2        3 
7 I had a feeling of shakiness (eg, legs going to give way)    0       1       2        3 
8 I found it difficult to relax    0       1       2        3 
9 I found myself in situations that made me so anxious I was 
most relieved when they ended 
   0       1       2        3 
10 I felt that I had nothing to look forward to    0       1       2        3 
11 I found myself getting upset rather easily    0       1       2        3 
12 I felt that I was using a lot of nervous energy    0       1       2        3 
13 I felt sad and depressed    0       1       2        3 
14 I found myself getting impatient when I was delayed in anyway 
(eg lifts, traffic lights, being kept waiting) 
   0       1       2        3 
15 I had a feeling of faintness    0       1       2        3 
16 I felt that I had lost interest in just about everything    0       1       2        3 
17 I felt I wasn’t worth much as a person    0       1       2        3 
18 I felt that I was rather touchy    0       1       2        3 
19 I perspired noticeably (eg hands sweaty) in the absence of 
high temperatures or physical exertion 
   0       1       2        3 
20 I felt scared without any good reason    0       1       2        3 
21 I felt that life wasn’t worthwhile    0       1       2        3 
Reminder of rating scale: 
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0 Did not apply to me at all 
1 Applied to me to some degree, or some of the time 
2 Applied to me to a considerable degree, or a good part of time 
3 Applied to me very much, or most of the time 
22 I found it hard to wind down      0       1       2        3 
23 I had difficulty in swallowing    0       1       2        3 
24 I couldn’t seem to get any enjoyment out of the things I did    0       1       2        3 
25 I was aware of the action of my heart in the absence of 
physical exertion (eg sense of heart rate increase, heart 
missing a beat) 
   0       1       2        3 
26 I felt down-hearted and blue    0       1       2        3 
27 I found that I was very irritable    0       1       2        3 
28 I felt close to panic    0       1       2        3 
29 I found it hard to calm down after something upset me    0       1       2        3 
30 I feared I would be “thrown” by some trivial but unfamiliar task    0       1       2        3 
31 I was unable to become enthusiastic about anything    0       1       2        3 
32 I found it difficult to tolerate interruptions to what I was doing    0       1       2        3 
33 I was in a state of nervous tension    0       1       2        3 
34 I felt I was pretty worthless    0       1       2        3 
35 I was intolerant of anything that kept me from getting on with 
what I was doing 
   0       1       2        3 
36 I felt terrified    0       1       2        3 
37 I could see nothing in the future to be hopeful about    0       1       2        3 
38 I felt that life was meaningless    0       1       2        3 
39 I found myself getting agitated    0       1       2        3 
40 I was worried about situation in which I might panic and make 
a fool of myself 
   0       1       2        3 
41 I experienced trembling (eg in the hands)    0       1       2        3 
42 I found it difficult to work up the initiative to do things    0       1       2        3 
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Appendix 2c:  Working Alliance Inventory (Client Version) 
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134 
 
Appendix 3 OMT Patient Consultation Forms 
 
 
Appendix 3a: OMT Patient Consultation Form - Initial  
Appendix 3b: OMT Patient Consultation Form - Subsequent 
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Appendix 3a: OMT Patient Consultation Form - Initial 
RECORD OF OSTEOPATHIC CONSULTATION 
Patient Name: ___________________________________  
Address:__________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
_______________ 
Phone No: _________________________working hours_______________after hours 
Email Address:  _________________________________________     
Date of Birth: ____________________________ Occupation: 
________________________ 
Informed Consent Signed: Yes No 
If No, give reason: 
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Initial Consultation Form 
 
         ID No.______________ 
Current Health:       Date: ______________ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Past Medical History: 
Trauma, Illness, Surgery, Medication, Exercise/Hobbies, Alcohol/Drug use. 
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Systems Screen ID No.______________ 
Respiratory Cardiovascular Digestive Urinary Reproductive
Neurological 
Family Medical History 
Orthopaedic Screens/Tests 
Neurological Screens/Tests 
Diagnostic Imagining or Tests Required 
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Osteopathic Examination ID 
No.______________ 
 
Record examination findings of the spine in the space below. 
OA C1 C2 C3 C4 C5 C6 C7 T1 T2 T3 T4 T5 T6 T7 T8 T9 T10 T11 T12 
L1 L2 L3 L4 L5 LS R 
SIJ 
L 
SIJ 
R 
ilia 
L 
ilia 
Sacrum 
Standing Flexion Test 
Sitting Flexion Test 
Peripheral Joint Examination Findings: 
Muscle Hypertonia or Dysfunctions: 
Note asymmetries of landmarks and fascial tension on diagram. Include any postural asymmetries. 
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Osteopathy in the Cranial Field Examination: ID 
No.______________ 
Treatment: 
Please identify what technique was utilized to treat dysfunctions as recorded above 
Management: 
Exercises, heat, ice, other management advice given. 
Practitioner:_____________________________________________ 
Practitioner’s signature:____________________________________ 
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Appendix 3b:  OMT Patient Consultation Form - Subsequent 
RECORD OF OSTEOPATHIC CONSULTATION – Subsequent Consultation 
         ID No.______________ 
         Date:_______________ 
 
 
 
 
State of health since last consultation: 
 
 
 
 
 
 
 
 
 
 
 
Orthopaedic Screens/Tests  
 
 
 
 
 
 
Neurological Screens/Tests 
 
 
 
 
 
 
 
 
Diagnostic Imagining or Tests Required 
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Osteopathic Examination      ID No.______________ 
 
     
 
 
 
 
Record examination findings of the spine in the space below. 
 
OA 
 
C1 C2 C3 C4 C5 C6 C7 T1 T2 T3 T4 T5 T6 T7 T8 T9 T10 T11 T12 
 
 
 
                   
 
L1 
 
L2 L3 L4 L5 LS R 
SIJ 
L 
SIJ 
R 
ilia 
L 
ilia 
Sacrum 
 
 
 
          
 
 
Standing Flexion Test 
 
Sitting Flexion Test 
 
 
Peripheral Joint Examination Findings: 
 
 
 
 
 
Muscle Hypertonia or Dysfunctions: 
 
 
Note asymmetries of landmarks and fascial tension on diagram. Include any postural asymmetries. 
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Osteopathy in the Cranial Field Examination: 
Treatment: 
Please be identify what technique was utilized to treat dysfunctions as recorded above 
Management: 
Exercises, heat, ice, other management advice given. 
Practitioner:_____________________________________________ 
Practitioner’s signature:____________________________________
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Appendix 4 Project Sequence of Events 
The following is a chart that highlights the activities and data collected throughout the 
project: 
Week Activity Instrument 
Pre-
Intervention 
Initial telephone expression of 
interest 
• Expression of
Interest
Documents.
Plain Language Statement and 
Screening Interview Consent form 
sent 
Appointment made for screening 
interview in approx.  one week 
Plain Language 
Statement 
Screening Interview 
Consent Form 
1 week after 
expression of 
interest 
Screening interview informed 
consent sighted and copied. 
Screening interview 
Inclusion/exclusion criteria 
determined 
Screening interview 
form 
GCS and STRAW 
Informed Consent 
Drop Out Form 
Checklist Form 
• Must attain a score
of 22 or more on
the GCS and/or
meet one of the
STRAW Criteria
• Meets criteria –
continue to next
step
• Does not meet
criteria – excluded
Informed consent form received 
Copy made for participant 
DASS completed as baseline 
control. 
DASS 
Waiting period 
of 4 weeks 
from screening 
interview 
Appointment made for cognitive 
behavioural therapy  and first 
osteopathic consultation made for 
participant group 
1-2 days prior 
to  first 
appointment 
Phone call to confirm appointment • Drop Out form • Informed Consent
Form must be
received
INTERVENTION 
Week 1 
First cognitive behavioural therapy 
(CBT) and OMT consultation. 
Informed Consent Confirmed 
• CBT and OMT
Informed Consent
forms
• DASS and GCS
before CBT session
• CBT homework
week 1 document
• WAI after session
(participant and
practitioner each
complete for both
CBT and OMT)
• Drop Out Form
• Must score 20 or
less on DASS
• Meets criteria –
continue CBT &
OMT
• Does not meet
criteria – referred
for appropriate
care
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Week 2  Second CBT consultation 
Possible 2nd OMT consultation 
• Homework week 2 
document 
• Drop Out Form 
• Meets criteria – 
continue CBT & 
OMT 
• Does not meet 
criteria – referred 
for appropriate 
care 
Week 3 Third CBT consultation 
Possible 2nd OMT consultation 
• Homework week 3 
document 
• Drop Out Form 
• Meets criteria – 
continue CBT & 
OMT 
• Does not meet 
criteria – referred 
for appropriate 
care 
Week 4  Fourth CBT consultation 
Possible 2nd OMT consultation 
• Homework week 4 
document 
• Drop Out Form 
• Meets criteria – 
continue CBT & 
OMT 
• Does not meet 
criteria – referred 
for appropriate 
care 
Week 5 Fifth CBT consultation 
Third OMT consultation 
• DASS and GCS 
before session 
• WAI after session 
• (participant and 
practitioner each 
complete for both 
CBT and OMT)  
• Homework week 5 
document 
• Drop Out Form 
• Meets criteria – 
continue CBT & 
OMT 
• Does not meet 
criteria – referred 
for appropriate 
care 
Week 6 Sixth CBT consultation 
 
• Homework week 6 
document 
• Drop Out Form 
• Meets criteria – 
continue CBT & 
OMT 
• Does not meet 
criteria – referred 
for appropriate 
care 
Week 7 Seventh CBT consultation 
 
• Homework week 7 
document 
• Drop Out Form 
• Meets criteria – 
continue CBT & 
OMT 
• Does not meet 
criteria – referred 
for appropriate 
care 
Week 8 Eighth CBT consultation 
Fourth and final OMT consultation 
• DASS and GCS 
before session 
• WAI after session 
• (participant and 
• Meets criteria – 
continue CBT 
• Does not meet 
criteria – referred 
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practitioner each 
complete for both 
CBT and OMT) 
• Homework week 8 
document 
• Drop Out Form 
for appropriate 
care 
Week 20 Cognitive behavioural therapy 
follow-up 
• DASS and GCS 
before session 
• Drop Out Form 
• Referred for 
appropriate care as 
necessary 
Twelve Months  Follow-up interview to discuss 
impressions of participating in the 
project 
• DASS and GCS  
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Appendix 5 Response Rate and Recruitment from Each 
Recruitment Strategy 
 
 
 
 
 
 
Form of Recruitment 
 
Number who 
responded 
(n = 40) 
 
Number who 
attended 
screening 
interview 
 
Number who 
entered the 
project 
 
Number who 
completed all 
components 
of the project 
 
Flyers in Medical Clinics 
 
2 1 1  
Flyers in women’s gyms 
 
2 1   
Flyers in osteopathic, 
naturopathic, psychology 
clinics 
4 2 2  
Posters placed at 
Bundoora RMIT campus 
1 0   
Advertisement in local 
paper (Leader) 
26 7 4 3 
Beyond Blue and 
Depressionet websites 
1 1   
RMIT internal staff 
newsletter 
1 0 1  
Word of mouth 
 
1 1   
Unknown 
 
2 0   
 
 
Of those participants who were eligible to participate in the project and did not complete all 
components: 
 
3 participants only attended counselling sessions and this data was excluded from the write up 
2 participants were not able to schedule appointments at a mutually agreed time and did not attend 
any consultations.  
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Appendix 6 Screening Documents and Plain Language    
Statement 
Appendix 6a: Initial Screening Form  
Appendix 6b: Screening Interview Form 
Appendix 6c: Plain Language Statement 
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Appendix 6a: Initial Screening Form 
Expression of Interest Screen Date: 
Thank you for inquiring about the trial. 
We are looking for women who are experiencing menopausal symptoms and mood changes 
that have started with the onset of other menopausal symptoms, who are between the age of 
45 – 60, but otherwise healthy. 
If you participate in the trial you would be asked to attend weekly counselling sessions for 
eight weeks and then another one three months later.   You may also be asked to attend 
four OMT sessions during the initial eight week period. 
Would you be interested in attending a Screening Interview to determine whether you meet 
all the criteria for this trial? This will take approximately 30 minutes and is held on the 
Bundoora campus. 
Yes: 
Name: 
Address: 
Email address: 
Contact No: 
I will send you out a PLS, Informed Consent form and campus map.   The Screening 
Interview will be: 
Date: 
Time: 
No.   Reason: 
Does not meet trial criteria 
Does not think they would have the time to attend regular consultations for the whole trial 
Did not want to provide personal or medical information 
Did not want to say 
Other………………………………………………………….. 
Before you go. 
Would you mind my asking you some questions to about how you found out about the trial 
and how the menopausal symptoms are affecting your day to day life?  It will take between 
5-10 minutes of your time. If there is any question you would prefer not to answer just let me 
know and we can move onto the next one.  The answers you give me will be placed on a 
form that has no identifying information, so that it is anonymous. It is intended to collate all 
the answers women provide and publish what we learn in academic journals. Any 
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information published will not be identifiable as coming from you.   Any information you 
provide can be disclosed only if (1) it is to protect you or others from harm, (2) a court order 
is produced, or (3) you provide the researchers with written permission. 
Yes    No 
How did you find out about the trial? 
Newspaper Ad – which paper(s)………………………………………………………….. 
Other media – TV, radio 
Electronic sources – email, other 
Word of mouth 
Flier 
Recommendation from health professional 
Unknown 
Other…………………………………………… 
What prompted you to make the inquiry? 
……………………………………………………………………………………………………………
……………………………………………………………………………………………………………
……………………………………………………………………………………………………………
……………………………………………………………………………………………………………
…………………… 
What do you hope to get out of participating in the trial? 
……………………………………………………………………………………………………………
……………………………………………………………………………………………………………
……………………………………………………………………………………………………………
……………………………………………………………………………………………………………
…………………… 
How old are you:  ……………………. 
What is your marital status:       Never married 
Married 
Divorced 
Separated 
Widowed 
Do you have children:  No   Yes 
Ages/Sex:  …………………………………………………………. 
Occupation:  ……………………………………………………… 
Highest level of education undertaken:………………………………………. 
Post code:  ……………………………………. 
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What symptoms are you experiencing: 
Symptom Experienced Rating 
1-10 
Frequency: 
Per day   Per week  
Hot flushes 
Night sweats 
Insomnia 
Anxiety 
Depression 
Forgetfulness 
Lack of concentration 
Weight gain 
Other 
How would you rate your symptom’s severity?   If 1 = no symptoms  and 10 is worst you 
could imagine. 
How often do you experience them each:   day week    month 
How does this impact on your daily life?  Eg work, relationships, self-image. 
……………………………………………………………………………………………………………
……………………………………………………………………………………………………………
……………………………………………………………………………………………………………
……………………………………………………………………………………………………………
…………………… 
What is the worst thing about the symptoms?  
……………………………………………………………………………………………………………
……………………………………………………………………………………………………………
……………………………………………………………………………………………………………
……………………………………………………………………………………………………………
…………………… 
What have you tried to help reduce the symptoms?  (GP, naturopath, medication, diet, etc)  
……………………………………………………………………………………………………………
……………………………………………………………………………………………………………
……………………………………………………………………………………………………………
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……………………………………………………………………………………………………………
…………………… 
 
How successful was this treatment? 
……………………………………………………………………………………………………………
……………………………………………………………………………………………………………
……………………………………………………………………………………………………………
……………………………………………………………………………………………………………
…………………... 
 
Were there any problems or side effects of this treatment? 
……………………………………………………………………………………………………………
……………………………………………………………………………………………………………
……………………………………………………………………………………………………………
……………………………………………………………………………………………………………
…………………… 
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Appendix 6b:   Screening Interview Form 
Screening Interview ID:…………………… 
Date:………………... 
Demographic Information 
Date of Birth: __________________ (d/m/y) 
Marital Status:  Single Married Divorced Defacto 
Number of Children:   __________________________ 
Age of Children:         __________________________ 
Place of Birth:  ___________________________ 
Ethnic/cultural Background: _____________________ 
Highest Level of Education Completed: HSCE/VCE Diploma Degree
PhD 
Other: ________________________________ 
Occupation: ____________________________________ 
If retired, pre-retirement occupation:  _____________________________________ 
Postcode: __________________________________ 
Greene Climacteric Scale and STRAW Criteria 
I will now ask you a series of questions that relate to your menopausal status. These 
questions are scored and at the end of the questions I will take a moment to add up the 
score to determine the level of menopausal symptoms you are experiencing. 
STRAW Criteria 
These questions are in relation to your menstrual cycle. 
Have you noticed a change in the interval between your periods that is seven or more days? 
Yes No 
Have you experienced an interval between your periods of more than 60 days? 
Yes No 
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The Greene Climacteric Scale 
 
 
Please indicate the extent to which you are bothered at the moment by any of these 
symptoms by placing a tick in the appropriate box. 
 
Symptoms Not at 
all 
A little Quite a 
bit 
Extremely Score   
0 - 3 
1.  Heart beating quickly or strongly      
2.  Feeling tense or nervous      
3.  Difficulty in sleeping      
4.  Excitable      
5.  Attacks of panic      
6.  Difficulty in concentrating      
7.  Feeling tired or lacking in energy      
8.  Loss of interest in most things      
9.  Feeling unhappy or depressed      
10.  Crying spells      
11.  Irritability      
12.  Feeling dizzy or faint      
13.  Pressure or tightness in head or body      
14.  Parts of body feel numb or tingling      
15.  Headaches      
16.  Muscle and joint pains      
17.  Loss of feeling in hands or feet      
18.  Breathing difficulties      
19.  Hot flushes      
20.  Sweating at night      
21.  Loss of interest in sex      
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Total Score: 
Depression Score (Q7-11): 
Anxiety Score (Q1-6): 
 
 
Scores that do not meet the inclusion criteria: 
 
Total score is less than 22 -   does not meet the criteria of women eligible to participate.  
Depression score greater than 10 – refer patient to their GP for further assessment if DASS 
scores above 20 
Anxiety score greater than 10 – refer patient to their GP for further assessment if DASS 
scores above 20 
 
Explanation as to why the person does not meet criteria given and any questions answered. 
 
Yes  No 
 
Referral given and explanation as to the reason for referral 
 
NA  Yes  No 
 
 
 
Permission to be contacted if criteria changes and/or to follow up on a referral given. 
 
No  Reason (if given)__________________________________ 
 
Yes 
 
__________________________________ ____________________________________
   
Name      Signature      
 
 
 
Scores of 22 or more - continue with the rest of the screening interview. 
 
 Question Yes  No Details or 
Comments 
1 Have you visited your doctor in the last six months? 
 
   
2 If yes, what was the purpose of the visit 
 
   
3 Do you have any ongoing medical conditions, eg, 
viruses, heart conditions, digestive problems, kidney, 
reproductive, surgical conditions, etc 
   
4 If yes, List conditions 
 
   
5 Are you taking any medications on a regular basis    
6 If yes, List 
 
   
7 If taking anti-depressants, did the depression occur 
prior to menopausal symptom onset 
   
8 Do you have a history of migraines    
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9 Do you have a history of headaches occurring on a 
regular basis (eg weekly) 
10 Do you attend a chiropractor, physiotherapist, 
osteopath or masseur on a regular basis.    
11 If yes how often 
12 Have you had any accidents or injuries in the last six 
months (ie recent car accident, sporting injury, etc) 
13 If yes – what treatment did you receive and for how 
long 
14 Is the injury still causing you pain or problems 
15 Has it caused you any disability 
16 Do you have any long term injury or disability that is 
still ongoing 
17 If yes, list 
18 Do you have a history of back problems eg disc 
bulges or herniations, back surgery, fractures 
19 If yes, list 
20 Do you experience pain into the legs or feet, back 
pain, muscle weakness 
21 History of drug abuse (Other medications must be 
evaluated for impact on the study.) 
22 Have you had any work-related injuries or other 
injuries with an unresolved legal action 
23 Have you experienced unexplained significant weight 
changes 
24 Is you weight more than 30% of ideal weight 
25 Are you pregnant or suspected pregnancy 
26 History of seizure disorder 
27 Have you served in the armed forces overseas – eg 
Afghanistan, Iraq. 
28 Do you have a history of mental illness 
29 Other relevant question indicated from observation or 
answers to above questions 
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A yes response will indicate that inclusion criteria is not met. 
 
The exception may be for questions 1-2, 5-6, and 10-11, if the episode is mild, of short 
duration and has no lasting impact on the woman’s health. 
 
 
Explanation as to why the person does not meet criteria given and any questions answered. 
 
Yes  No 
 
Referral given and explanation as to the reason for referral 
 
Not applicable  Yes  No 
 
Reason for Referral:  
 
 
 
 
 
 
Permission to be contacted if criteria changes and/or to follow up on a referral given. 
 
No  Reason (if given)__________________________________ 
 
Yes 
 
__________________________________ __________________________________  
  
Name      Signature     
  
 
 
 
 
 
Meets inclusion criteria 
 
 
Participant is willing to participate in project 
 
No 
 
Reason: 
 
 
 
Would like to think about it: 
 
Permission given to follow up with the woman to determine their willingness to participate 
 
Yes   No Reason: 
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YES 
General Informed Consent Form Signed Yes No 
DASS Completed: Yes No – why? 
Allocation to group:  Control Intervention 
If control: have been informed that they may receive OMT (4 sessions) if proved to be of 
benefit. 
Appointment(s) made: Yes No 
If no,    why? 
Action necessary to make appointment: 
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Appendix 6c:  Plain Language Statement 
 
Plain Language Statement 
 
 
Invitation to participate in a research project. 
 
Project Information Statement 
 
Project Title:  
Investigators: 
 
• Dr Paula Henderson (Osteopathy Masters degree student, Registered Osteopath) 
• Prof. Eleanor Holroyd (Project Primary Supervisor, Discipline Head, Lecturer, Nursing and 
Midwifery, RMIT University, eleanor.holroyd@rmit.edu.au, 9925 7179) 
• Dr Keong Yap (Project Second Supervisor, Senior Lecturer, Psychology, RMIT University, 
keong.yap@rmit.edu.au, 9925 6692) 
 
 
Dear, 
 
You are invited to participate in a research project being conducted by RMIT University. This 
information sheet describes the project in straightforward language, or ‘plain English’. Please read this 
sheet carefully and be confident that you understand its contents before deciding whether to 
participate. If you have any questions about the project, please ask one of the investigators. 
 
Who is involved in this research project? Why is it being conducted? 
 
This research project is being undertaken by Dr Paula Henderson as part of a Master of Osteopathy 
degree project and has been approved by the RMIT Human Research Ethics Committee. Master of 
Psychology and Doctor of Psychology students, under supervision, and registered osteopaths, with a 
minimum of five years experience will provide the care of those who participate in the project. We are 
looking to find better ways of supporting menopausal women who have been experiencing depressed 
moods. 
 
The project has been approved by the RMIT Human Research Ethics Committee. 
 
Why have you been approached? 
 
You have been approached with this invitation because you have answered an advertisement inviting 
peri-menopausal women who are experiencing depressed moods to participate in a clinical trial being 
undertaken at RMIT University. You may also have been recommended to inquire about this trial by 
one of your health professionals.  
 
What is the project about? What are the questions being addressed? 
 
Peri-menopause is the three years, or more, prior to menopause, which is the final menstrual period a 
woman experiences.  During this time up to 80 percent of women can experience a variety of 
symptoms, some of which include hot flushes, night sweats, anxiety and depression. Between 30-60 
percent of peri-menopausal women will experience depressed mood of varying intensity. 
 
This project aims to determine whether a combination of counselling and osteopathic manipulative 
treatment will increase the recovery of those peri-menopausal women who are feeling depressed. It 
will answer several questions relating to this goal. Information regarding common osteopathic 
examination findings in this group of women and whether osteopathic treatment improves other 
menopausal symptoms will be analysed. 
 
It is anticipated that between 40 and 60 women will participate in this project. 
If I agree to participate, what will I be required to do? 
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You will need to be available to: 
 
• attend weekly counselling sessions for eight weeks 
• attend four osteopathic consultations during the first eight weeks of the project if you are 
allocated to the intervention group. Half of the participants will be allocated to the intervention 
group which includes both the counselling and osteopathic consultations.  
• complete three different questionnaires at varying intervals throughout the project  
• attend a follow-up counselling session three months after the end of the original eight weeks  
 
It is estimated that these consultations and questionnaires will take up to two hours a week, plus 
travelling time. 
All consultations will be conducted on the RMIT campuses in Bundoora.  Please note that the 
counselling sessions will be videotaped for supervision purposes to ensure that the counselling is of 
the highest standard.   
 
All consultations are free of charge and therefore you will not be required to pay for any consultation 
associated with the project. Please note that you may continue with the counselling during the three 
months prior to the follow-up counselling session and after the project is completed. However, these 
sessions will be at your own expense. To help maintain the integrity of the project you will be asked to 
refrain from attending any additional osteopathic, or like treatment, during the period of the project 
unless health issues require such treatment. It is likely that if you do require such treatment during the 
project you will be withdrawn from the project. 
 
 
What are the risks or disadvantages associated with participation? 
 
Risks associated by participating in this project are minimal, but may include:  
a. Counselling consultations: unpleasant emotions my be experienced 
b. Osteopathic consultations: minor muscular aches and pains, headaches, nausea and 
dizziness that normally resolve within 24-48 hours after the osteopathic treatment. Risks associated 
with manipulation of the spine can include: headache, nausea and dizziness, disc injury, fractures, 
pinched nerves, soft tissue strains and artery damage that may cause stroke or stroke-like episodes, 
cauda equine injury. Studies indicate that the likelihood of this occurring may be between 1 in 200,000 
to one in several million treatments.  
 
It is anticipated that if you are accepted into the project, the potential for you to be at risk will be 
minimal. You can request not to have the manipulation technique performed as part of your 
osteopathic treatment. You will be provided with contact details of research staff or professional 
services you can contact if you feel any discomfort at any point in the project. 
 
What are the benefits associated with participation? 
 
The counselling sessions will help you learn to understand why you are feeling depressed and 
provide strategies that will help you deal with low mood and negative thinking. The skills and the 
understanding that you can gain from participating in this project may support you throughout the rest 
of your life. 
 
For those who also receive osteopathic manipulative treatment you have the opportunity of learning 
new ways to keep yourself fit and healthy.  If the study shows that osteopathic manipulative treatment 
helps, those who did not receive the osteopathic treatments during the trial will be eligible to have four 
treatments after the results of the trial are concluded. 
 
By participating in the project you are assisting in greater understanding of how depression can best 
be treated and managed.  
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What will happen to the information I provide? 
 
All information gathered in this project will be securely stored for a minimum of five years, after which 
time it may be destroyed. We plan to publish results in academic journals. In any publication, 
information will be provided in such a way that you cannot be identified. Any information you provide 
can be disclosed only if (1) it is to protect you or others from harm, (2) a court order is produced, or (3) 
you provide the researchers with written permission. 
 
What are my rights as a participant? 
 
You have the right to: 
 
• Withdraw your participation in the project at any time, without any on going bias or prejudice 
• The right to have any unprocessed data withdrawn and destroyed, provided it can be reliably 
identified, and provided that doing so does not increase the risk for you. 
• The right to have any questions concerning the project answered at any time 
• The right for all information to be both confidential and anonymous 
 
 
Whom should I contact if I have any questions? 
 
If you have any questions regarding the project you may contact: 
 
Dr Paula Henderson  9925 7221     or   paula.henderson@rmit.edu.au 
 
or 
 
Prof Eleanor Holroyd  9925 7179  or     eleanor.holroyd@rmit.edu.au  
 
 
What other issues should I be aware of before deciding whether to participate? 
 
Before choosing to participate in this project it would be advisable to ensure you have the time to 
commit to the project’s requirements as stated above; are comfortable with the way that your privacy 
is protected; you have no known health concerns other than menopausal symptoms and depression; 
and that you are satisfied that know all the potential risks associated with both osteopathic 
manipulative treatment and cognitive behavioural therapy. 
 
 
Yours sincerely, 
 
 
 
 
 
Dr Paula Henderson   Prof. Eleanor Holroyd   Dr Keong Yap 
Registered Osteopath   Professor of Nursing Research  Psychologist 
Master of Osteopathy Student  RN and Anthropologist   Senior Lecturer 
 
 
 
 
Any complaints about your participation in this project may be directed to the Executive Officer, 
RMIT Human Research Ethics Committee, Research and Innovation, RMIT, GPO Box 2476V, 
Melbourne, 3001. 
Details of the complaints procedure are available on the ‘Complaints with respect to participation in 
research at RMIT’ page and can be found at the RMIT University website www.rmit.edu.au 
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Appendix 7 Consent Forms 
 
 
 
Appendix 7a: Screening Interview Consent Form  
Appendix 7b: General Informed Consent Form 
Appendix 7c: OMT Consent Form 
Appendix 7d: CBT Consent Form 
 
 
  
162 
 
Appendix 7a:  Screening Interview Consent Form 
 
Screening Interview Consent Form 
 
 
 
 
  
 
I, …………………………………………………………..,  agree to take part in the screening 
interview for the above study. 
 
I understand that I will be asked to provide personal information. I am aware that this 
interview is for the purpose of establishing whether or not I am eligible to participate in the 
above study, and that I may not be invited to participate. 
 
I have been informed that all information I provide during this interview will be treated as 
confidential. It will be safeguarded by code and only disclosed in a de-identified form. 
 
I have had an opportunity to ask questions regarding the study and these have been 
answered to my satisfaction. 
 
I am aware that I may withdraw from this interview at any time prior or during the interview. 
 
 
Participant’s Consent: 
 
Name: …………………………………………………………………. Date: ………………………. 
   (Participant) 
 
 
Name: …………………………………………………………………. Date: ………………………. 
   (Witness to signature) 
 
 
Any complaints about your participation in this project may be directed to the Executive Officer, RMIT Human Research Ethics 
Committee, Research & Innovation, RMIT, GPO Box 2476V, Melbourne, 3001.  The telephone number is (03) 9925 2251.   
Details of the complaints procedure are available from the above address.   
 
 
 
 
 
Names of Investigators: 
 
Paula Henderson (Investigator)   Professor Eleanor Holroyd (Supervisor) 
Tel:    03   9925 7221     Tel:   03 9925 7179 
Email:  paula.henderson@rmit.edu.au  Email:  eleanor.holroyd@rmit.edu.au 
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Appendix 7b:  General Informed Consent Form 
Prescribed Consent Form For Persons Participating In Research 
Projects Involving Tests and/or Medical Procedures 
 
 
College  Science, Engineering and Health 
School of Health Science 
Name of participant:  
Project Title:  
  
Name(s) of investigators:    (1) Dr Paula Henderson Phone: 9925 7221 
(2) Prof Eleanor Holroyd Phone: 9925 7179 
 
1. I have received a statement explaining the tests/procedures involved in this project. 
 
2. I consent to participate in the above project, the particulars of which - including details of tests or 
procedures - have been explained to me. 
 
3. I authorise the investigator or his or her assistant to use with me the tests or procedures referred to in 1 
above. 
 
4. I acknowledge that: 
 
(a) The possible effects of the tests or procedures have been explained to me to my satisfaction. 
(b) I have been informed that I am free to withdraw from the project at any time and to withdraw any 
unprocessed data previously supplied (unless follow-up is needed for safety). 
(c) The project is for the purpose of research and/or teaching.  It may not be of direct benefit to me. 
(d) The privacy of the personal information I provide will be safeguarded and only disclosed where I have 
consented to the disclosure or as required by law.  
(e) The security of the research data is assured during and after completion of the study.  The data 
collected during the study may be published, and a report of the project outcomes will be provided to the 
Discipline of Osteopathy and Discipline of Psychology, RMIT University.   Any information which will identify me 
will not be used. 
 
 
Participant’s Consent 
 
 
Participant:  Date:  
(Signature) 
 
 
Witness:  Date:  
(Signature) 
 
Where participant is under 18 years of age: 
 
I consent to the participation of ____________________________________ in the above project. 
 
Signature: (1)                                             (2) Date:  
(Signatures of parents or guardians) 
 
Witness:  Date:  
(Witness to signature) 
 
Participants should be given a photocopy of this consent form after it has been signed. 
 
 
Any complaints about your participation in this project may be directed to the Executive Officer, RMIT Human Research Ethics 
Committee, Research & Innovation, RMIT, GPO Box 2476V, Melbourne, 3001.  The telephone number is (03) 9925 2251.   
Details of the complaints procedure are available from the above address.   
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.Appendix 7c: OMT Consent Form 
Patient Consent for Osteopathic Treatment and Management Plan 
Osteopathic care is recognized as being an effective and safe method of care for many 
conditions. However it is important to recognize that there are risks associated with all health 
care procedures to which any patient should be informed. Please read the following carefully 
and ask any questions you need to clarify the information. 
1. I have disclosed to the osteopath all the information asked regarding my present
and past state of health.
2. I acknowledge that I have had the opportunity to discuss my proposed care with
the osteopath and that I have had the opportunity to ask questions about the
nature, extent and purpose of my proposed care and I have been given sufficient
time to make a decision giving consent for the care to proceed.
3. I acknowledge that I have discussed with the osteopath the risks associated with
my proposed care, which includes, although is not limited to: muscle and joint
soreness or strains, headaches, nausea and dizziness, fractures, disc injuries,
and an exacerbation and/or aggravation of my underlying condition. I also
acknowledge the following additional potential risks insofar as my proposed care
is concerned have been explained to
me…………………………………………………………………………………..
4. I acknowledge that I have discussed with the osteopath the rare risk of adverse
events associated with manipulation of the neck, including: headache, nausea
and dizziness, disc injury, pinched nerves, soft tissue strains and artery damage
that may cause stroke or stroke-like episodes. I have discussed with the
osteopath the alternatives to manipulation.
5. I acknowledge that I am aware of and understand the potential risks. I appreciate
that results are not guaranteed. I do not expect the osteopath to be able to
anticipate all potential risks and complications associated with my proposed care.
6. I hereby acknowledge my consent to the performance of the proposed
osteopathic care as outlined by the osteopath named below.
7. I understand that I can withdraw my consent at any time.
Patient’s signature…………………………………………………..  Date………………………. 
Patient’s name……………………………………………………….. 
Practitioner’s…………………………………………………………  Date……………………….. 
Practitioner’s name………………………………………………….. 
Any complaints about your participation in this project may be directed to the Executive Officer, RMIT Human Research Ethics 
Committee, Research & Innovation, RMIT, GPO Box 2476V, Melbourne, 3001.  The telephone number is (03) 9925 2251.   
Details of the complaints procedure are available from the above address.   
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Appendix 7d:  CBT Consent Form 
Psychological Services 
As part of providing a psychological service, the clinician with whom you are consulting at the RMIT 
University Psychology Clinic will need to collect and record relevant information from you. This 
information will be a necessary part of the psychological assessment and intervention that is 
conducted. Information will be used for research purposes. Information may be recorded in three 
ways: 
 
1. Case files. Your personal information is kept in a secure (locked) filing cabinet that is accessible 
only to the RMIT University Psychology Clinic staff and authorised provisional psychologists. 
Your clinician will be able to discuss information in your file with you. 
2. Videotapes. The RMIT University Psychology Clinic has a training function in addition to its 
community service emphasis. Postgraduate students within the professional training programs 
participate in clinical sessions under the supervision of professionally registered psychologists. 
Student supervision occurs through a combination of videotaped viewing of clinical sessions by 
the supervisor and case discussion. This practice assists student professional development and 
serves as a quality assurance mechanism for the community. These tapes are kept in a secure 
location and are accessible only to the RMIT University Psychology Clinic staff and authorised 
provisional psychologists. 
3. Research Publications. Data collected from the scores on questionnaires completed in this trial 
may be published as grouped information, but any information which will identify you will not be 
used. The security of the research data is assured during and after completion of your 
involvement with the Clinic. 
 
Client access to recorded information 
Case Files. You may access the material recorded in your file on request, subject to the exceptions 
contained in National Privacy Principal 6 (e.g. actual test scores, proformas, etc.) of the Privacy 
Amendment (Private Sector) Act* (2000).  Any requests for access to these records should be made 
in writing to the RMIT University Psychology Clinic Director. 
Videotapes.  Videotapes of interviews are used for professional training purposes and are erased 
when their usefulness is outlived. However, arrangements can be made for you to view the 
videotapes if you wish. Requests for videotapes access should be made in writing to the RMIT 
University Psychology Clinic Director. 
Case Observation. At times, trainee psychologists may view a client session from the observation 
room. You will be advised if this is to occur. Arrangements can be made for you to meet the trainee 
psychologist/s who will be observing if you wish. 
 
*Further information about these laws can be found on the website of the Office of the Federal Privacy 
Commissioner (OFPC) www.privacy.gov.au   You can also write to the OFPC Commissioner (GPO Box 5218, 
Sydney, NSW, 1042) or telephone (1300 363 992) if you wish to lodge a formal complaint about the use of, or 
access to, your personal information. 
 
Confidentiality 
All personal information gathered by the psychologist or the provisional psychologist during the 
provision of psychological services will remain confidential and secure, except when: 
 
1. Your prior approval has been obtained to: 
(a) provide a written report to another professional or agency (e.g. GP, etc); or 
(b) discuss the material with another person (e.g. GP, etc) 
2. Failure to disclose the information would place you and/or another person at risk; or 
3. It is subpoenaed by a Court. 
 
Cancellation Policy 
If for any reason you need to cancel or postpone an appointment, at least 24 hours notice must be 
given. This may mean you will be excluded from continuing to participate in the project. If you are 
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excluded, you may continue to receive counselling at the RMIT University Psychology Clinic at your 
own expense. 
Withdrawal: I understand that I can with draw from the project and psychology consultations at any 
time. 
I,………………………………………………………………………, have read and understand the above 
Consent Form. I agree to these conditions for the psychological service provided by the RMIT 
Psychology Clinic. 
Signatures 
Client……………………………………………………………………………….Date…………………….. 
Provisional Psychologist/Psychologist…………………………………………..Date……………………. 
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Appendix 9 OMT and CBT Protocol and Checklists  
 
 
 
Appendix 9a. OMT Protocol and Checklists  
Appendix 9b: CBT Protocol and Checklists 
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Appendix 9a.  OMT Protocol and Checklists  
Osteopathic Consultations Protocol 
 
Project Title:   Piloting osteopathic manipulative treatment for depression in peri-
menopausal women 
 
 
Length of consultation  
 
Initial consultation:  1 hour 
 
Follow-up consultations: 30-40 minutes 
 
Consultations 
 
A total of four consultations will be conducted within eight weeks of commencing the trial. 
Three of these consultations will occur within the first five weeks, with a final session being 
held within the eighth week of the trial. 
 
 
Files 
 
Patient/Participant record of consultations will be made on A4 paper ‘record of consultation 
sheets’ within in folder manila folders with permaclips to hold ‘records of consultation’ 
sheets. 
 
Within each file will be four sheet protectors; one for each session. At the front of these is a 
checklist of the documents that must be completed, filed, or given to participant. 
 
Files will be kept in a secure room in the RMIT Osteopathic Teaching Clinic during the 
treatment phase of the trial.  Once the treatment phase has been completed, files will be 
moved to a secure room in building 202, level 4 of the Bundoora West RMIT campus.    In 
both locations, the documents will be locked within a secure storage cabinet within a locked 
room. 
 
 
Appointments  
 
Initially appointment will be made by the researcher (or assistant) and the clinics receptionist 
will be informed of the appointment details.  
 
On arrival at the clinic, the participant will let the receptionist know that they have arrived and 
the osteopath will be notified. The participants file will be ready for the osteopath who will 
then greet the participant and direct them into the consultation room. 
 
After each consultation another appointment will be made, in person by the participant, at 
the time interval specified by the osteopathic practitioner.   
 
 
After the first, third and fourth consultation a WAI (working alliance inventory) is to be 
completed by the participant. The participant’s ID number should be noted on this document 
(not their name) and should be placed in a sealable envelope and placed within the secure 
filing cabinet for collection by the researcher. 
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Cancellations, changes or missed appointments.  
As long as the consultations occur as required, three in the first five weeks and one in the 
eighth week, participants will have met the trial requirements and so some latitude in 
changes to appointments can be accommodated. 
Cancellations or changes to appointments may be made with a minimum of 24 hours notice. 
Another appointment will be made depending on the availability of a practitioner to provide 
the consultation at an alternate time within the trial requirements.  
Should a participant fail to attend three sessions within the first 5 weeks, or miss the last 
appointment, then they may be excluded from trial. If they are excluded from the trial, they 
will still  be eligible for the a total of four consultations. 
Consultations 
During the first consultation a thorough medical history will be taken and appropriate 
physical, neurological and orthopaedic examinations will be conducted. A thorough 
osteopathic examination as outlined on the Record of Patient Consultation will be conducted 
and information recorded. This data will form the basis of determining if there are consistent 
findings within this cohort of women. All findings will be recorded on the patient consultation 
sheet. 
Prior to commencing treatment the osteopath will discuss their examination findings and 
outline the treatment and management plan with the participant. The participant will be 
asked to sign the informed consent form for osteopathic treatment BEFORE any treatment 
commences. 
Treatment and techniques used will be individualised for each participant and determined by 
the examination findings.  
Consultations 2 to 4 
The interval between the second and third consultations will be determined by the osteopath. 
They must both be completed within four weeks of the original consultation (ie week five of 
the trial). The fourth consultation will occur in week eight of the trail.  
The same osteopathic examination will occur in these consultations and recorded on a 
separate sheet for each consultation. The reason for a standard examination protocol is to 
ensure that the examinations are consistent across the study. This will enhance the reliability 
of the data being collected and analysed. 
Treatment will be individualised, as in the first consultation, to the participant’s requirements 
at each consultation. 
Examination to include any orthopaedic and neurological or physical examination indicated 
by history taking of patient. 
Examination to be thorough and ensure that there is no evidence of dysfunction or pathology 
that would mean that the participant does not meet inclusion criteria and requires further 
investigation or other management referral. 
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Osteopathic Examination 
The osteopathic examination includes the following: 
Postural assessment 
Assessment of anatomical landmarks 
Assessment of fascial tension 
- Zink’s 
- 10 step fascial screen  
Assessment of spine from OA to LS, include SIJ 
Assessment of ROM of peripheral joints 
Assessment of muscle tone 
- note down mm that are hypertonic 
- any mm that are wasted/atrophied 
Assessment of Cranial Rhythm 
Assessment of Autonomic Nervous System 
- signs of acute sympathetic hypertonia 
- signs of chronic sympathetic hypertonia 
- signs of sympathetic hypotonia 
- signs of parasympathetic hypertonia 
- signs of parasympathetic hypotonia 
red reflexes, sweating, dry skin, oedema, respiratory signs, digestive signs. 
Clear and precise notes on examination findings should be recorded in the space provided. 
Further Diagnostic Procedures 
The osteopath will refer the participant for appropriate diagnostic procedures as determined 
by examination or information obtained from the patient. The outcome of these procedures 
may lead to the exclusion of the participant from the trial. Should the participant be excluded 
from the trial they will be eligible for free osteopathic consultations for the remainder of the 
consultations still remaining if they desire.  
Working Alliance Inventory (WAI) 
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The osteopath will complete a WAI after the first, third and fourth consultations. The ID 
number of each participant will be placed on each of these forms in order to correlate them 
with the form completed by the participant. These forms will be placed in a sealable 
envelope and placed within the secure filing cabinet. They will be collected by the researcher 
to analyse. 
 
Adverse Events 
All adverse events need to be recorded on the Adverse Event Form. The definition of an 
adverse event is: 
“Any undesirable clinical occurrence in a subject, whether it is considered to be device-
related or not, that includes a clinical sign, symptom or condition and/or an observation of an 
unintended technical performance or performance outcome of a device.” (NHMRC, 2007) 
A non-serious adverse event is one that presents no long lasting harm to the participant and 
is largely self-limiting. A non-serious adverse event may include, but not limited to,: 
Muscle and joint soreness or strains, headaches, nausea and dizziness, or other mild 
responses to treatment that resolve within a few days of treatment. 
A serious adverse event is one that places the participation in an injured state that can lead 
to long-term or permanent disability, be life threatening or leads to death of the participant. A 
serious adverse event may include, but not limited to,: 
Severe muscle or joint strain or sprain, headaches or migraines, disc injury, fractures, 
pinched nerves, arterial damage that may cause stroke or stroke-like episodes, or cauda 
equina injury. 
 
 
 
 
Protocol 
 
All adverse events must be recorded (even mild adverse events) on the appropriate form.  
 
Non-serious adverse event 
 
If the participant tells you about a non-serious adverse event it needs to be documented and 
any action required ensuring the health and safety of the participant taken.  
 
The Adverse Event Form should be filled out and a copy sent to the researcher and the 
original copy is to remain in the patient file. Any subsequent adverse event is to be recorded 
on the original form and a copy of the new information forwarded to the researcher. 
 
Serious adverse event 
 
In the event of a serious adverse event action must be taken to minimize harmful 
consequences to the participant. This may include calling emergency services, 
hospitalization of the participant, etc. 
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Once the serious adverse event has been managed, details of the event must be 
documented on both the Adverse Event Form and the Serious Adverse Event Form. The 
researcher must be notified by phone and copies of the form must be sent to the researcher 
who will forward it on to the senior supervisor, Head of School and Chair of the Ethics 
Committee. 
 
The participant should be contacted at an appropriate interval to follow-up on their progress. 
The outcome of this follow-up should be noted on a Serious Adverse Event Form. The form 
must be sent to the researcher who will then forward it on as above.  If this follow-up also 
produces a finalisation of the serious adverse event, no further forms or action need to be 
taken.  If the serious adverse event is not resolved, then additional follow-ups are required 
until resolution is achieved. Each contact with the participant should be documented. 
 
Intervals between follow-up contact with the participant will be determined in consultation 
with the practitioner, researcher and supervisor. 
 
If you have any concerns about the way that the adverse event is managed by the 
researcher, the senior supervisor should be contacted. If unresolved the Head of School or 
Ethics Committee should be contacted. 
 
Contact Details 
 
Researcher:  Dr Paula Henderson  9925 7221 
 
Senior Supervisor: Prof. Eleanor Holroyd  9925 7179 
 
Head of School: Prof. Charlie Xue  9925 7360 
 
Ethics Committee: Peter Burke   9925 2251 
 
 
 
Reference 
 
National Health and Medical Research Council. (2007). National Statement on Ethical 
Conduct in Human Research. Australian Government. Canberra.  
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OMT Consultation 1 Check List     ID:_________________ 
 
 
The table below is a list of actions required as part of this project. 
Please place a tick against each of the items below to that the action has occurred. 
Thank you. 
 
 
General Informed Consent form – checked that copy 
is in file 
 
 
Informed Consent for OMT form signed and copy 
placed in file 
 
 
Copy of OMT Consent form given to participant 
 
 
WAI – Client version completed and placed in file 
 
 
WAI – Therapist version completed and placed in file 
 
 
Patient Notes on File with ID number 
 
 
All documents have the participants ID number on 
them 
 
 
 
 
 Yes No 
Drop Out Form completed   
Adverse Event Form completed   
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Appendix 9b:  CBT Protocol and Checklists 
Cognitive Behavioural Therapy Consultations Protocol 
Length of consultation 
Consultations: 50 minutes 
Consultations 
A total of nine consultations will be conducted, the first eight will be conducted at weekly 
intervals and the ninth will be held three months later. 
Files 
Patient/Participant record of consultations will be made on record of consultation sheets 
within in folder manila folders with permaclips to hold ‘records of consultation’ sheets.  
Within each file will be nine sheet protectors; one for each session. At the front of these is a 
checklist of the documents that must be completed, filed, or given to participant. 
The sessions will also be video recorded to ensure consistency across the trial and allow for 
supervision to occur. 
Files will be kept in a secure room in the RMIT University Psychology Clinic during the 
treatment phase of the trial.  Once the treatment phase has been completed, files will be 
moved to a secure room in building 202, level 4 of the Bundoora West RMIT campus.    In 
both locations, the documents will be locked within a secure storage cabinet within a locked 
room. 
Appointments 
Initially appointment will be made by the researcher (or assistant) and the clinics receptionist 
will be informed of the appointment details.  
On arrival at the clinic, the participant will let the receptionist know that they have arrived and 
at this time they will be asked to read and sign the Informed Consent Form for CBT. They 
will also be asked to complete the Depression Anxiety Stress Scale (DASS) and Greene 
Climacteric Scale (GCS).  Once completed, the DASS will be evaluated by the practitioner 
and the session will commence. If a score higher than 20 is observed then the participant will 
be informed that for their safety they are being excluded from the trial, however, they may 
have at the nine sessions, free of charge, as per the trial at the RMIT University Psychology 
Clinic. They will also be given the option to be referred to an external private clinical 
psychologist, however, this would be at their own expense.  
For those participants who score 20 or under, they will continue on in the trial. At the end of 
the initial CBT session they will be asked to complete the Working Alliance Inventory (WAI). 
The participant’s ID number should be noted on this document (not their name) and should 
be placed in a sealable envelope and placed within the secure filing cabinet for collection by 
the researcher. 
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After each consultation another appointment will be made, in person by the participant for 
the next consultation, until all nine are completed. 
 
 
The DASS, GCS and WAI will be completed at weeks one, five and eight of the trial. The 
DASS and GCS will also be completed in week 20 at the follow up and final CBT session. A 
copy of the DASS completed at the screening interview will be placed on file.  
 
 
Cancellations, changes or missed appointments.   
 
It is envisaged that not every participant will be able to have eight consecutive CBT sessions 
due to personal commitments or the RMIT University Psychology Clinic being closed. It is 
anticipated that all sessions should be completed within ten weeks. Participants may be 
excluded from the trial if this time frame is extended. If excluded they will be eligible to 
continue receiving CBT for the rest of the sessions not completed. 
 
Cancellations or changes to appointments may be made with a minimum of 24 hours notice. 
Another appointment will be made depending on the availability of a practitioner to provide 
the consultation at an alternate time within the trial requirements.  
 
 
Consultations 
 
Consultations will be based on the CBT Session Outline. 
 
Particpant consultation notes should be placed in the appropriate sheet protector with the ID 
number written in the top right hand corner. 
 
 A weekly homework document is to be given to each participant. The homework documents 
are from the Centre for Clinical Interventions ‘Back from the Bluez’ workbook. Note chapter 8 
is not going to be used in this project, however, participants can access it via the internet if 
interested. The CCI’s web address is: 
 
www.cci.health.wa.gov.au 
 
Permission to use these documents is based on the agreement that no changes will be 
made to any of the documents. 
 
 
Working Alliance Inventory (WAI) 
 
The practitioner will complete a WAI after the first, fifth and eighth consultations. The ID 
number of each participant will be placed on each of these forms in order to correlate them 
with the form completed by the participant. These forms will be placed in a sealable 
envelope and placed within the secure filing cabinet. They will be collected by the researcher 
to analyse. 
 
 
Adverse Events 
 
All adverse events need to be recorded on the Adverse Event Form. The definition of an 
adverse event is: 
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“Any undesirable clinical occurrence in a subject, whether it is considered to be device-
related or not, that includes a clinical sign, symptom or condition and/or an observation of an 
unintended technical performance or performance outcome of a device.” (NHMRC, 2007) 
 
 
A non-serious adverse event is one that presents no long lasting harm to the participant and 
is largely self-limiting.  
 
 
A serious adverse event is one that places the participation in an injured state that can lead 
to long-term or permanent disability, be life threatening or leads to death of the participant, 
e.g. exacerbation of the depression resulting in suicidal thoughts.  
 
 
Protocol 
 
All adverse events must be recorded (even mild adverse events) on the appropriate form.  
 
Non-serious adverse event 
 
If the participant tells you about a non-serious adverse event it needs to be documented and 
any action required ensuring the health and safety of the participant taken.  
 
The Adverse Event Form should be filled out and a copy sent to the researcher and the 
original copy is to remain in the patient file. Any subsequent adverse event is to be recorded 
on the original form and a copy of the new information forwarded to the researcher. 
 
Serious adverse event 
 
In the event of a serious adverse event action must be taken to minimize harmful 
consequences to the participant. This may include calling emergency services, 
hospitalization of the participant, etc. 
 
Once the serious adverse event has been managed, details of the event must be 
documented on both the Adverse Event Form and the Serious Adverse Event Form. The 
researcher must be notified by phone and copies of the form must be sent to the researcher 
who will forward it on to the senior supervisor, Head of School and Chair of the Ethics 
Committee. 
 
The participant should be contacted at an appropriate interval to follow-up on their progress. 
The outcome of this follow-up should be noted on a Serious Adverse Event Form. The form 
must be sent to the researcher who will then forward it on as above.  If this follow-up also 
produces a finalisation of the serious adverse event, no further forms or action need to be 
taken.  If the serious adverse event is not resolved, then additional follow-ups are required 
until resolution is achieved. Each contact with the participant should be documented. 
 
Intervals between follow-up contact with the participant will be determined in consultation 
with the practitioner, researcher and supervisor. 
 
If you have any concerns about the way that the adverse event is managed by the 
researcher, the senior supervisor should be contacted. If unresolved the Head of School or 
Ethics Committee should be contacted. 
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Contact Details 
 
Researcher:  Dr Paula Henderson  9925 7221 
 
Senior Supervisor: Prof. Eleanor Holroyd  9925 7179 
 
Head of School: Prof. Charlie Xue  9925 7360 
 
Ethics Committee: Peter Burke   9925 2251 
 
 
Reference 
 
National Health and Medical Research Council. (2007). National Statement on Ethical 
Conduct in Human Research. Australian Government. Canberra.  
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Week 1 Check List ID:_________________ 
The table below is a list of actions required as part of this project. 
Please place a tick against each of the items below to that the action has occurred. 
Thank you. 
General Informed Consent form – checked that 
copy is in file 
Informed Consent for CBT form signed and 
copy placed in file 
Copy of CBT Consent form given to participant 
Copy of DASS completed at screening interview 
- checked that copy is in file 
DASS completed and placed in file 
GSC completed and placed in file 
WAI – Client version completed and placed in 
file 
WAI – Therapist version completed and placed 
in file 
Homework week 1 given to participant 
Patient Notes on File with ID number 
All documents have the participants ID number 
on them 
Yes No 
Drop Out Form completed 
Adverse Event Form completed 
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Weeks 2, 3, 4, 6 Check List (Example) ID:_________________ 
The table below is a list of actions required as part of this project. 
Please place a tick against each of the items below to that the action has occurred. 
Thank you. 
Homework week 2 given to participant 
Participant’s Notes on File with ID number 
All documents have the participants ID number 
on them 
Yes No 
Drop Out Form completed 
Adverse Event Form completed 
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Week 5 and 8 Check List      ID:_________________ 
 
 
 
The table below is a list of actions required as part of this project. 
Please place a tick against each of the items below to that the action has occurred. 
Thank you. 
 
 
DASS completed and placed in file 
 
 
GSC completed and placed in file 
 
 
WAI – Client version completed and placed in 
file 
 
 
WAI – Therapist version completed and placed 
in file 
 
 
Homework week 5 given to participant 
 
 
Patient Notes on File with ID number 
 
 
All documents have the participants ID number 
on them 
 
 
 
 
 Yes No 
Drop Out Form completed   
Adverse Event Form completed   
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Week 20 Check List ID:________________ 
The table below is a list of actions required as part of this project. 
Please place a tick against each of the items below to that the action has occurred. 
Thank you. 
DASS completed and placed in file 
GSC completed and placed in file 
Patient Notes on File with ID number 
All documents have the participants ID number 
on them 
Number of sessions attended between week 8 
and week 20 
Participant to continue with CBT after week 20 
Yes No 
Adverse Event Form completed 
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Appendix 10 Drop-out and Adverse Event Protocols and Forms 
Appendix 10a: Drop-Out Protocol  
Appendix 10b: Participant Drop-Out Form 
Appendix 10c: Adverse Event Protocol 
Appendix 10d: Adverse Event Form 
Appendix 10e: Serious Adverse Event Form (SAE) 
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Appendix 10a:  Drop-Out Protocol  
Participant Drop-Out Form Instructions 
 
In the event of a participant dropping out the “Participant Drop-Out Form” must be 
completed. 
 
Drop-out originated from participant. 
 
If the participant indicates their intention to drop-out, the person notified of this intention 
should have a short conversation that enquires about the well-being of the participant and 
ensure that they are not experiencing any adverse effects from participating in the project. If 
participants are experiencing adverse effects one or more of the following options should be 
undertaken: 
 
- enquire if they need immediate medical attention? 
- if the answer is yes, arrange for the most appropriate intervention, eg ambulance 
- do they need to consult with the Psychology Clinic’s supervisor? 
- if yes, arrange for a telephone or face-to-face meeting 
- do they need to consult with the osteopath? 
- if yes, arrange for a telephone or face-to-face meeting 
- do they need to consult with their GP? 
- If yes, encourage them to make an appointment 
 
If you are concerned that the participant is showing signs of distress but is unwilling to 
acknowledge this, then the researcher or supervisor should be contacted and informed of 
your concerns. 
 
Once ensured that the participant is not experiencing adverse effects from the project, 
please ask them for the reasons they have withdrawn and note these details on the form. If 
the participant does not wish to elaborate then note this alongside the ‘other’ option on the 
form and comment section. 
 
If the participant does not turn up for an appointment, either CBT or OMT, a follow-up call by 
the receptionist or researcher should be made to determine reason and ensure participant is 
not experiencing any adverse effects from participating in the project. 
 
Drop-out originated from Practitioner 
 
Please indicate reason why the participant is being dropped from the project. Where referral 
is required please indicate what action was taken to ensure the safety and well-being of the 
participant. Follow-up of the outcome of referral or action taken should be undertaken and 
noted on the ‘Drop-out Form’. 
 
 
The form should be forwarded to the researcher once all details have been entered. 
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Appendix 10b:  Participant Drop-Out Form 
This form is to be completed when a participant drops out of the project or is excluded by the 
practitioner, researcher or supervisors. 
Participant’s Name: ……………………………………………………   ID No. 
………………………… 
Date of withdrawal from the project:  ……../………./……….. 
Withdrawal requested by: 
a. Participant d. Osteopath
b. Researcher e. Psychologist
c. Research Supervisor
Reason for withdrawal: 
a. Too much time required for participation
b. No reason given
c. Participant scores higher than 20 on the DASS
d. Participant has signs and/or symptoms of mental illness outside the scope of this
trial
e. Participant has signs and/or symptoms of a condition requiring further
assessment and is outside the scope of this project
f. Other.   Please
specify…………………………………………………………………………
……………………………………………………………………………………… 
Write a brief comment giving further details relating to reason for withdrawal as circled 
above. 
……………………………………………………………………………………………………………
……………………………………………………………………………………………………………
……………………………………………………………………………………………………………
……………………………………………………………………………………………………………
…………………… 
If the participant was dropped due to health related reasons, was the participant followed-up 
to determine outcome of referral? 
Yes    No 
Give a brief summary of the outcome of this follow-up. 
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……………………………………………………………………………………………………………
……………………………………………………………………………………………………………
……………………………………………………………………………………………………………
……………………………………………………………………………………………………………
…………………… 
The participant has granted permission to be contacted at a further date about participation 
in this project.  
Yes    No 
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Appendix 10c:  Adverse Event Protocol  
Protocol for Adverse Event 
 
 
The following outlines the steps to be taken in the event of an adverse event occurring 
during the participation of any person involved in this project. Please ensure you are familiar 
with this document and what you are required to do should an adverse event occur. 
 
Definition of an adverse event 
 
“Any undesirable clinical occurrence in a subject, whether it is considered to be device-
related or not, that includes a clinical sign, symptom or condition and/or an observation of an 
unintended technical performance or performance outcome of a device.” (NHMRC, 2007) 
 
 
A non-serious adverse event is one that presents no long lasting harm to the participant and 
is largely self-limiting. A non-serious adverse event may include: 
 
Osteopathic 
 
Muscle and joint soreness or strains, headaches, nausea and dizziness, or other mild 
responses to treatment that resolve within a few days of treatment. 
 
Cognitive Behavioural Therapy 
 
Mild exacerbation of depressive symptoms, unpleasant emotions such as: anger, guilt, 
shame, etc. Mild anxiety or elevation of stress. 
 
 
A serious adverse event is one that places the participation in an injured or damaged state 
that can lead to long-term or permanent disability, be life threatening or leads to death of the 
participant. A serious adverse event may include: 
 
Osteopathic 
 
Severe muscle or joint strain or sprain, headaches or migraines, disc injury, fractures, 
pinched nerves, arterial damage that may cause stroke or stroke-like episodes, or cauda 
equina injury. 
 
Cognitive Behavioural Therapy 
 
Severe exacerbation of depressive symptoms, suicidality, onset of severe mental illness, 
behaviour that may lead to harm of the participant or persons near them. 
 
 
Protocol 
 
All adverse events must be recorded (even mild adverse events) on the appropriate form.  
 
Non-serious adverse event 
 
If the participant tells you about a non-serious adverse event it needs to be documented and 
any action required ensuring the health and safety of the participant taken.  
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The Adverse Event Form should be filled out and a copy sent to the researcher and the 
original copy is to remain in the patient file. Any subsequent adverse event is to be recorded 
on the original form and a copy of the new information forwarded to the researcher. 
Serious adverse event 
In the event of a serious adverse event action must be taken to minimize the harmful 
consequences to the participant. This may include calling emergency services, 
hospitalization of the participant, etc. 
Once the serious adverse event has been managed, details of the event must be 
documented on the Serious Adverse Event Form. The researcher must be notified by phone 
and copies of the form must be sent to the researcher who will forward it on to the senior 
supervisor, Head of School and Chair of the Ethics Committee. 
The participant should be contacted at an appropriate interval to follow-up on their progress. 
The outcome of this follow-up should be noted on a Serious Adverse Event Form. The form 
must be sent to the researcher who will then forward it on as above.  If this follow-up also 
produces a finalisation of the serious adverse event, no further forms or action need to be 
taken.  If the serious adverse event is not resolved, then additional follow-ups are required 
until resolution is achieved. Each contact with the participant should be documented. 
Intervals between follow-up contact with the participant will be determined in consultation 
with the practitioner, researcher and supervisor. 
If you have any concerns about the way that the adverse event is managed by the 
researcher, the senior supervisor should be contacted. If unresolved the Head of School or 
Ethics Committee should be contacted. 
Contact Details 
Researcher: Dr Paula Henderson 9925 7221 
Senior Supervisor: Prof. Eleanor Holroyd 9925 7179 
Head of School: Prof. Ken Greenwood 9925 7360 
Ethics Committee: Peter Burke 9925 2251 
Reference 
National Health and Medical Research Council. (2007). National Statement on Ethical 
Conduct in Human Research. Australian Government. Canberra. 
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Appendix 10d:  Adverse Event Form 
 
Adverse Event Form 
 
Clinic or site: …………………………………………………………………………. 
 
Patient ID or name:……………………………………………………………………. 
 
 
Severity Study Intervention 
Relationship 
Action Taken Regarding Study 
Intervention 
Outcome of Adverse Event (AE) Expected Serious 
1 = Mild 
2 = Moderate 
3 = Severe 
1 = Definitely related 
2 = Possibly related 
3 = Not related 
1 = None 
2 = Participant notified 
3 = Managed with OMT 
4 = OMT discontinued temporarily  
5= OMT discontinued permanently 
6 = Managed within CBT consultation 
7 = CBT discontinued temporarily 
8 = CBT discontinued permanently 
9 = Referred medical intervention 
10 = Referred psychological intervention  
 
1 = Resolved, No Sequel 
2 = AE still present – no treatment 
3 = AE still present – being treated 
4 = Residual effects present – not treated 
5 = Residual effects present – treated 
6 = Death 
7 = Unknown 
1 = Yes 
2 = No 
1 = Yes 
2 = No 
 
If yes, complete 
SAE form 
 
Use the above key to complete 
 
Adverse Event Description Date of 
Adverse 
Event 
Date 
Resolved 
Severity Relationship 
to study 
intervention 
Action 
Taken 
Outcome of 
Adverse 
Event 
Expected Serious 
Adverse 
Event 
Initials of 
Reporter 
1. 
 
         
2. 
 
         
3. 
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Appendix 10e: Serious Adverse Event Form (SAE) 
Serious Adverse Event Form  (SAE) 
Clinic:  ……………………………………………………… 
Patient ID: …………………………………………………. 
1. SAE Onset Date…………………………………
2. SAE Stop Date………………………………….
3. Location of serious adverse event:……………………………………………………
4. Was this an unexpected adverse event?   Yes   No 
5. Brief description of the nature of the serious adverse event (attach a separate
page if more space is required)
……………………………………………………………………………………………………………
…………………………………………………………………………………………… 
6. Category of serious adverse event
O Required intervention to prevent permanent impairment 
O Life-threatening 
O Hospitalization – initial or prolonged 
O Disability or incapacity 
O Severe mental illness exacerbation or first episode 
O Death 
7. Intervention type: Osteopathic Cognitive Behavioural Therapy 
8. Relationship of event to the intervention
O Unrelated (clearly not related to the intervention)
O Possible (may be related to the intervention)
O Definite (clearly related to the intervention)
9. Was the study intervention discontinued due to the event?       Yes  No 
10. What steps were taken to treat the serious adverse event?
……………………………………………………………………………………………………………
……………………………………………………………………………………………………………
……………………………………………………………………………………………………………
……………………………………………………………………………………………………………
……………………………………………………………………………………………………………
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……………………………………………………………………………………………………………
……………… 
 
 
11. List any relevant examinations, history (including pre-existing medical conditions), 
etc., associated with serious adverse event and action taken to treat the event. 
 
……………………………………………………………………………………………………………
……………………………………………………………………………………………………………
……………………………………………………………………………………………………………
……………………………………………………………………………………………………………
…………………… 
 
 
12. Type of report: 
 
  Initial 
  Follow-up 
  Final 
 
 
 
Signature of 
Clinician………………………………………………………………..Date…………………. 
 
 
Signature of Principal 
Investigator…………………………………………………Date………………… 
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Appendix Table 2: Patricia’s Reliable and Clinical Change Data for the DASS Depression Scale 
Case Study 1 
Patricia 
DASS:  
Depression Scale 
Test-retest reliability* r = .71 Standard deviation used to 
measure reliability* 
 SD = 9.25 
Clinical sample Mean** M = 10.65 Normal sample mean** M = 6.34 
Clinical sample standard 
deviation** 
SD = 9.30 Normal sample standard 
deviation** 
SD = 6.97 
Standard error of measurement 4.98128 Standard error of the 
difference 
7.04459 
To change with 68.26% (1 SD) there must be a change of at least 7.045 
To change with 95% (1.96 SD) there must be a change of at least 13.80714 
To change with 99% (2.58 SD) there must be a change of at least 18.14566 
Scores: Week 1 = 13 Week 9 = 12 Week 22 = 4 12 months = 2 
Outcome Week 9 Week 22 12 month 
68.26% confidence of change (1 SD) no yes yes 
95% confidence of change (1.96 SD) no no no 
99% confidence of change (2.58 SD) no no no 
Has the client reliably changed (with at least 95% confidence) AND 
changed from being within 1.96 standard deviations of the clinical 
mean to now being 1.96 standard deviations away from the clinical 
means  (1.96 standard deviation = -7.578) 
Some 
criteria not 
met 
Some 
criteria not 
met 
Some 
criteria not 
met 
Has the client reliably changed (with at least 95% confidence) AND 
changed from being more than 1.96 standard deviations away from 
the normal mean to now being 1.96 standard deviations of the 
normal mean  (1.96 standard deviation = 20.0012) 
Some 
criteria not 
met 
Some 
criteria not 
met 
Some 
criteria not 
met 
Has the client reliably changed (with at least 95% confidence) AND 
changed clinical status according to the intersection of the clinical 
and normal distributions   (intersection = 8.18639) 
Some 
criteria not 
met 
Some 
criteria not 
met 
Some 
criteria not 
met 
*Brown TA, Chorpita BF, Korotitsch W and Barlow DH. Psychometric Properties of the Depression Anxiety Stress
Scales (DASS) in Clinical Samples. Behav. Res Ther. 1997. 35(1):79-89 
** Australian Centre for Posttraumatic Mental Health. The University of Melbourne. Taken from:   Lovibond, SH & 
Lovibond PF. Manual for the  Depression Anxiety Stress Scales. 2nd Ed. Sydney:Psychology Foundation. 1995. 
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Appendix Table 3: Patricia’s Reliable and Clinical Change Data for the DASS Anxiety Scale 
Case Study 1 
Patricia 
DASS:  
Anxiety Scale 
 
Test-retest reliability* r = .78 Standard deviation used to 
measure reliability* 
 SD = 9.06 
 
Clinical sample Mean** M = 10.90 Normal sample mean** M = 4.7 
Clinical sample standard 
deviation** 
SD = 8.12 Normal sample standard 
deviation** 
SD = 4.91 
Standard error of measurement 4.24952 Standard error of the 
difference 
6.00972 
 
To change with 68.26% (1 SD) there must be a change of at least 6.01 
To change with 95% (1.96 SD) there must be a change of at least 11.77884 
To change with 99% (2.58 SD) there must be a change of at least 15.48002 
 
Scores: Week 1 = 13 Week 9 = 11 Week 22 = 1 12 months = 4 
 
Outcome Week 9 
 
Week 22 
 
12 month  
68.26% confidence of change (1 SD) no yes yes 
95% confidence of change (1.96 SD) no yes no 
99% confidence of change (2.58 SD) no no no 
Has the client reliably changed (with at least 95% confidence) AND 
changed from being within 1.96 standard deviations of the clinical 
mean to now being 1.96 standard deviations away from the clinical 
means   (1.96 standard deviation = -5.0152) 
Some 
criteria not 
met 
Some 
criteria not 
met 
Some 
criteria not 
met 
Has the client reliably changed (with at least 95% confidence) AND 
changed from being more than 1.96 standard deviations away from 
the normal mean to now being 1.96 standard deviations of the 
normal mean  (1.96 standard deviation = 14.3236)  
Some 
criteria not 
met 
Some 
criteria not 
met 
Some 
criteria not 
met 
Has the client reliably changed (with at least 95% confidence) AND 
changed clinical status according to the intersection of the clinical 
and normal distributions  (intersection  = 7.0363) 
Some 
criteria not 
met 
yes Some 
criteria not 
met 
*Brown TA, Chorpita BF, Korotitsch W and Barlow DH. Psychometric Properties of the Depression Anxiety Stress 
Scales (DASS) in Clinical Samples. Behav. Res Ther. 1997. 35(1):79-89 
** Australian Centre for Posttraumatic Mental Health. The University of Melbourne. Taken from:   Lovibond, SH & 
Lovibond PF. Manual for the  Depression Anxiety Stress Scales. 2nd Ed. Sydney:Psychology Foundation. 1995. 
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Appendix Table 4: Patricia’s Reliable and Clinical Change Data for the DASS Stress Scale 
Case Study 1 
Patricia 
DASS:  
Stress Scale 
Test-retest reliability* r = .81 Standard deviation used to 
measure reliability* 
 SD = 12.45 
Clinical sample Mean** M = 21.1 Normal sample mean** M = 10.11 
Clinical sample standard 
deviation** 
SD = 11.15 Normal sample standard 
deviation** 
SD = 7.91 
Standard error of measurement 5.42683 Standard error of the 
difference 
7.6747 
To change with 68.26% (1 SD) there must be a change of at least 7.675 
To change with 95% (1.96 SD) there must be a change of at least 15.04213 
To change with 99% (2.58 SD) there must be a change of at least 19.76871 
Scores: Week 1 = 33 Week 9 = 23 Week 22 = 7 12 months = 7 
Outcome Week 9 Week 22 12 month 
68.26% confidence of change (1 SD) yes yes yes 
95% confidence of change (1.96 SD) no yes yes 
99% confidence of change (2.58 SD) no yes yes 
Has the client reliably changed (with at least 95% confidence) AND 
changed from being within 1.96 standard deviations of the clinical 
mean to now being 1.96 standard deviations away from the clinical 
means  (1.96 standard deviation = -0.754) 
Some 
criteria not 
met 
Some 
criteria not 
met 
Some 
criteria not 
met 
Has the client reliably changed (with at least 95% confidence) AND 
changed from being more than 1.96 standard deviations away from 
the normal mean to now being 1.96 standard deviations of the 
normal mean   (1.96 standard deviation = 25.6136) 
Some 
criteria not 
met 
yes Some 
criteria not 
met 
Has the client reliably changed (with at least 95% confidence) AND 
changed clinical status according to the intersection of the clinical 
and normal distributions  (intersection  = 14.67091)  
Some 
criteria not 
met 
yes Some 
criteria not 
met 
*Brown TA, Chorpita BF, Korotitsch W and Barlow DH. Psychometric Properties of the Depression Anxiety Stress
Scales (DASS) in Clinical Samples. Behav. Res Ther. 1997. 35(1):79-89 
** Australian Centre for Posttraumatic Mental Health. The University of Melbourne. Taken from:   Lovibond, SH & 
Lovibond PF. Manual for the  Depression Anxiety Stress Scales. 2nd Ed. Sydney:Psychology Foundation. 1995. 
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Appendix Table 5: Patricia’s Reliable and Clinical Change Generator for the GCS 
Psychological Subscale 
Case Study 1 
Patricia 
GCS:  
Psychological Scale      
 
Test-retest reliability* r = .87 Standard deviation used to 
measure reliability* 
 SD = 9.69 
 
Clinical sample Mean* M = 19.69 Normal sample mean** M = 9.69 
Clinical sample standard 
deviation* 
SD = 7.42 Normal sample standard 
deviation** 
SD = 6.41 
Standard error of measurement 3.49378 Standard error of the 
difference 
4.94095 
 
To change with 68.26% (1 SD) there must be a change of at least 4.941 
To change with 95% (1.96 SD) there must be a change of at least 9.68408 
To change with 99% (2.58 SD) there must be a change of at least 12.72704 
 
Scores: Week 1 = 11 Week 9 = 15 Week 22 = 6 12 months = 4 
 
Outcome Week 9 
 
Week 22 
 
12 month  
68.26% confidence of change (1 SD) no yes yes 
95% confidence of change (1.96 SD) no no no 
99% confidence of change (2.58 SD) no no no 
Has the client reliably changed (with at least 95% confidence) AND 
changed from being within 1.96 standard deviations of the clinical 
mean to now being 1.96 standard deviations away from the clinical 
means   (1.96 standard deviation = 0.6276) 
Some 
criteria not 
met 
Some 
criteria not 
met 
Some 
criteria not 
met 
Has the client reliably changed (with at least 95% confidence) AND 
changed from being more than 1.96 standard deviations away from 
the normal mean to now being 1.96 standard deviations of the 
normal mean   (1.96 standard deviation = 19.9836) 
Some 
criteria not 
met 
Some 
criteria not 
met 
Some 
criteria not 
met 
Has the client reliably changed (with at least 95% confidence) AND 
changed clinical status according to the intersection of the clinical 
and normal distributions  (intersection  = 12.27727) 
Some 
criteria not 
met 
Some 
criteria not 
met 
Some 
criteria not 
met 
 
*Greene JG. A factor analytic study of climacteric symptoms. Journal of Psychosomatic Research. 
1976. 20:425-430. 
**Green JG. Guide to the Greene Climacteric Scale. Glasgow:University of Glasgow. 1991  
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Appendix Table 6: Patricia’s Reliable and Clinical Change Generator for the GCS Somatic 
Subscale 
Case Study 1 
Patricia 
GCS:  
Somatic Scale 
Test-retest reliability* r = .84 Standard deviation used to 
measure reliability* 
 SD = 4.57 
Clinical sample Mean* M = 7.18 Normal sample mean** M = 3.25 
Clinical sample standard 
deviation* 
SD = 4.57 Normal sample standard 
deviation** 
SD = 3.64 
Standard error of measurement 1.828 Standard error of the 
difference 
2.58518 
To change with 68.26% (1 SD) there must be a change of at least 2.505 
To change with 95% (1.96 SD) there must be a change of at least 5.06686 
To change with 99% (2.58 SD) there must be a change of at least 6.65899 
Scores: Week 1 = 3 Week 9 = 3 Week 22 = 0 12 months = 2 
Outcome Week 9 Week 22 12 month 
68.26% confidence of change (1 SD) no yes no 
95% confidence of change (1.96 SD) no no no 
99% confidence of change (2.58 SD) no no no 
Has the client reliably changed (with at least 95% confidence) AND 
changed from being within 1.96 standard deviations of the clinical 
mean to now being 1.96 standard deviations away from the clinical 
means  (1.96 standard deviation = -1.7772) 
Some 
criteria not 
met 
Some 
criteria not 
met 
Some 
criteria not 
met 
Has the client reliably changed (with at least 95% confidence) AND 
changed from being more than 1.96 standard deviations away from 
the normal mean to now being 1.96 standard deviations of the 
normal mean   (1.96 standard deviation = 10.3844) 
Some 
criteria not 
met 
Some 
criteria not 
met 
Some 
criteria not 
met 
Has the client reliably changed (with at least 95% confidence) AND 
changed clinical status according to the intersection of the clinical 
and normal distributions (intersection  = 4.99241)  
Some 
criteria not 
met 
Some 
criteria not 
met 
Some 
criteria not 
met 
*Greene JG. A factor analytic study of climacteric symptoms. Journal of Psychosomatic Research.
1976. 20:425-430. 
**Green JG. Guide to the Greene Climacteric Scale. Glasgow:University of Glasgow. 1991 
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Appendix Table 7: Patricia’s Reliable and Clinical Change Generator for the GCS Vasomotor 
Subscale 
Case Study 1 
Patricia 
GCS:  
Vasomotor Scale 
 
Test-retest reliability* r = .83 Standard deviation used to 
measure reliability* 
 SD = 2.79 
 
Clinical sample Mean* M = 6.46 Normal sample mean** M = 1.79 
Clinical sample standard 
deviation* 
SD = 2.79 Normal sample standard 
deviation** 
SD = 1.12 
Standard error of measurement 1.15035 Standard error of the 
difference 
1.62684 
 
To change with 68.26% (1 SD) there must be a change of at least 1.627 
To change with 95% (1.96 SD) there must be a change of at least 3.18854 
To change with 99% (2.58 SD) there must be a change of at least 4.19045 
 
Scores: Week 1 = 4 Week 9 = 2 Week 22 = 4 12 months = 0 
 
Outcome Week 9 
 
Week 22 
 
12 month  
68.26% confidence of change (1 SD) yes no yes 
95% confidence of change (1.96 SD) no no yes 
99% confidence of change (2.58 SD) no no no 
Has the client reliably changed (with at least 95% confidence) AND 
changed from being within 1.96 standard deviations of the clinical 
mean to now being 1.96 standard deviations away from the clinical 
means   (1.96 standard deviation = 0.9916) 
Some 
criteria not 
met 
Some 
criteria not 
met 
yes 
Has the client reliably changed (with at least 95% confidence) AND 
changed from being more than 1.96 standard deviations awy from 
the normal mean to now being 1.96 standard deviations of the 
normal mean   (1.96 standard deviation = 3.9852) 
Some 
criteria not 
met 
Some 
criteria not 
met 
yes 
Has the client reliably changed (with at least 95% confidence) AND 
changed clinical status according to the intersection of the clinical 
and normal distributions  (intersection  = 3.1277) 
Some 
criteria not 
met 
Some 
criteria not 
met 
yes 
*Greene JG. A factor analytic study of climacteric symptoms. Journal of Psychosomatic Research. 
1976. 20:425-430. 
**Green JG. Guide to the Greene Climacteric Scale. Glasgow:University of Glasgow. 1991  
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Appendix Table 8: Dianne’s Reliable and Clinical Change Data for the DASS Depression Scale 
Case Study 2 
Dianne 
DASS:  
Depression Scale 
Test-retest reliability* r = .71 Standard deviation used to 
measure reliability* 
 SD = 9.25 
Clinical sample Mean** M = 10.65 Normal sample mean** M = 6.34 
Clinical sample standard 
deviation** 
SD = 9.30 Normal sample standard 
deviation** 
SD = 6.97 
Standard error of measurement 4.98128 Standard error of the 
difference 
7.04459 
To change with 68.26% (1 SD) there must be a change of at least 7.045 
To change with 95% (1.96 SD) there must be a change of at least 13.80714 
To change with 99% (2.58 SD) there must be a change of at least 18.14566 
Scores: Week 1 = 8 Week 9 = 0 Week 20 = 1 12 months = 2 
Outcome Week 9 Week 20 12 month 
68.26% confidence of change (1 SD) yes no no 
95% confidence of change (1.96 SD) no no no 
99% confidence of change (2.58 SD) no no no 
Has the client reliably changed (with at least 95% confidence) AND 
changed from being within 1.96 standard deviations of the clinical 
mean to now being 1.96 standard deviations away from the clinical 
means  (1.96 standard deviation = -7.578) 
Some 
criteria not 
met 
Some 
criteria not 
met 
Some 
criteria not 
met 
Has the client reliably changed (with at least 95% confidence) AND 
changed from being more than 1.96 standard deviations away from 
the normal mean to now being 1.96 standard deviations of the 
normal mean  (1.96 standard deviation = 20.0012) 
Some 
criteria not 
met 
Some 
criteria not 
met 
Some 
criteria not 
met 
Has the client reliably changed (with at least 95% confidence) AND 
changed clinical status according to the intersection of the clinical 
and normal distributions   (intersection = 8.18639) 
Some 
criteria not 
met 
Some 
criteria not 
met 
Some 
criteria not 
met 
*Brown TA, Chorpita BF, Korotitsch W and Barlow DH. Psychometric Properties of the Depression Anxiety Stress
Scales (DASS) in Clinical Samples. Behav. Res Ther. 1997. 35(1):79-89 
** Australian Centre for Posttraumatic Mental Health. The University of Melbourne. Taken from:   Lovibond, SH & 
Lovibond PF. Manual for the  Depression Anxiety Stress Scales. 2nd Ed. Sydney:Psychology Foundation. 1995. 
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Appendix Table 9: Dianne’s Reliable and Clinical Change Data for the DASS Anxiety Scale 
Case Study 2 
Dianne 
DASS:  
Anxiety Scale 
 
Test-retest reliability* r = .78 Standard deviation used to 
measure reliability* 
 SD = 9.06 
 
Clinical sample Mean** M = 10.90 Normal sample mean** M = 4.7 
Clinical sample standard 
deviation** 
SD = 8.12 Normal sample standard 
deviation** 
SD = 4.91 
Standard error of measurement 4.24952 Standard error of the 
difference 
6.00972 
 
To change with 68.26% (1 SD) there must be a change of at least 6.01 
To change with 95% (1.96 SD) there must be a change of at least 11.77884 
To change with 99% (2.58 SD) there must be a change of at least 15.48002 
 
Scores: Week 1 = 10 Week 9 = 0 Week 20 = 1 12 months = 5 
 
Outcome Week 9 
 
Week 20 
 
12 month  
68.26% confidence of change (1 SD) yes yes no 
95% confidence of change (1.96 SD) no no no 
99% confidence of change (2.58 SD) no no no 
Has the client reliably changed (with at least 95% confidence) AND 
changed from being within 1.96 standard deviations of the clinical 
mean to now being 1.96 standard deviations away from the clinical 
means   (1.96 standard deviation = -5.0152) 
Some 
criteria not 
met 
Some 
criteria not 
met 
Some 
criteria not 
met 
Has the client reliably changed (with at least 95% confidence) AND 
changed from being more than 1.96 standard deviations away from 
the normal mean to now being 1.96 standard deviations of the 
normal mean  (1.96 standard deviation = 14.3236)  
Some 
criteria not 
met 
Some 
criteria not 
met 
Some 
criteria not 
met 
Has the client reliably changed (with at least 95% confidence) AND 
changed clinical status according to the intersection of the clinical 
and normal distributions  (intersection  = 7.0363) 
Some 
criteria not 
met 
Some 
criteria not 
met 
Some 
criteria not 
met 
*Brown TA, Chorpita BF, Korotitsch W and Barlow DH. Psychometric Properties of the Depression Anxiety Stress 
Scales (DASS) in Clinical Samples. Behav. Res Ther. 1997. 35(1):79-89 
** Australian Centre for Posttraumatic Mental Health. The University of Melbourne. Taken from:   Lovibond, SH & 
Lovibond PF. Manual for the  Depression Anxiety Stress Scales. 2nd Ed. Sydney:Psychology Foundation. 1995. 
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Appendix Table 10: Dianne’s Reliable and Clinical Change Data for the DASS Stress Scale 
Case Study 2 
Dianne 
DASS:  
Stress Scale 
Test-retest reliability* r = .81 Standard deviation used to 
measure reliability* 
 SD = 12.45 
Clinical sample Mean** M = 21.1 Normal sample mean** M = 10.11 
Clinical sample standard 
deviation** 
SD = 11.15 Normal sample standard 
deviation** 
SD = 7.91 
Standard error of measurement 5.42683 Standard error of the 
difference 
7.6747 
To change with 68.26% (1 SD) there must be a change of at least 7.675 
To change with 95% (1.96 SD) there must be a change of at least 15.04213 
To change with 99% (2.58 SD) there must be a change of at least 19.76871 
Scores: Week 1 = 30 Week 9 = 4 Week 20 = 4 12 months = 
23 
Outcome Week 9 Week 20 12 month 
68.26% confidence of change (1 SD) yes yes no 
95% confidence of change (1.96 SD) yes yes no 
99% confidence of change (2.58 SD) yes yes no 
Has the client reliably changed (with at least 95% confidence) AND 
changed from being within 1.96 standard deviations of the clinical 
mean to now being 1.96 standard deviations away from the clinical 
means  (1.96 standard deviation = -0.754) 
Some 
criteria not 
met 
Some 
criteria not 
met 
Some 
criteria not 
met 
Has the client reliably changed (with at least 95% confidence) AND 
changed from being more than 1.96 standard deviations away from 
the normal mean to now being 1.96 standard deviations of the 
normal mean   (1.96 standard deviation = 25.6136) 
yes yes Some 
criteria not 
met 
Has the client reliably changed (with at least 95% confidence) AND 
changed clinical status according to the intersection of the clinical 
and normal distributions  (intersection  = 14.67091)  
yes yes Some 
criteria not 
met 
*Brown TA, Chorpita BF, Korotitsch W and Barlow DH. Psychometric Properties of the Depression Anxiety Stress
Scales (DASS) in Clinical Samples. Behav. Res Ther. 1997. 35(1):79-89 
** Australian Centre for Posttraumatic Mental Health. The University of Melbourne. Taken from:   Lovibond, SH & 
Lovibond PF. Manual for the  Depression Anxiety Stress Scales. 2nd Ed. Sydney:Psychology Foundation. 1995. 
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Appendix Table 11: Dianne’s Reliable and Clinical Change Generator for the GCS 
Psychological Subscale 
Case Study 2 
Dianne 
GCS:  
Psychological Scale 
Test-retest reliability* r = .87 Standard deviation used to 
measure reliability* 
 SD = 9.69 
Clinical sample Mean* M = 19.62 Normal sample mean** M = 7.42 
Clinical sample standard 
deviation* 
SD = 9.69 Normal sample standard 
deviation** 
SD = 6.41 
Standard error of measurement 3.49378 Standard error of the 
difference 
4.94095 
To change with 68.26% (1 SD) there must be a change of at least 4.941 
To change with 95% (1.96 SD) there must be a change of at least 9.68408 
To change with 99% (2.58 SD) there must be a change of at least 12.72704 
Scores: Week 1 = 15 Week 9 = 6 Week 20 = 6 12 months = 
12 
Outcome Week 9 Week 20 12 month 
68.26% confidence of change (1 SD) yes yes no 
95% confidence of change (1.96 SD) no no no 
99% confidence of change (2.58 SD) no no no 
Has the client reliably changed (with at least 95% confidence) AND 
changed from being within 1.96 standard deviations of the clinical 
mean to now being 1.96 standard deviations away from the clinical 
means   (1.96 standard deviation = 0.6276) 
Some 
criteria not 
met 
Some 
criteria not 
met 
Some 
criteria not 
met 
Has the client reliably changed (with at least 95% confidence) AND 
changed from being more than 1.96 standard deviations away from 
the normal mean to now being 1.96 standard deviations of the 
normal mean   (1.96 standard deviation = 19.9836) 
Some 
criteria not 
met 
Some 
criteria not 
met 
Some 
criteria not 
met 
Has the client reliably changed (with at least 95% confidence) AND 
changed clinical status according to the intersection of the clinical 
and normal distributions  (intersection  = 12.27727) 
Some 
criteria not 
met 
Some 
criteria not 
met 
Some 
criteria not 
met 
*Greene JG. A factor analytic study of climacteric symptoms. Journal of Psychosomatic Research.
1976. 20:425-430. 
**Green JG. Guide to the Greene Climacteric Scale. Glasgow:University of Glasgow. 1991 
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Appendix Table 12: Dianne’s Reliable and Clinical Change Generator for the GCS Somatic 
Subscale 
Case Study 2 
Dianne 
GCS:  
Somatic Scale 
Test-retest reliability* r = .84 Standard deviation used to 
measure reliability* 
 SD = 4.57 
Clinical sample Mean* M = 7.18 Normal sample mean M = 3.25 
Clinical sample standard 
deviation* 
SD = 4.57 Normal sample standard 
deviation** 
SD = 3.64 
Standard error of measurement 1.828 Standard error of the 
difference** 
2.58518 
To change with 68.26% (1 SD) there must be a change of at least 2.505 
To change with 95% (1.96 SD) there must be a change of at least 5.06686 
To change with 99% (2.58 SD) there must be a change of at least 6.65899 
Scores: Week 1 = 1 Week 9 = 3 Week 20 = 0 12 months = 3 
Outcome Week 9 Week 20 12 month 
68.26% confidence of change (1 SD) no no no 
95% confidence of change (1.96 SD) no no no 
99% confidence of change (2.58 SD) no no no 
Has the client reliably changed (with at least 95% confidence) AND 
changed from being within 1.96 standard deviations of the clinical 
mean to now being 1.96 standard deviations away from the clinical 
means  (1.96 standard deviation = -1.7772) 
Some 
criteria not 
met 
Some 
criteria not 
met 
Some 
criteria not 
met 
Has the client reliably changed (with at least 95% confidence) AND 
changed from being more than 1.96 standard deviations away from 
the normal mean to now being 1.96 standard deviations of the 
normal mean   (1.96 standard deviation = 10.3844) 
Some 
criteria not 
met 
Some 
criteria not 
met 
Some 
criteria not 
met 
Has the client reliably changed (with at least 95% confidence) AND 
changed clinical status according to the intersection of the clinical 
and normal distributions (intersection  = 4.99241)  
Some 
criteria not 
met 
Some 
criteria not 
met 
Some 
criteria not 
met 
*Greene JG. A factor analytic study of climacteric symptoms. Journal of Psychosomatic Research.
1976. 20:425-430. 
**Green JG. Guide to the Greene Climacteric Scale. Glasgow:University of Glasgow. 1991 
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Appendix Table 13: Dianne’s Reliable and Clinical Change Generator for the GCS Vasomotor 
Subscale 
Case Study 2 
Dianne 
GCS:  
Vasomotor Scale 
Test-retest reliability* r = .83 Standard deviation used to 
measure reliability* 
 SD = 2.79 
Clinical sample Mean* M = 6.46 Normal sample mean** M = 1.79 
Clinical sample standard 
deviation* 
SD = 2.79 Normal sample standard 
deviation** 
SD = 1.12 
Standard error of measurement 1.5035 Standard error of the 
difference 
1.62684 
To change with 68.26% (1 SD) there must be a change of at least 1.627 
To change with 95% (1.96 SD) there must be a change of at least 3.18854 
To change with 99% (2.58 SD) there must be a change of at least 4.19045 
Scores: Week 1 = 2 Week 9 = 2 Week 20 = 0 12 months = 2 
Outcome Week 9 Week 20 12 month 
68.26% confidence of change (1 SD) no yes no 
95% confidence of change (1.96 SD) no no no 
99% confidence of change (2.58 SD) no no no 
Has the client reliably changed (with at least 95% confidence) AND 
changed from being within 1.96 standard deviations of the clinical 
mean to now being 1.96 standard deviations away from the clinical 
means  (1.96 standard deviation = -1.7772) 
Some 
criteria not 
met 
Some 
criteria not 
met 
Some 
criteria not 
met 
Has the client reliably changed (with at least 95% confidence) AND 
changed from being more than 1.96 standard deviations away from 
the normal mean to now being 1.96 standard deviations of the 
normal mean   (1.96 standard deviation = 10.3844) 
Some 
criteria not 
met 
Some 
criteria not 
met 
Some 
criteria not 
met 
Has the client reliably changed (with at least 95% confidence) AND 
changed clinical status according to the intersection of the clinical 
and normal distributions (intersection  = 4.99241)  
Some 
criteria not 
met 
Some 
criteria not 
met 
Some 
criteria not 
met 
*Greene JG. A factor analytic study of climacteric symptoms. Journal of Psychosomatic Research.
1976. 20:425-430. 
**Green JG. Guide to the Greene Climacteric Scale. Glasgow:University of Glasgow. 1991 
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Appendix Table 14: Sarah’s Reliable and Clinical Change Data for the DASS Depression Scale 
Case Study 3 
Sarah 
DASS:  
Depression Scale 
Test-retest reliability* r = .71 Standard deviation used to 
measure reliability* 
 SD = 9.25 
Clinical sample Mean** M = 10.65 Normal sample mean** M = 6.34 
Clinical sample standard 
deviation** 
SD = 9.30 Normal sample standard 
deviation** 
SD = 6.97 
Standard error of measurement 4.98128 Standard error of the 
difference 
7.04459 
To change with 68.26% (1 SD) there must be a change of at least 7.045 
To change with 95% (1.96 SD) there must be a change of at least 13.80714 
To change with 99% (2.58 SD) there must be a change of at least 18.14566 
Scores: Week 1 = 9 Week 8 = 1 Week 20 = 1 12 months = 2 
Outcome Week 8 Week 20 12 month 
68.26% confidence of change (1 SD) yes yes no 
95% confidence of change (1.96 SD) no no no 
99% confidence of change (2.58 SD) no no no 
Has the client reliably changed (with at least 95% confidence) AND 
changed from being within 1.96 standard deviations of the clinical 
mean to now being 1.96 standard deviations away from the clinical 
means  (1.96 standard deviation = -7.578) 
Some 
criteria not 
met 
Some 
criteria not 
met 
Some 
criteria not 
met 
Has the client reliably changed (with at least 95% confidence) AND 
changed from being more than 1.96 standard deviations away from 
the normal mean to now being 1.96 standard deviations of the 
normal mean  (1.96 standard deviation = 20.0012) 
Some 
criteria not 
met 
Some 
criteria not 
met 
Some 
criteria not 
met 
Has the client reliably changed (with at least 95% confidence) AND 
changed clinical status according to the intersection of the clinical 
and normal distributions   (intersection = 8.18639) 
Some 
criteria not 
met 
Some 
criteria not 
met 
Some 
criteria not 
met 
*Brown TA, Chorpita BF, Korotitsch W and Barlow DH. Psychometric Properties of the Depression Anxiety Stress
Scales (DASS) in Clinical Samples. Behav. Res Ther. 1997. 35(1):79-89 
** Australian Centre for Posttraumatic Mental Health. The University of Melbourne. Taken from:   Lovibond, SH & 
Lovibond PF. Manual for the  Depression Anxiety Stress Scales. 2nd Ed. Sydney:Psychology Foundation. 1995. 
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Appendix Table 15: Sarah’s Reliable and Clinical Change Data for the DASS Anxiety Scale 
Case Study 3 
Sarah 
DASS:  
Anxiety Scale 
Test-retest reliability* r = .78 Standard deviation used to 
measure reliability* 
 SD = 9.06 
Clinical sample Mean** M = 10.90 Normal sample mean** M = 4.7 
Clinical sample standard 
deviation** 
SD = 8.12 Normal sample standard 
deviation** 
SD = 4.91 
Standard error of measurement 4.24952 Standard error of the 
difference 
6.00972 
To change with 68.26% (1 SD) there must be a change of at least 6.01 
To change with 95% (1.96 SD) there must be a change of at least 11.77884 
To change with 99% (2.58 SD) there must be a change of at least 15.48002 
Scores: Week 1 = 6 Week 8 = 5 Week 20 = 0 12 months = 2 
Outcome Week 8 Week 20 12 month 
68.26% confidence of change (1 SD) no no no 
95% confidence of change (1.96 SD) no no no 
99% confidence of change (2.58 SD) no no no 
Has the client reliably changed (with at least 95% confidence) AND 
changed from being within 1.96 standard deviations of the clinical 
mean to now being 1.96 standard deviations away from the clinical 
means   (1.96 standard deviation = -5.0152) 
Some 
criteria not 
met 
Some 
criteria not 
met 
Some 
criteria not 
met 
Has the client reliably changed (with at least 95% confidence) AND 
changed from being more than 1.96 standard deviations away from 
the normal mean to now being 1.96 standard deviations of the 
normal mean  (1.96 standard deviation = 14.3236)  
Some 
criteria not 
met 
Some 
criteria not 
met 
Some 
criteria not 
met 
Has the client reliably changed (with at least 95% confidence) AND 
changed clinical status according to the intersection of the clinical 
and normal distributions  (intersection  = 7.0363) 
Some 
criteria not 
met 
Some 
criteria not 
met 
Some 
criteria not 
met 
*Brown TA, Chorpita BF, Korotitsch W and Barlow DH. Psychometric Properties of the Depression Anxiety Stress
Scales (DASS) in Clinical Samples. Behav. Res Ther. 1997. 35(1):79-89 
** Australian Centre for Posttraumatic Mental Health. The University of Melbourne. Taken from:   Lovibond, SH & 
Lovibond PF. Manual for the  Depression Anxiety Stress Scales. 2nd Ed. Sydney:Psychology Foundation. 1995. 
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Appendix Table 16: Sarah’s Reliable and Clinical Change Data for the DASS Stress Scale 
Case Study 3 
Sarah 
DASS:  
Stress Scale 
 
Test-retest reliability* r = .81 Standard deviation used to 
measure reliability* 
 SD = 12.45 
 
Clinical sample Mean** M = 21.1 Normal sample mean** M = 10.11 
Clinical sample standard 
deviation** 
SD = 11.15 Normal sample standard 
deviation** 
SD = 7.91 
Standard error of measurement 5.42683 Standard error of the 
difference 
7.6747 
 
To change with 68.26% (1 SD) there must be a change of at least 7.675 
To change with 95% (1.96 SD) there must be a change of at least 15.04213 
To change with 99% (2.58 SD) there must be a change of at least 19.76871 
 
Scores: Week 1 = 18 Week 8 = 12 Week 20 = 7 12 months = 11 
 
Outcome Week 8 
 
Week 20 
 
12 month  
68.26% confidence of change (1 SD) no yes no 
95% confidence of change (1.96 SD) no no no 
99% confidence of change (2.58 SD) no  no  no  
Has the client reliably changed (with at least 95% confidence) AND 
changed from being within 1.96 standard deviations of the clinical 
mean to now being 1.96 standard deviations away from the clinical 
means  (1.96 standard deviation = -0.754) 
Some 
criteria not 
met 
Some 
criteria not 
met 
Some 
criteria not 
met 
Has the client reliably changed (with at least 95% confidence) AND 
changed from being more than 1.96 standard deviations away from 
the normal mean to now being 1.96 standard deviations of the 
normal mean   (1.96 standard deviation = 25.6136) 
Some 
criteria not 
met 
Some 
criteria not 
met 
Some 
criteria not 
met 
Has the client reliably changed (with at least 95% confidence) AND 
changed clinical status according to the intersection of the clinical 
and normal distributions  (intersection  = 14.67091)  
Some 
criteria not 
met 
Some 
criteria not 
met 
Some 
criteria not 
met 
*Brown TA, Chorpita BF, Korotitsch W and Barlow DH. Psychometric Properties of the Depression Anxiety Stress 
Scales (DASS) in Clinical Samples. Behav. Res Ther. 1997. 35(1):79-89 
** Australian Centre for Posttraumatic Mental Health. The University of Melbourne. Taken from:   Lovibond, SH & 
Lovibond PF. Manual for the  Depression Anxiety Stress Scales. 2nd Ed. Sydney:Psychology Foundation. 1995. 
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Appendix Table 17: Sarah’s Reliable and Clinical Change Generator for the GCS Psychological 
Subscale 
Case Study 3 
Sarah 
GCS:  
Psychological Scale 
 
Test-retest reliability* r = .87 Standard deviation used to 
measure reliability* 
 SD = 9.69 
 
Clinical sample Mean* M = 19.62 Normal sample mean** M = 7.42 
Clinical sample standard 
deviation* 
SD = 9.69 Normal sample standard 
deviation** 
SD = 6.41 
Standard error of measurement 3.49378 Standard error of the 
difference 
4.94095 
 
To change with 68.26% (1 SD) there must be a change of at least 4.941 
To change with 95% (1.96 SD) there must be a change of at least 9.68408 
To change with 99% (2.58 SD) there must be a change of at least 12.72704 
 
Scores: Week 1 = 15 Week 8 = 5 Week 20 = 3 12 months = 6 
 
Outcome Week 9 
 
Week 20 
 
12 month  
68.26% confidence of change (1 SD) yes yes yes 
95% confidence of change (1.96 SD) yes yes no 
99% confidence of change (2.58 SD) no no no 
Has the client reliably changed (with at least 95% confidence) AND 
changed from being within 1.96 standard deviations of the clinical 
mean to now being 1.96 standard deviations away from the clinical 
means   (1.96 standard deviation = 0.6276) 
Some 
criteria not 
met 
Some 
criteria not 
met 
Some 
criteria not 
met 
Has the client reliably changed (with at least 95% confidence) AND 
changed from being more than 1.96 standard deviations away from 
the normal mean to now being 1.96 standard deviations of the 
normal mean   (1.96 standard deviation = 19.9836) 
Some 
criteria not 
met 
Some 
criteria not 
met 
Some 
criteria not 
met 
Has the client reliably changed (with at least 95% confidence) AND 
changed clinical status according to the intersection of the clinical 
and normal distributions  (intersection  = 12.27727) 
yes yes Some 
criteria not 
met 
*Greene JG. A factor analytic study of climacteric symptoms. Journal of Psychosomatic Research. 
1976. 20:425-430. 
**Green JG. Guide to the Greene Climacteric Scale. Glasgow:University of Glasgow. 1991 
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Appendix Table 18: Sarah’s Reliable and Clinical Change Generator for the GCS Somatic 
Subscale 
Case Study 3 
Sarah 
GCS:  
Somatic Scale 
Test-retest reliability* r = .84 Standard deviation used to 
measure reliability* 
 SD = 4.57 
Clinical sample Mean* M = 7.18 Normal sample mean** M = 3.25 
Clinical sample standard 
deviation* 
SD = 4.57 Normal sample standard 
deviation** 
SD = 3.64 
Standard error of measurement 1.828 Standard error of the 
difference 
2.58518 
To change with 68.26% (1 SD) there must be a change of at least 2.505 
To change with 95% (1.96 SD) there must be a change of at least 5.06686 
To change with 99% (2.58 SD) there must be a change of at least 6.65899 
Scores: Week 1 = 2 Week 8 = 2 Week 20 = 0 12 months = 2 
Outcome Week 9 Week 20 12 month 
68.26% confidence of change (1 SD) no no no 
95% confidence of change (1.96 SD) no no no 
99% confidence of change (2.58 SD) no no no 
Has the client reliably changed (with at least 95% confidence) AND 
changed from being within 1.96 standard deviations of the clinical 
mean to now being 1.96 standard deviations away from the clinical 
means  (1.96 standard deviation = -1.7772) 
Some 
criteria not 
met 
Some 
criteria not 
met 
Some 
criteria not 
met 
Has the client reliably changed (with at least 95% confidence) AND 
changed from being more than 1.96 standard deviations away from 
the normal mean to now being 1.96 standard deviations of the 
normal mean   (1.96 standard deviation = 10.3844) 
Some 
criteria not 
met 
Some 
criteria not 
met 
Some 
criteria not 
met 
Has the client reliably changed (with at least 95% confidence) AND 
changed clinical status according to the intersection of the clinical 
and normal distributions (intersection  = 4.99241)  
Some 
criteria not 
met 
Some 
criteria not 
met 
Some 
criteria not 
met 
*Greene JG. A factor analytic study of climacteric symptoms. Journal of Psychosomatic Research.
1976. 20:425-430. 
**Green JG. Guide to the Greene Climacteric Scale. Glasgow:University of Glasgow. 1991 
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Appendix Table 19: Sarah’s Reliable and Clinical Change Generator for the GCS Vasomotor 
Subscale 
Case Study 3 
Sarah 
GCS:  
Vasomotor Scale 
 
Test-retest reliability* r = .83 Standard deviation used to 
measure reliability* 
 SD = 2.79 
 
Clinical sample Mean* M = 6.46 Normal sample mean** M = 1.79 
Clinical sample standard 
deviation* 
SD = 2.79 Normal sample standard 
deviation** 
SD = 1.12 
Standard error of measurement 1.15035 Standard error of the 
difference 
1.62684 
 
To change with 68.26% (1 SD) there must be a change of at least 1.627 
To change with 95% (1.96 SD) there must be a change of at least 3.18854 
To change with 99% (2.58 SD) there must be a change of at least 4.19045 
 
Scores: Week 1 = 5 Week 8 = 2 Week 20 = 1 12 months = 5 
 
Outcome Week 9 
 
Week 20 
 
12 month  
68.26% confidence of change (1 SD) yes yes no 
95% confidence of change (1.96 SD) no yes no 
99% confidence of change (2.58 SD) no no no 
Has the client reliably changed (with at least 95% confidence) AND 
changed from being within 1.96 standard deviations of the clinical 
mean to now being 1.96 standard deviations away from the clinical 
means  (1.96 standard deviation = -1.7772) 
Some 
criteria not 
met 
Some 
criteria not 
met 
Some 
criteria not 
met 
Has the client reliably changed (with at least 95% confidence) AND 
changed from being more than 1.96 standard deviations away from 
the normal mean to now being 1.96 standard deviations of the 
normal mean   (1.96 standard deviation = 10.3844) 
Some 
criteria not 
met 
yes Some 
criteria not 
met 
Has the client reliably changed (with at least 95% confidence) AND 
changed clinical status according to the intersection of the clinical 
and normal distributions (intersection  = 4.99241)  
Some 
criteria not 
met 
yes Some 
criteria not 
met 
 
*Greene JG. A factor analytic study of climacteric symptoms. Journal of Psychosomatic Research. 
1976. 20:425-430. 
**Green JG. Guide to the Greene Climacteric Scale. Glasgow:University of Glasgow. 1991 
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Appendix Table 200: Mean Reliable and Clinical Change Data for the DASS Depression Scale 
 
Mean  DASS:  
Depression Scale 
 
Test-retest reliability* r = .71 Standard deviation used to 
measure reliability* 
 SD = 9.25 
 
Clinical sample Mean** M = 10.65 Normal sample mean** M = 6.34 
Clinical sample standard 
deviation** 
SD = 9.30 Normal sample standard 
deviation** 
SD = 6.97 
Standard error of measurement 4.98128 Standard error of the 
difference 
7.04459 
 
To change with 68.26% (1 SD) there must be a change of at least 7.045 
To change with 95% (1.96 SD) there must be a change of at least 13.80714 
To change with 99% (2.58 SD) there must be a change of at least 18.14566 
 
Scores: Week 1 = 13 Week 8 = 4 Week 20 = 2 12 months = 2 
 
Outcome Week 8 
 
Week 20 
 
12 month  
68.26% confidence of change (1 SD) yes yes yes 
95% confidence of change (1.96 SD) no no no 
99% confidence of change (2.58 SD) no no no 
Has the client reliably changed (with at least 95% confidence) AND 
changed from being within 1.96 standard deviations of the clinical 
mean to now being 1.96 standard deviations away from the clinical 
means  (1.96 standard deviation = -7.578) 
Some 
criteria not 
met 
Some 
criteria not 
met 
Some 
criteria not 
met 
Has the client reliably changed (with at least 95% confidence) AND 
changed from being more than 1.96 standard deviations away from 
the normal mean to now being 1.96 standard deviations of the 
normal mean  (1.96 standard deviation = 20.0012) 
Some 
criteria not 
met 
Some 
criteria not 
met 
Some 
criteria not 
met 
Has the client reliably changed (with at least 95% confidence) AND 
changed clinical status according to the intersection of the clinical 
and normal distributions   (intersection = 8.18639) 
Some 
criteria not 
met 
Some 
criteria not 
met 
Some 
criteria not 
met 
*Brown TA, Chorpita BF, Korotitsch W and Barlow DH. Psychometric Properties of the Depression Anxiety Stress 
Scales (DASS) in Clinical Samples. Behav. Res Ther. 1997. 35(1):79-89 
** Australian Centre for Posttraumatic Mental Health. The University of Melbourne. Taken from:   Lovibond, SH & 
Lovibond PF. Manual for the  Depression Anxiety Stress Scales. 2nd Ed. Sydney:Psychology Foundation. 1995. 
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Appendix Table 211: Mean Reliable and Clinical Change Data for the DASS Anxiety Scale 
Mean DASS:  
Anxiety Scale 
Test-retest reliability* r = .78 Standard deviation used to 
measure reliability* 
 SD = 9.06 
Clinical sample Mean** M = 10.90 Normal sample mean** M = 4.7 
Clinical sample standard 
deviation** 
SD = 8.12 Normal sample standard 
deviation** 
SD = 4.91 
Standard error of measurement 4.24952 Standard error of the 
difference 
6.00972 
To change with 68.26% (1 SD) there must be a change of at least 6.01 
To change with 95% (1.96 SD) there must be a change of at least 11.77884 
To change with 99% (2.58 SD) there must be a change of at least 15.48002 
Scores: Week 1 = 10 Week 8 = 5 Week 20 = 1 12 months = 3 
Outcome Week 8 Week 20 12 month 
68.26% confidence of change (1 SD) no yes yes 
95% confidence of change (1.96 SD) no no no 
99% confidence of change (2.58 SD) no no no 
Has the client reliably changed (with at least 95% confidence) AND 
changed from being within 1.96 standard deviations of the clinical 
mean to now being 1.96 standard deviations away from the clinical 
means   (1.96 standard deviation = -5.0152) 
Some 
criteria not 
met 
Some 
criteria not 
met 
Some 
criteria not 
met 
Has the client reliably changed (with at least 95% confidence) AND 
changed from being more than 1.96 standard deviations away from 
the normal mean to now being 1.96 standard deviations of the 
normal mean  (1.96 standard deviation = 14.3236)  
Some 
criteria not 
met 
Some 
criteria not 
met 
Some 
criteria not 
met 
Has the client reliably changed (with at least 95% confidence) AND 
changed clinical status according to the intersection of the clinical 
and normal distributions  (intersection  = 7.0363) 
Some 
criteria not 
met 
Some 
criteria not 
met 
Some 
criteria not 
met 
*Brown TA, Chorpita BF, Korotitsch W and Barlow DH. Psychometric Properties of the Depression Anxiety Stress
Scales (DASS) in Clinical Samples. Behav. Res Ther. 1997. 35(1):79-89 
** Australian Centre for Posttraumatic Mental Health. The University of Melbourne. Taken from:   Lovibond, SH & 
Lovibond PF. Manual for the  Depression Anxiety Stress Scales. 2nd Ed. Sydney:Psychology Foundation. 1995. 
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Appendix Table 22: Mean Reliable and Clinical Change Data for the DASS Stress Scale 
Mean  DASS:  
Stress Scale 
 
Test-retest reliability* r = .81 Standard deviation used to 
measure reliability* 
 SD = 12.45 
 
Clinical sample Mean** M = 21.1 Normal sample mean** M = 10.11 
Clinical sample standard 
deviation** 
SD = 11.15 Normal sample standard 
deviation** 
SD = 7.91 
Standard error of measurement 5.42683 Standard error of the 
difference 
7.6747 
 
To change with 68.26% (1 SD) there must be a change of at least 7.675 
To change with 95% (1.96 SD) there must be a change of at least 15.04213 
To change with 99% (2.58 SD) there must be a change of at least 19.76871 
 
Scores: Week 1 = 27 Week 8 = 13 Week 20 = 6 12 months = 14 
 
Outcome Week 8 
 
Week 20 
 
12 month  
68.26% confidence of change (1 SD) yes yes yes 
95% confidence of change (1.96 SD) no yes no 
99% confidence of change (2.58 SD) no  yes  no  
Has the client reliably changed (with at least 95% confidence) AND 
changed from being within 1.96 standard deviations of the clinical 
mean to now being 1.96 standard deviations away from the clinical 
means  (1.96 standard deviation = -0.754) 
Some 
criteria not 
met 
Criteria 
met 
Some 
criteria not 
met 
Has the client reliably changed (with at least 95% confidence) AND 
changed from being more than 1.96 standard deviations away from 
the normal mean to now being 1.96 standard deviations of the 
normal mean   (1.96 standard deviation = 25.6136) 
Some 
criteria not 
met 
Criteria 
met 
Some 
criteria not 
met 
Has the client reliably changed (with at least 95% confidence) AND 
changed clinical status according to the intersection of the clinical 
and normal distributions  (intersection  = 14.67091)  
Some 
criteria not 
met 
Criteria 
met 
Some 
criteria not 
met 
*Brown TA, Chorpita BF, Korotitsch W and Barlow DH. Psychometric Properties of the Depression Anxiety Stress 
Scales (DASS) in Clinical Samples. Behav. Res Ther. 1997. 35(1):79-89 
** Australian Centre for Posttraumatic Mental Health. The University of Melbourne. Taken from:   Lovibond, SH & 
Lovibond PF. Manual for the  Depression Anxiety Stress Scales. 2nd Ed. Sydney:Psychology Foundation. 1995. 
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Appendix Table 23: Mean Reliable and Clinical Change Generator for the GCS Psychological 
Subscale 
Mean GCS:  
Psychological Scale 
Test-retest reliability* r = .87 Standard deviation used to 
measure reliability* 
 SD = 9.69 
Clinical sample Mean* M = 19.62 Normal sample mean** M = 7.42 
Clinical sample standard 
deviation* 
SD = 9.69 Normal sample standard 
deviation** 
SD = 6.41 
Standard error of measurement 3.49378 Standard error of the 
difference 
4.94095 
To change with 68.26% (1 SD) there must be a change of at least 4.941 
To change with 95% (1.96 SD) there must be a change of at least 9.68408 
To change with 99% (2.58 SD) there must be a change of at least 12.72704 
Scores: Week 1 = 14 Week 8 = 9 Week 20 = 5 12 months = 8 
Outcome Week 9 Week 20 12 month 
68.26% confidence of change (1 SD) yes yes yes 
95% confidence of change (1.96 SD) no no no 
99% confidence of change (2.58 SD) no no no 
Has the client reliably changed (with at least 95% confidence) AND 
changed from being within 1.96 standard deviations of the clinical 
mean to now being 1.96 standard deviations away from the clinical 
means   (1.96 standard deviation = 0.6276) 
Some 
criteria not 
met 
Some 
criteria not 
met 
Some 
criteria not 
met 
Has the client reliably changed (with at least 95% confidence) AND 
changed from being more than 1.96 standard deviations away from 
the normal mean to now being 1.96 standard deviations of the 
normal mean   (1.96 standard deviation = 19.9836) 
Some 
criteria not 
met 
Some 
criteria not 
met 
Some 
criteria not 
met 
Has the client reliably changed (with at least 95% confidence) AND 
changed clinical status according to the intersection of the clinical 
and normal distributions  (intersection  = 12.27727) 
Some 
criteria not 
met 
Some 
criteria not 
met 
Some 
criteria not 
met 
*Greene JG. A factor analytic study of climacteric symptoms. Journal of Psychosomatic Research.
1976. 20:425-430. 
**Green JG. Guide to the Greene Climacteric Scale. Glasgow:University of Glasgow. 1991 
